

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/24781 A2**(51) International Patent Classification<sup>7</sup>: **A61K 31/00** (74) Agent: **HELLER, David, J.; Ridout & Maybee, One Queen Street East, Suite 2400, Toronto, Ontario M5C 3B1 (CA).**(21) International Application Number: **PCT/CA00/01188**

(22) International Filing Date: 6 October 2000 (06.10.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English  
 (26) Publication Language: English  
 (30) Priority Data:

|                                       |   |                |
|---------------------------------------|---|----------------|
| 2,285,690<br>60/158,043<br>60/217,765 | 7 October 1999 (07.10.1999)<br>7 October 1999 (07.10.1999)<br>12 July 2000 (12.07.2000) | CA<br>US<br>US |
|---------------------------------------|---|----------------|

(71) Applicant (*for all designated States except US*): NOVA-NEURON INC. [CA/CA]; 5859 University Avenue, Sir Charles Tupper Medical Bldg., Room 15D7, Halifax, Nova Scotia B3H 4H7 (CA).(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and  
 (75) Inventors/Applicants (*for US only*): **ROBERTSON, Harold, A.** [CA/CA]; 2384 Clifton Street, Halifax, Nova Scotia B3K 4V1 (CA). **DENOAN-WRIGHT, Eileen, M.** [CA/CA]; 22 Fleming Drive, Halifax, Nova Scotia B3P 1A9 (CA).

**Published:**

— *Without international search report and to be republished upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# Best Available Copy

WO 01/24781 A2

(54) Title: GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME

(57) Abstract: PDE10A, a gene that is normally highly expressed in mammalian striatum and elsewhere, has been found to decrease in expression during the development of CAG repeat disorders such as Huntington's disease. The invention teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder. Compounds which modulate CAG repeat disorders and their uses are taught. Methods for screening for further compounds to modulate CAG repeat disorders are also taught.

Gene Necessary for Striatal Function, Uses Thereof, and  
Compounds for Modulating Same

#### CROSS-REFERENCE

This patent claims priority from Canadian Patent application no. 2,285,690 filed October 7, 1999, US provisional application no. 60/158,043 filed October 7, 1999, and US provisional application no. 60/217,765 filed July 12, 2000, entitled Gene Necessary for Striatal Function, Uses Thereof, and Compounds for Modulating Same.

#### FIELD OF THE INVENTION

The present invention relates to a polynucleotide, PDE10A, which is down-regulated during the development of CAG repeat disorders, such as Huntington's disease. The present invention also describes compounds that modulate CAG repeat disorders, processes for expressing PDE10A, and its agonists and antagonists, and uses of PDE10A, and its variants, derivatives, agonists and antagonists.

#### BACKGROUND OF THE INVENTION

Very few if any effective treatments exist for neurological disorders characterized by progressive cell loss, known as neurodegenerative diseases, as well as those involving acute cell loss, such as stroke and trauma.

Huntington's disease (HD) is an inherited neurological disorder that is transmitted in

autosomal dominant fashion. HD results from genetically programmed degeneration of neurons in certain areas of the brain. Huntington's disease is caused by a mutation of the gene *IT-15* that codes for the protein huntingtin. The huntingtin gene contains a polymorphic stretch of repeated CAG trinucleotides that encode a polyglutamine tract within huntingtin. If this tract exceeds 35 in number, Huntington's disease results. Huntington's disease is only one of a number of neurological diseases which are characterised by these polyglutamine repeats (Ross, 1997). Schizophrenia, Alzheimer's disease, stroke, trauma, and Parkinson's disease also affect the basal ganglia.

Huntingtin has no sequence similarity to known proteins (Group THDCR, 1993; Sisodia, 1998). The function of the normal or mutated HD form of huntingtin has not been defined by the prior art. It is evident, however, that the expression of the HD form of huntingtin leads to progressive and selective neuronal loss. It has been demonstrated that the GABA- and enkephalin-containing medium spiny projection neurons of the caudate-putamen eventually die as a result of HD (Richfield et al., 1994). Patients with minimal cell loss, however, still present with motor and cognitive symptoms suggesting that neuronal dysfunction, and not simply cell loss, contribute to the symptoms of HD. The motor symptoms of HD include the development of chorea, dystonia, bradykinesia and tremors (Young et al., 1986). Voluntary movements may also be affected such that there may be disturbances in speech (Ludlow et al., 1987) and degradation of fine motor co-ordination (Young et al., 1986). In addition to motor decline, emotional disturbances and cognitive loss are also evident during the progression of HD (Caine et al., 1978).

Despite the fact that huntingtin is ubiquitously expressed, HD specifically affects cells of the

basal ganglia, structures deep within the brain that have a number of important functions, including co-ordinating movement. The basal ganglia includes the caudate nucleus, the putamen, the nucleus accumbens and the olfactory tubercle. HD also affects the brain's outer surface, or cortex, which controls thought, perception, and memory. The mechanism by which only a small group of neurons in the striatum and cortex are rendered vulnerable to this ubiquitously expressed mutant protein is not known. There are no effective treatments for Huntington's disease.

Huntington's disease is widely believed to be a gain-of function disorder but neither the normal function nor the gained function of huntingtin is known. Because the function for huntingtin is not known, there is little insight into the disease process. It was believed that huntingtin was related to neuronal intranuclear inclusions (NII). However, recent results have cast doubt on our understanding of the role of the NII in Huntington's disease (Saudou et al., 1998) or in other CAG repeat disorders (Klement et al., 1998; see also commentary by Sisodia, 1998).

The development of a mouse carrying the 5' end of the human Huntington's disease gene (the promoter and first exon; Mangiarini et al., 1996) was an important step in the development of the tools that will allow us to understand the function (and gain-of-function) associated with huntingtin. R6/2 mice exhibit a rapidly progressing neurological phenotype with onset at about 8 weeks. This phenotype includes a movement disorder characterised by shuddering, resting tremor, epileptic seizures and stereotyped behaviour. These symptoms suggest that the function of the basal ganglia is affected by the expression of the human exon 1 transgene prior to neuronal cell death. By 12 weeks the affected mice have significantly reduced brain

weights and they die by about 13 weeks of age. Neuronal intranuclear inclusions (NII) develop at about 4 weeks (Davies et al., 1997). As is observed in human Huntington's disease patient, the R6/2 mice show changes in neuronal receptors (Cha et al., 1998). The present inventors have also demonstrated that changes in the expression of DARPP-32 and cannabinoid receptors change over time in HD mice; such changes have also been observed in human Huntington's disease patients (unpublished results). The loss of the cannabinoid receptor is one of the earliest documented changes that occur prior to neuronal degeneration in human HD patients. The R6/2 model, therefore, mimics the early phases of HD; a point in disease development where intervention would be most appropriate.

Human PDE10 was recently identified by identification of cDNA fragments published on the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database (Loughney et al., WO99/42596). While PDE10 was found to share homology with known PDEs, no function could be identified for PDE10.

#### SUMMARY OF THE INVENTION

The present invention provides the function and uses of a nucleotide segment, PDE10A, and compounds which inhibit or promote the development of CAG repeat disorders such as Huntington's Disease.

The invention teaches a method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of: (a) selecting a control animal having PDE10A and a test animal having PDE10A; (b) treating said test animal using a compound; and (c)

determining the relative quantity of RNA corresponding to PDE10A, as between said animals. In an embodiment, the animal is a mammal, preferably a mouse, and preferably a transgenic mouse. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention also teaches a method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of: (a) selecting a host cell containing PDE10A; (b) cloning said host cell and separating said clones into a test group and a control group; (c) treating said test group using a compound; and (c) determining the relative quantity of RNA corresponding to PDE10A, as between said test group and said control group. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention further teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder, said method comprising determining the level of expression of RNA corresponding to PDE10A in an individual relative to a predetermined control level of expression, wherein a decreased expression of said RNA as compared to said control is indicative of a CAG repeat disorder. Preferably, the expression is measured by in situ hybridization, fluorescent in situ hybridization, polymerase chain reaction, or DNA fingerprinting technique. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention further teaches compositions for treating a CAG repeat disorder comprising a compound which modulates PDE10 expression and a pharmaceutically acceptable carrier. The compound can be selected from the group consisting of: quinpirole, alloxan, miconazole nitrate, MDL-12330A and tetracycline derivatives such as demeclocycline. The compound

may be selected from the group consisting of: (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione, (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and (3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, or from the group consisting of: KS-505, IC224, SCH 51866, IBMX and Dipyradomole. The disorder can be HD.

The invention also teaches the use of a composition which modulates PDE10 for treating a CAG repeat disorder comprising administering the composition to a subject in need of such treatment, and such use of the composition which modulates PDE10 for treating HD.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a portion of an autoradiogram of the differential display reaction identifying PDE10A in mouse brain mRNA.

FIG. 2 is a northern blot confirming that PDE10A has a lower steady-state level of expression in the striatum of transgenic HD mice.

FIG. 3 is a nucleotide sequence of the differential display cDNA fragment of pPDE10A.

FIG. 4 shows the *in situ* hybridization of probe 1 to coronal and saggital brain sections of 10 week-old wild-type and HD mice.

FIG. 5 shows the *in situ* hybridization corresponding to spatial and temporal expression of PDE10A in brain sections of wild-type and HD mice over the period of time that the HD mice develop abnormal movements and postures.

FIG. 6 shows the *in situ* hybridization corresponding to expression of PDE10A in brain sections of one day old wild-type and HD mice.

FIG. 7 shows the *in situ* hybridization corresponding to distribution of the mRNA of PDE10A in mouse striatal neurons.

FIG. 8 is the *in situ* hybridization corresponding to mRNA distribution of the rat homologue of PDE10A in rat brain tissue.

FIG. 9 shows a Southern blot analysis of DNA from wild-type and transgenic HD mice hybridized to the pPDE10A cDNA probe.

FIG. 10 is a nucleotide sequence of cPDE10-1, and corresponds to SEQ ID NO. 1.

FIG. 11 is a restriction map of cPDE10-1.

FIG. 12 is a nucleotide sequence of cPDE10-2, and corresponds to SEQ ID NO. 2.

FIG. 13 is a restriction map of cPDE10-2.

FIG. 14 is a schematic diagram showing the alignment of cPDE10-1 and -2 and the regions that are identical and unique between the two clones.

FIG. 15 is a nucleotide sequence of cPDE10A and RACEs, corresponding to SEQ ID NO. 11.

FIG. 16 is a map of PDE10A coding sequence and restriction sites.

FIG. 17 is a map of PDE10A coding sequence and features.

FIG. 18 is a restriction map of PDE10A.

FIG. 19 is a nucleotide sequence of cPDE10A and corresponds to SEQ ID NO. 12.

#### DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

The following illustrative explanations are provided to facilitate understanding of certain terms used frequently herein. The explanations are provided as a convenience and are not limitative of the invention.

“Host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

“Identity”, “similarity” or “homologous”, as used in the art, are relationships between two or

more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Both identity and similarity can be readily calculated (Lesk, A. M., 1988; Smith, D. W., 1993; Griffin, A. M., and Griffin, H. G., 1994; von Heinje, G., 1987; and Gribskov, M. and Devereux, J., 1991). While there exist a number of methods to measure identity and similarity between two polynucleotide sequences, both terms are well known to skilled artisans (von Heinje, G., 1987; Gribskov, M. and Devereux, 1991; and Carillo, H., and Lipman, D., 1988). Methods commonly employed to determine identity or similarity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D. (1988). Methods to determine identity and similarity are codified in computer programs. Computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., 1984), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., 1990).

"Isolated" means altered "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring polynucleotide naturally present in a living organism in its natural state is not "isolated," but the same polynucleotide separated from coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, such polynucleotides can be joined to other polynucleotides, such as DNA, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated polynucleotides, alone or joined to other polynucleotides such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in

culture or in whole organisms, such DNA still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the polynucleotides may occur in a composition, such as a media formulations, solutions for introduction of polynucleotides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated polynucleotides within the meaning of that term as it is employed herein.

"Plasmids". Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well known, published procedures. Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art. Moreover, those of skill readily may construct any number of other plasmids suitable for use in the invention.

"Polynucleotide(s)" of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be double-stranded or single-stranded. Single-stranded polynucleotides may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. Polynucleotides generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single-and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-,

double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term polynucleotide also includes DNA or RNA that contain one or more modified bases. Thus, DNA or RNA with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNA or RNA comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, *inter alia*. Polynucleotides embraces short polynucleotides often referred to as oligonucleotide(s). It will also be appreciated that RNA made by transcription of this doubled stranded nucleotide sequence, and an antisense strand of a nucleic acid molecule of the invention or an oligonucleotide fragment of the nucleic acid molecule, are contemplated within the scope of the invention. An antisense sequence is constructed by inverting the sequence of a nucleic acid molecule of the invention, relative to its normal presentation for transcription. Preferably, an antisense sequence is

constructed by inverting a region preceding the initiation codon or an unconserved region. The antisense sequences may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.

"Stringent hybridization conditions" are those which are stringent enough to provide specificity, reduce the number of mismatches and yet are sufficiently flexible to allow formation of stable hybrids at an acceptable rate. Such conditions are known to those skilled in the art and are described, for example, in Sambrook, et al, (1989). By way of example only, stringent hybridization with short nucleotides may be carried out at 5-10° below the  $T_m$  using high concentrations of probe such as 0.01-1.0 pmole/ml. Preferably, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

"Variant(s)" of polynucleotides are polynucleotides that differ in nucleotide sequence from another, reference polynucleotide. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical. Changes in the nucleotide sequence of the variant may be silent. That is, they may not alter the amino acids encoded by the polynucleotide. Where alterations are limited to silent changes of this type a variant will encode a polypeptide or polynucleotide with the same amino acid sequence as the reference. Changes in the nucleotide sequence of the variant may alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Such nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide or polynucleotide encoded by the reference sequence.

As hereinbefore mentioned, the present inventors have identified and sequenced a DNA sequence encoding PDE10A. The DNA sequence is shown in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11.

It will be appreciated that the invention includes nucleotide or amino acid sequences which have substantial sequence homology with the nucleotide sequences shown in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11. The term "sequences having substantial sequence homology" means those nucleotide and amino acid sequences which have slight or inconsequential sequence variations from the sequences disclosed in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11; i.e. the homologous sequences function in substantially the same manner to produce substantially the same polypeptides as the actual sequences. The variations may be attributable to local mutations or structural modifications. It is expected that a sequence having 85-90% sequence homology with the DNA sequence of the invention will provide a functional PDE10 polypeptide.

As used herein, "PDE10A" comprises a polynucleotide sequence which is down regulated in the course of CAG repeat disorders selected from the group consisting of: (a) a sequence comprising SEQ ID NO:1; (b) a sequence comprising SEQ ID NO:2; (c) a sequence comprising SEQ ID NO:11; (d) a sequence comprising nucleotides 257 to 2596 of SEQ ID NO:11; (e) a sequence which is at least 90% homologous with a sequence of (a), (b), (c) or (d); and; (f) a sequence which hybridizes to (a), (b), (c) or (d) under stringent conditions. In an embodiment, the isolated polynucleotide segment is cDNA. The invention also teaches an isolated polynucleotide segment, which retains substantially the same biological function or

activity as the polynucleotide encoded by the polynucleotide sequence.

Further embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding PDE10 polypeptide or polynucleotide, and polynucleotides which are complementary to such polynucleotides. Other embodiments are polynucleotides that comprise a region that is at least 80% identical over their entire length to a polynucleotide encoding PDE10 of SEQ ID NO.11 and polynucleotides complementary thereto. This includes polynucleotides at least 90% identical over their entire length to the same, and among these embodiments are polynucleotides with at least 95%. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

The polynucleotides of the present invention may be employed as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein.

Analysis of the complete nucleotide and amino acid sequences of the protein of the invention using the procedures of Sambrook et al., supra, have been used to determine the expressed region, initiation codon and untranslated sequences of the PDE10A gene. The transcription regulatory sequences of the gene are determined by analyzing fragments of the DNA for their ability to express a reporter gene such as the bacterial gene lacZ.

The nucleic acid molecules of the invention allow those skilled in the art to construct

nucleotide probes for use in the detection of nucleotide sequences in biological materials. As shown in FIG. 11, 13, 15 and 16, a number of unique restriction sequences for restriction enzymes are incorporated in the nucleic acid molecule identified in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11, and these provide access to nucleotide sequences which code for polypeptides unique to the PDE10A polypeptide of the invention. Nucleotide sequences unique to PDE10A or isoforms thereof, can also be constructed by chemical synthesis and enzymatic ligation reactions carried out by procedures known in the art.

A nucleotide probe may be labeled with a detectable marker such as a radioactive label which provides for an adequate signal and has sufficient half-life such as 32p, 3H, 14C or the like. Other detectable markers which may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and chemiluminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. The nucleotide probes may be used to detect genes related to or analogous to PDE10A of the invention.

Accordingly, the present invention also provides a method of detecting the presence of nucleic acid molecules encoding a polypeptide related to or analogous to PDE10A in a sample comprising contacting the sample under hybridization conditions with one or more of the nucleotide probes of the invention labeled with a detectable marker, and determining the degree of hybridization between the nucleic acid molecule in the sample and the nucleotide probes.

Hybridization conditions which may be used in the method of the invention are known in the art and are described for example in Sambrook J, et al., *supra*. The hybridization product may be assayed using techniques known in the art. The nucleotide probe may be labeled with a detectable marker as described herein and the hybridization product may be assayed by detecting the detectable marker or the detectable change produced by the detectable marker.

The nucleic acid molecule of the invention also permits the identification and isolation, or synthesis of nucleotide sequences which may be used as primers to amplify a polynucleotide molecule of the invention, for example in polymerase chain reaction (PCR). The length and bases of the primers for use in the PCR are selected so that they will hybridize to different strands of the desired sequence and at relative positions along the sequence such that an extension product synthesized from one primer when it is separated from its template can serve as a template for extension of the other primer into a nucleic acid of defined length.

Primers which may be used in the invention are oligonucleotides i.e. molecules containing two or more deoxyribonucleotides of the nucleic acid molecule of the invention which occur naturally as in a purified restriction endonuclease digest or are produced synthetically using techniques known in the art such as, for example, phosphotriester and phosphodiester methods (See Good et al, 1977) or automated techniques (see, for example, Conolly, B. A., 1987). The primers are capable of acting as a point of initiation of synthesis when placed under conditions which permit the synthesis of a primer extension product which is complementary to the DNA sequence of the invention e.g. in the presence of nucleotide substrates, an agent for polymerization such as DNA polymerase and at suitable temperature and pH. Preferably, the primers are sequences that do not form secondary structures by base

pairing with other copies of the primer or sequences that form a hair pin configuration. The primer may be single or double-stranded. When the primer is double-stranded it may be treated to separate its strands before using it to prepare amplification products. The primer preferably contains between about 7 and 25 nucleotides.

The primers may be labeled with detectable markers which allow for detection of the amplified products. Suitable detectable markers are radioactive markers such as P-32, S-35, I-125, and H-3, luminescent markers such as chemiluminescent markers, preferably luminol, and fluorescent markers, preferably dansyl chloride, fluoresein-5-isothiocyanate, and 4-fluor-7-nitrobenz-2-oxa-1,3 diazole, enzyme markers such as horseradish peroxidase, alkaline phosphatase, .beta.-galactosidase, acetylcholinesterase, or biotin.

It will be appreciated that the primers may contain non-complementary sequences provided that a sufficient amount of the primer contains a sequence which is complementary to a nucleic acid molecule of the invention or oligonucleotide sequence thereof, which is to be amplified. Restriction site linkers may also be incorporated into the primers allowing for digestion of the amplified products with the appropriate restriction enzymes facilitating cloning and sequencing of the amplified product.

Thus, a method of determining the presence of a nucleic acid molecule having a sequence encoding PDE10A or a predetermined oligonucleotide fragment thereof in a sample, is provided comprising treating the sample with primers which are capable of amplifying the nucleic acid molecule or the predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions which permit the formation of

amplified sequences and, assaying for amplified sequences.

The polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al, Academic Press, 1989, in Mullis et al., U.S. Pat. No. 4,863,195 and Mullis, U.S. Pat. No. 4,683,202 which are incorporated herein by reference. Conditions for amplifying a nucleic acid template are described in M. A. Innis and D. H. Gelfand, 1989, which is also incorporated herein by reference.

The amplified products can be isolated and distinguished based on their respective sizes using techniques known in the art. For example, after amplification, the DNA sample can be separated on an agarose gel and visualized, after staining with ethidium bromide, under ultra violet (UV) light. DNA may be amplified to a desired level and a further extension reaction may be performed to incorporate nucleotide derivatives having detectable markers such as radioactive labeled or biotin labeled nucleoside triphosphates. The primers may also be labeled with detectable markers. The detectable markers may be analyzed by restriction and electrophoretic separation or other techniques known in the art.

The conditions which may be employed in the methods of the invention using PCR are those which permit hybridization and amplification reactions to proceed in the presence of DNA in a sample and appropriate complementary hybridization primers. Conditions suitable for the polymerase chain reaction are generally known in the art. For example, see M. A. Innis and D. H. Gelfand, 1989, which is incorporated herein by reference. Preferably, the PCR utilizes polymerase obtained from the thermophilic bacterium *Thermus aquatics* (Taq polymerase, GeneAmp Kit, Perkin Elmer Cetus) or other thermostable polymerase may be used to amplify

DNA template strands.

It will be appreciated that other techniques such as the Ligase Chain Reaction (LCR) and Nucleic-Acid Sequence Based Amplification (NASBA) may be used to amplify a nucleic acid molecule of the invention. In LCR, two primers which hybridize adjacent to each other on the target strand are ligated in the presence of the target strand to produce a complementary strand (Barney, 1991 and European Published Application No. 0320308, published Jun. 14, 1989). NASBA is a continuous amplification method using two primers, one incorporating a promoter sequence recognized by an RNA polymerase and the second derived from the complementary sequence of the target sequence to the first primer (U.S. Ser. No. 5,130,238 to Malek).

The present invention also teaches vectors which comprise a polynucleotide or polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polynucleotides of the invention by recombinant techniques.

In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. In certain embodiments in this regard, the vectors provide for specific expression. Such specific expression may be inducible expression or expression only in certain types of cells or both inducible and cell-specific. Particular among inducible vectors are vectors that can be induced for expression by environmental factors that are easy to manipulate, such as temperature and nutrient additives. A variety of vectors suitable to this

aspect of the invention, including constitutive and inducible expression vectors for use in prokaryotic and eukaryotic hosts, are well known and employed routinely by those of skill in the art. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids, all may be used for expression in accordance with this aspect of the present invention.

The following vectors, which are commercially available, are provided by way of example. Among vectors for use in bacteria are pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia, and pBR322 (ATCC 37017). Among eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. These vectors are listed solely by way of illustration of the many commercially available and well known vectors that are available to those of skill in the art for use in accordance with this aspect of the present invention. It will be appreciated that any other plasmid or vector suitable for, for example, introduction, maintenance, propagation or expression of a polynucleotide or polypeptide of the invention in a host may be used in this aspect of the invention. Generally, any vector suitable to maintain, propagate or express polynucleotides to express a polypeptide or polynucleotide in a host may be used

for expression in this regard.

The appropriate DNA sequence may be inserted into the vector by any of a variety of well-known and routine techniques. In general, expression constructs will contain sites for transcription initiation and termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polynucleotide to be translated.

The DNA sequence in the expression vector is operatively linked to appropriate expression control sequence(s), including, for instance, a promoter to direct mRNA transcription. Promoter regions can be selected from any desired gene using vectors that contain a reporter transcription unit lacking a promoter region, such as a chloramphenicol acetyl transferase ("CAT") transcription unit, downstream of restriction site or sites for introducing a candidate promoter fragment; i.e., a fragment that may contain a promoter. As is well known, introduction into the vector of a promoter-containing fragment at the restriction site upstream of the cat gene engenders production of CAT activity, which can be detected by standard CAT assays. Vectors suitable to this end are well known and readily available, such as pKK232-8 and pCM7. Promoters for expression of polynucleotides of the present invention include not only well known and readily available promoters, but also promoters that readily may be obtained by the foregoing technique, using a reporter gene. Among known prokaryotic promoters suitable for expression of polynucleotides and polypeptides in accordance with the present invention are the E. coli lacI and lacZ and promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter. Among

known eukaryotic promoters suitable in this regard are the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Vectors for propagation and expression generally will include selectable markers and amplification regions, such as, for example, those set forth in Sambrook et al., *supra*.

As hereinbefore mentioned, the present invention also teaches host cells which are genetically engineered with vectors of the invention.

Polynucleotide constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. The PDE10A polynucleotide or polypeptide products or isoforms or parts thereof, may be obtained by expression in a suitable host cell using techniques known in the art. Suitable host cells include prokaryotic or eukaryotic organisms or cell lines, for example bacterial, mammalian, yeast, or other fungi, viral, plant or insect cells. Methods for transforming or transfecting cells to express foreign DNA are well known in the art (See for example, Itakura et al., U.S. Pat. No. 4,704,362; Hinnen et al., 1978; Murray et al., U.S. Pat. No. 4,801,542; Upshall et al., U.S. Pat. No. 4,935,349; Hagen et al., U.S. Pat. No. 4,784,950; Axel et al., U.S. Pat. No. 4,399,216; Goeddal et al., U.S. Pat. No. 4,766,075; and Sambrook et al, 1989, all of which are incorporated herein by reference). Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, streptomycetes and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2*

and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

Host cells can be genetically engineered to incorporate polynucleotides and express polynucleotides of the present invention. Introduction of polynucleotides into the host cell can be affected by calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. (1986) and Sambrook et al. (1989).

As hereinbefore mentioned, the present invention also teaches the production of polynucleotides of the invention by recombinant techniques.

The PDE10 polynucleotides encode a polypeptide which is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed

such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the present invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences which are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

The polypeptides of the invention may be prepared by culturing the host/vector systems described above, in order to express the recombinant polypeptides. Recombinantly produced PDE10A based protein or parts thereof, may be further purified using techniques known in the art such as commercially available protein concentration systems, by salting out the protein followed by dialysis, by affinity chromatography, or using anion or cation exchange resins.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using DNA derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., *supra*.

Polynucleotides of the invention, encoding the heterologous structural sequence of a

polynucleotide or polypeptide of the invention generally will be inserted into a vector using standard techniques so that it is operably linked to the promoter for expression. The polynucleotide will be positioned so that the transcription start site is located appropriately 5' to a ribosome binding site. The ribosome binding site will be 5' to the AUG that initiates translation of the polynucleotide or polypeptide to be expressed. Generally, there will be no other open reading frames that begin with an initiation codon, usually AUG, and lie between the ribosome binding site and the initiation codon. Also, generally, there will be a translation stop codon at the end of the expressed polynucleotide and there will be a polyadenylation signal in constructs for use in eukaryotic hosts. Transcription termination signal appropriately disposed at the 3' end of the transcribed region may also be included in the polynucleotide construct.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polynucleotide or polypeptide. These signals may be endogenous to the polynucleotide or they may be heterologous signals. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art. PDE10A polynucleotide or polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for

purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polynucleotide is denatured during isolation and or purification.

In an embodiment, a nucleic acid molecule of the invention may be cloned into a glutathione S-transferase (GST) gene fusion system for example the pGEX-1 T, pGEX-2T and pGEX-3X of Pharmacia. The fused gene may contain a strong lac promoter, inducible to a high level of expression by IPTG, as a regulatory element. Thrombin or factor Xa cleavage sites may be present which allow proteolytic cleavage of the desired polypeptide from the fusion product.

The glutathione S-transferase-PDE10A fusion protein may be easily purified using a glutathione sepharose 4B column, for example from Pharmacia. The 26 kd glutathione S-transferase polypeptide can be cleaved by thrombin (pGEX-1 or pGEX-2T) or factor Xa (pGEX-3X) and resolved from the using the polypeptide using the same affinity column. Additional chromatographic steps can be included if necessary, for example Sephadex or DEAE cellulose. The two enzymes may be monitored by protein and enzymatic assays and purity may be confirmed using SDS-PAGE.

The PDE10A protein or parts thereof may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964) or synthesis in homogenous solution (Houbenweyl, 1987).

Within the context of the present invention, PDE10A polypeptide includes various structural forms of the primary protein which retain biological activity. For example, PDE10A polypeptide may be in the form of acidic or basic salts or in neutral form. In addition,

individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions or additions may be made to the amino acid or nucleic acid sequences, the net effect being that biological activity of PDE10A is retained. Due to code degeneracy, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the C- or N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, fusion proteins may be added to the polynucleotide or polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polynucleotide or polypeptide. The addition of peptide moieties to polynucleotide or polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughput screening assays to identify antagonists (see Bennett et al., 1995, and Johanson et al., 1995).

#### *Detecting Presence of or Predisposition for CAG Repeat Disorders*

This invention is also related to the use of the PDE10A polynucleotides to detect complementary polynucleotides as a diagnostic reagent. Detection of the level of expression of PDE10A in a eukaryote, particularly a mammal, and especially a human, will provide a

method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, exhibiting decreased levels of PDE10A may be detected by a variety of techniques. Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as the striatum, nucleus accumbens and olfactory tubercle. RNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki et al., 1986) prior to analysis. As an example, PCR primers complementary to the nucleic acid encoding PDE10A can be used to identify and analyze PDE10A presence and/or expression. Using PCR, characterization of the level of PDE10A present in the individual may be made by comparative analysis.

The invention thus provides a process for detecting disease by using methods known in the art and methods described herein to detect decreased expression of PDE10 polynucleotide. For example, decreased expression of PDE10 polynucleotide can be measured using any one of the methods well known in the art for the quantification of polynucleotides, such as, for example, PCR, RT-PCR, DNase protection, northern blotting and other hybridization methods. Thus, the present invention provides a method for detecting triplet-repeat disorders, and a method for detecting a genetic pre-disposition for triplet-repeat disorders and other disorders of the basal ganglia including schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease (AD). More generally, the present invention provides a method for detecting a genetic pre-disposition for neurological disorders characterized by progressive cell loss.

*Drug Screening Assays*

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of PDE10 polypeptides or polynucleotides, such as its interaction with PDE10-binding molecules. The identification of mutations in specific genes in inherited neurodegenerative disorders, combined with advances in the field of transgenic methods, provides those of skill in the art with the information necessary to further study human diseases. This is extraordinarily useful in modeling familial forms of triplet-repeat disorders and other disorders of the basal ganglia including schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease (AD). More generally, the present invention is useful for modeling neurological disorders characterized by progressive cell loss, as well as those involving acute cell loss, such as stroke and trauma.

For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds PDE10. The preparation is incubated with labeled PDE10 in the absence or the presence of a candidate molecule which may be a PDE10 agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labeled ligand.

PDE10-like effects of potential agonists and antagonists may be measured, for instance, by determining activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of PDE10 or molecules that elicit the same effects as PDE10. Reporter systems that may be useful in this

regard include, but are not limited to, colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in PDE10 activity, and binding assays known in the art.

Another example of an assay for PDE10 antagonists is a competitive assay that combines PDE10 and a potential antagonist with membrane-bound PDE10-binding molecules, recombinant PDE10 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. PDE10 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of PDE10 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing PDE10-induced activities, thereby preventing the action of PDE10 by excluding PDE10 from binding.

Potential antagonists include a small molecule which binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, 1988, for a description of these molecules).

Potential antagonists include compounds related to and derivatives of PDE10.

Developing modulators of the biological activities of specific PDEs requires differentiating PDE isozymes present in a particular assay preparation. The classical enzymological approach of isolating PDEs from natural tissue sources and studying each new isozyme may be used. Another approach has been to identify assay conditions which might favor the contribution of one isozyme and minimize the contribution of others in a preparation. Still another approach has been the separation of PDEs by immunological means. Each of the foregoing approaches for differentiating PDE isozymes is time consuming. As a result many attempts to develop selective PDE modulators have been performed with preparations containing more than one isozyme. Moreover, PDE preparations from natural tissue sources are susceptible to limited proteolysis and may contain mixtures of active proteolytic products that have different kinetic, regulatory and physiological properties than the full length PDEs.

Recombinant PDE10 polypeptide products of the invention greatly facilitate the development of new and specific PDE10 modulators. The need for purification of an isozyme can be avoided by expressing it recombinantly in a host cell that lacks endogenous phosphodiesterase activity (e.g., yeast strain YKS45 deposited as ATCC 74225). Once a compound that modulates the activity of the PDE10 is discovered, its selectivity can be evaluated by comparing its activity on the PDE10 to its activity on other PDE isozymes. Thus, the combination of the recombinant PDE10 products of the invention with other recombinant PDE products in a series of independent assays provides a system for developing selective modulators of PDE10. Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to the PDE10 or PDE10 nucleic acid,

oligonucleotides which specifically bind to the PDE10 (see Patent Cooperation Treaty International Publication No. WO93/05182 published Mar. 18, 1993 which describes methods for selecting oligonucleotides which selectively bind to target biomolecules) or PDE10 nucleic acid (e.g., antisense oligonucleotides) and other non-peptide natural or synthetic compounds which specifically bind to the PDE10 or PDE10 nucleic acid. Mutant forms of the PDE10 which alter the enzymatic activity of the PDE10 or its localization in a cell are also contemplated. Crystallization of recombinant PDE10 alone and bound to a modulator, analysis of atomic structure by X-ray crystallography, and computer modelling of those structures are methods useful for designing and optimizing non-peptide selective modulators. See, for example, Erickson et al., *Ann. Rep. Med. Chem.*, 27: 271-289 (1992) for a general review of structure-based drug design.

Targets for the development of selective modulators include, for example: (1) the regions of the PDE10 which contact other proteins and/or localize the PDE10 within a cell, (2) the regions of the PDE10 which bind substrate, (3) the allosteric cGMP-binding site(s) of PDE10, (4) the metal-binding regions of the PDE10, (5) the phosphorylation site(s) of PDE10 and (6) the regions of the PDE10 which are involved in dimerization of PDE10 subunits.

Thus, the present invention provides a method for screening and selecting compounds which promote triplet-repeat disorders, and a method for screening and selecting compounds which treat or inhibit triplet-repeat disorders, as well as schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease. More generally, the present invention provides a method for screening and selecting compounds which promote or inhibit neurological disorders characterized by progressive cell loss, as well as those involving acute cell loss, such as

stroke and trauma.

The selected antagonists and agonists may be administered, for instance, to inhibit progressive and acute neurological disorders, such as Huntington's disease, Parkinson's disease, schizophrenia, Alzheimer's disease (AD), stroke or trauma.

Antagonists and agonists and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds. The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by direct microinjection into the affected area, or by intravenous or other routes. These compositions of the present invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of antagonists or agonists of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation is prepared to suit the mode of administration.

Inhibition of PDE10A will be highly detrimental to striatal brain function. The progressive decline in PDE10A mRNA levels in HD may lead to dysregulation of cAMP levels and neuronal dysfunction. Up-regulation of PDE10A will be effective in combating such neuronal dysfunction.

*Gene Therapy*

A variety of gene therapy approaches may be used in accordance with the invention to modulate expression of the PDE10A gene in vivo. For example, antisense DNA molecules may be engineered and used to block translation of PDE10A mRNA in vivo. Alternatively, ribozyme molecules may be designed to cleave and destroy the PDE10A mRNAs in vivo. In another alternative, oligonucleotides designed to hybridize to the 5' region of the PDE10A gene (including the region upstream of the coding sequence) and form triple helix structures may be used to block or reduce transcription of the PDE10A gene. In yet another alternative, nucleic acid encoding the full length wild-type PDE10A message may be introduced in vivo into cells which otherwise would be unable to produce the wild-type PDE10A gene product in sufficient quantities or at all.

In a preferred embodiment, the antisense, ribozyme and triple helix nucleotides are designed to inhibit the translation or transcription of PDE10A. To accomplish this, the oligonucleotides used should be designed on the basis of relevant sequences unique to PDE10A.

For example, and not by way of limitation, the oligonucleotides should not fall within those regions where the nucleotide sequence of PDE10A is most homologous to that of other PDEs, such as PDE2 PDE5 and PDE6, herein referred to as "unique regions".

In the case of antisense molecules, it is preferred that the sequence be chosen from the unique regions. It is also preferred that the sequence be at least 18 nucleotides in length in order to

achieve sufficiently strong annealing to the target mRNA sequence to prevent translation of the sequence. Izant and Weintraub, 1984, Cell, 36:1007-1015; Rosenberg et al., 1985, Nature, 313:703-706.

In the case of the "hammerhead" type of ribozymes, it is also preferred that the target sequences of the ribozymes be chosen from the unique regions. Ribozymes are RNA molecules which possess highly specific endoribonuclease activity. Hammerhead ribozymes comprise a hybridizing region which is complementary in nucleotide sequence to at least part of the target RNA, and a catalytic region which is adapted to cleave the target RNA. The hybridizing region contains nine (9) or more nucleotides. Therefore, the hammerhead ribozymes of the present invention have a hybridizing region which is complementary to the sequences listed above and is at least nine nucleotides in length. The construction and production of such ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, 1988, Nature, 334:585-591.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in *Tetrahymena Thermophila* (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al., 1984, Science, 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et al., 1986, Nature, 324:429-433; published International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, Cell, 47:207-216). The Cech endoribonucleases have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences

that are present in PDE10A but not other PDEs.

The foregoing compounds can be administered by a variety of methods which are known in the art including, but not limited to the use of liposomes as a delivery vehicle. Naked DNA or RNA molecules may also be used where they are in a form which is resistant to degradation such as by modification of the ends, by the formation of circular molecules, or by the use of alternate bonds including phosphothionate and thiophosphoryl modified bonds. In addition, the delivery of nucleic acid may be by facilitated transport where the nucleic acid molecules are conjugated to poly-lysine or transferrin. Nucleic acid may also be transported into cells by any of the various viral carriers, including but not limited to, retrovirus, vaccinia, AAV, and adenovirus.

Alternatively, a recombinant nucleic acid molecule which encodes, or is, such antisense, ribozyme, triple helix, or PDE10A molecule can be constructed. This nucleic acid molecule may be either RNA or DNA. If the nucleic acid encodes an RNA, it is preferred that the sequence be operatively attached to a regulatory element so that sufficient copies of the desired RNA product are produced. The regulatory element may permit either constitutive or regulated transcription of the sequence. *In vivo*, that is, within the cells or cells of an organism, a transfer vector such as a bacterial plasmid or viral RNA or DNA, encoding one or more of the RNAs, may be transfected into cells e.g. (Llewellyn et al., 1987, *J. Mol. Biol.*, 195:115-123; Hanahan et al. 1983, *J. Mol. Biol.*, 166:557-580). Once inside the cell, the transfer vector may replicate, and be transcribed by cellular polymerases to produce the RNA or it may be integrated into the genome of the host cell. Alternatively, a transfer vector containing sequences encoding one or more of the RNAs may be transfected into cells or

introduced into cells by way of micromanipulation techniques such as microinjection, such that the transfer vector or a part thereof becomes integrated into the genome of the host cell.

*Composition, Formulation, and Administration of Pharmaceutical Compositions*

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules,

liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In

addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds

may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer,

and an aqueous phase. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding

free base forms.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, transdermal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into an affected area, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with an antibody specific for affected cells. The liposomes will be targeted to and taken up selectively by the cells.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications. It is appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms associated with such disorders. Techniques for formulation and administration of the compounds of the instant

application may be found in "*Remington's Pharmaceutical Sciences*," Mack Publishing Co., Easton, Pa., latest edition. For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.001 mg/kg to 10 mg/kg, typically around 0.01 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The invention further provides diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

## EXAMPLES

The present invention is further described by the following examples. These examples, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

## EXAMPLE 1 - Isolation of PDE10A

Wild-type (B6CBAF1) and HD transgenic [B6CBA-TgN(Hdexon1)62Gpb] mice (Jackson Laboratories) and adult Sprague-Dawley rats (250-300 g; Charles River Laboratories) were used in this study. The genotype of the mice was determined by PCR amplification of a 100 bp region of the integrated human HD exon 1 transgene using primers corresponding to nts 3340-3459 (5'-AGG GCT GTC AAT CAT GCT GG-3') and nts 3836-3855 (5'-AAA CTC ACG GTC GGT GCA GC-3') of clone E4.1 of the human HD gene (Accession number L34020). PCR conditions used are described in Mangiarini et al.(1996). DNA was extracted from a tail clip and an ear punch from each mouse used in this study. Both samples were subjected to PCR genotype analysis. For *in situ* hybridization analysis, the animals were anesthetized with >100 mg/kg sodium pentobarbital, decapitated, the brains removed and stored at -70°C prior to sectioning. For RNA isolation, animals were anesthetized, decapitated and the striatum and cortex were excised and stored in liquid nitrogen prior to RNA extraction. Animal care was given according to protocols approved by Dalhousie University and the Canadian Council of Animal Care.

Differential display was used to identify novel mDNA or previously described mDNA whose relative expression levels are altered as a result of the presence of the transgene. Using differential display, the mRNA populations derived from the striatum of 10 week old wild type were compared with age-matched R6/2 transgenic mice. Differential display has been used extensively (> 750 references) since its development (Liang and Pardee, 1992) to identify changes in gene expression in cells and in tissues including brain (Douglass et al., 1995; Babity et al., 1997a; Livesey et al., 1997; Berke et al., 1998). Perhaps the most

important finding was the demonstration by Qu et al., (1996) that differential display can be used to isolate genes differentially expressed in inbred strains of mice. The power of differential display is that the sequence information obtained can be directly related to the experimental paradigm. Moreover, such sequence information includes sufficient information to identify transcripts and can then lead to experiments that reveal function of the cognate protein in the experimental model.

DNA sequence information of potentially differentially expressed cDNA can be used to generate oligonucleotide probes for *in situ* hybridization to define the anatomical and temporal patterns of expression of specific transcripts (see Babity et al., 1997a). This technique is especially useful to study changes in steady-state levels of mRNA in heterogeneous tissue such as brain. Brain tissue can be micro-dissected (Babity et al., 1997b). This enabled the present inventors to reduce the requirement for tissue, and hence compare the mRNA populations derived from individual animals for each experimental group.

Thus RT-PCR (Denovan-Wright et al., 1999) was used to identify differences in the patterns of gene expression between the striatum of wild-type and transgenic mice that were hemizygous for the 5' UTR, exon 1 and part of intron 1 of the human Huntington's Disease gene. Total cellular RNA was isolated from the striatum and cortex of three 10 week-old wild-type and three 10 week-old R6/2 HD mice (Mangiarini et al., 1996) and used as the template to generate single-stranded cDNA. Total cellular RNA from each animal and tissue was purified using Trizol™ reagent (Gibco BRL) and the manufacturer's protocol. 10 µg aliquots of total RNA were treated with RQ1 DNase-free DNase (Promega) in the presence

of DNAsin™ (Promega) DNase inhibitor to remove trace genomic DNA and then converted to single-stranded cDNA. The primers and conditions for PCR amplification follow those of the Delta™ RNA fingerprinting manual (Clontech).

The cDNA was then used as the substrate for PCR reactions using 57 differential display primer combinations. The radio-labelled PCR products were fractionated on a denaturing acrylamide sequencing gels using a Genomyx LR™ sequencing apparatus, transferred to 3MM filter paper and dried. The dried acrylamide gels were exposed to autoradiography film (BioMax MR™) overnight. After fractionating the radio-labelled PCR products on denaturing acrylamide gels, it was found that the overwhelming majority of the approximately 18,000 PCR products screened were common to both the wild-type and HD mice (data not shown). One PCR product, amplified using the primers P7 (5'-ATT AAC CCT CAC TAA ATG CTG TAT G- 3') and T6 (5'- CAT TAT GCT GAG TGA TAT CTT TTT TTT TCG- 3') of approximately 500 bp, was observed in each of three samples derived from the striatum of wild-type mice (FIG. 1). This 500 bp band was absent from the samples derived from the striatum of the HD mice (FIG. 1) and was absent from each of the samples derived from the cortical tissue (data not shown).

FIG. 1 shows the Down-regulated in Huntington's Disease (PDE10A) transcript, identified by differential display RT PCR. A band of approximately 500 bp (arrow) was amplified from cDNA made form 10 week-old wild-type but not 10 week-old HD striatal tissue. Total RNA from individual animals (numbered 1-6) was used as the substrate for the generation of single-stranded cDNA. Animals 1, 2 and 3 were transgenic HD mice. Animals 4, 5 and 6 were wild-type mice.

### EXAMPLE 2 - Cloning of PDE10A

The 500 bp band, designate PDE10ApCR, was excised from the dried gel and rehydrated in 40 µl of H<sub>2</sub>O for 10 min at room temperature. The eluted DNA was subjected to PCR re-amplification using the P7 and T6 primers, rTaq polymerase (Pharmacia) and the following conditions: 60" @ 94°C, 19 x (30" @ 94°C, 30" @ 58°C, 120" @ 68°C + 4" per cycle), 7' @ 68°C. The PCR reaction was subjected to agarose gel electrophoresis and the 500 bp band was removed from the gel, extracted from the agarose using the Qiagen gel extraction protocol and cloned into the vector, pGem-T using standard methods. Plasmid DNA was isolated from selected transformants using Qiagen spin columns. The resultant clone was named pPDE10A.

### EXAMPLE 3 - Identification of PDE10A

The cloned insert of pPDE10A was radio-labelled and used as a hybridization probe in northern blot analysis (FIG. 2). Northern blots of total RNA were prepared using the method described in Denovan-Wright et al. (1998). The 500 bp cloned insert of PDE10A was radio-labelled with [ $\alpha$ -32P]dCTP (3000 Ci/mmol) using the Ready-to-Go dCTP beads (Pharmacia). Northern blot hybridization, brain tissue preparation and *in situ* hybridization are described in Denovan-Wright et al. (1998). The 500 bp cloned insert of pPDE10A annealed to a transcript of approximately 9.5 kb in total RNA isolated from the striatum of ten week-old wild-type mice.

FIG. 2 demonstrates that PDE10A is expressed in the striatum but not the cortex of wild-type mice and the steady-state levels of PDE10A are reduced in 10 week old transgenic HD mice. The differential expression of PDE10A in HD mice was confirmed by northern blot analysis. The cloned insert of pPDE10A was radio-labelled and used as a hybridization probe in northern blot analysis. The northern blot was prepared by size-fractionating total RNA from the striatum and cortex of three individual 10 week-old HD (1, 2 and 3) and wild-type (4, 5 and 6) mice. Following the hybridization of pPDE10A, the radio-label was removed and the blot was subsequently allowed to hybridize with a probe that detects constitutively expressed cyclophilin. The hybridization pattern of the cyclophilin probe is aligned below the northern blot demonstrating that equivalent amount of RNA were present in each lane. The relative mobility of RNA molecular weight standards (RNA ladder, Gibco BRL) are shown on the left of the northern blot.

The hybridization signal of pPDE10A was significantly lower in the RNA samples derived from the striatum of 10 week-old HD mice. No expression of the PDE10A mRNA was detected in the cortical RNA samples derived from either the wild-type or HD mice.

#### EXAMPLE 4 - Sequencing PDE10A

The sequence of the cloned differential display band, pPDE10A, was determined using M13 universal forward and reverse sequencing primers and the T7 sequencing kit (Pharmacia). The 484 bp cDNA fragment did not have sequence similarity to any Genbank entries.

FIG. 3 shows the nucleotide sequence of the cloned PDE10A differential display product,

pPDE10A. The position of the primers used to amplify the fragment are underlined and labelled. The nucleotide sequence and position of oligonucleotide probes 1 and 2 within the pPDE10A sequence are shown.

#### EXAMPLE 5 - Isolation and Characterization of cDNA PDE10A

In order to isolate PDE10A cDNA clones, oligonucleotide probes 1 and 2 were used in 5' and 3' Rapid Amplification of cDNA Ends (RACE) reactions using commercially prepared RACE-ready mouse striatal cDNA (Clontech). Several independent clones were isolated and those that contained the sequence of pPDE10A were selected for further analysis. Each of the 5' RACE clones was identical in sequence over the length that the clones could be aligned.

The difference in length between these clones is a result of termination of the original reverse-transcriptase reaction at different positions along the mRNA. No difference in size or sequence was detected between several 3' RACE clones. The longest 5' RACE clone and one 3' RACE clone were completely sequenced using internal primers. The present inventors were able to isolate a very short clone that extended the 5' RACE clone using an internal primer (probe 3, 5'- CTA TTT CAC AAG AGA CTG ACC AGC CAA TAA ATC TC- 3').

The compiled sequence of the first PDE10A cDNA clone, named cPDE10A-1 is presented in FIG. 10. cPDE10A-1 is 3235 bp in length. The restriction map of cPDE10A-1 is shown in FIG. 11.

The mRNA that hybridized with pPDE10A was approximately 9.5 kilobases in length. In order to obtain PDE10A cDNA clone that was larger than cPDE10-1, the present inventors screened a mouse brain cDNA library. Several clones were identified that hybridized with

the pPDE10 probe. The sequence of the largest of these cDNA clones, cPDE10-2, was determined. The sequence (FIG. 12) was 5753 base pairs in length. The restriction map of cPDE10-2 is shown in FIG. 13.

cPDE10-1 and cPDE10-2 share sequence identity over 2095 bp. However, the 5' 1142 bp of cPDE10-1 and the 5' 1689 bp of cPDE10-2 are unique to each clone. Clone cPDE10-2 extends 1969 bp in the 3' direction compared to cPDE10-1. A schematic showing the regions of sequence identity and the unique sequences of cPDE10-1 and -2 are shown in FIG. 14.

The compiled sequence of the mouse PDE10 cDNA clone, named cPDE10A, is presented in FIG. 15 with RACEs. A further sequence, without RACEs, is shown in FIG. 19. The coding sequence and restriction map of cPDE10A is shown in FIG. 16, and updated at FIG. 17. FIG. 18 is a restriction map of PDE10A. The coding region has a met initiator commencing at nucleotide 257, with a stop codon ending at nucleotide 2596.

PDE10A was found to have extremely high homology with human PDE10s identified by Loughney et al., WO99/42596, the contents of which are incorporated herein by reference.

#### EXAMPLE 6 - Localization of PDE10A in the Brain

In order to identify the coding strand and to localize the transcript in the wild-type mouse brain, two oligonucleotide probes were designed (probe 1, 5'- GAA CAT GTA GCA TAT ACT CCA GAC AAC AGA TCA TAT GG - 3'; probe 2, 5' – CAG CTT CTC CAC AGG AAC ACA GTA ACA AAG AG -3') that were complementary to different regions and

strands of the 484 bp pPDE10A clone. These oligonucleotides were used for *in situ* hybridization analysis. Using high stringency post *in situ* hybridization washes (2 x 30' in 1X SSC @ 58°C, 4 x 15' in 1X SSC @ 58°C, 4 x 15' in 0.5X SSC @ 58°C, 4 x 15' in 0.25X SSC @ 58°C), it was found that oligonucleotide probe 1 annealed with mRNA in the striatum, nucleus accumbens and olfactory tubercle of ten week-old wild-type mice (FIG. 4). The hybridization signal was significantly reduced in the striatum, nucleus accumbens and olfactory tubercle of the 10 week-old HD mice (FIG. 4).

FIG. 5 shows *in situ* hybridization of probe 1 to coronal (top three sections) and saggital (bottom section) 10 week-old wild-type (WT) and HD mouse brain sections. Specific hybridization of the probe was observed in the striatum, nucleus accumbens and olfactory tubercle of wild-type mice. The top three sections represent the distribution of PDE10A throughout the rostral-caudal axis of the striatum.

The *in situ* hybridization results confirmed the northern blot analysis demonstrating, 1) that the expression of PDE10A mRNA was restricted to the striatum, nucleus accumbens and olfactory tubercle and 2) that the levels of PDE10A mRNA were decreased in HD mice compared to the wild-type. The probe did not anneal with mRNA in any other brain nuclei. No hybridization of oligonucleotide probe 2 was observed in any region of the brain in wild-type or HD mice (Fig. 3). Based on this hybridization, the coding strand, complementary to probe 1, of pPDE10A was defined.

**EXAMPLE 7 - Characterization of PDE10**

The *in situ* hybridization using oligonucleotide probe 1 demonstrated that PDE10A mRNA levels in the striatum, nucleus accumbens and olfactory tubercle were decreased in ten week-old HD mice. By ten weeks of age, the HD mice all showed motor symptoms including resting tremor and stereotypic involuntary movements. Moreover, these mice immediately clasped their feet together and curled into a tight ball when picked up by their tails.

As the phenotypic signs are progressive over a number of weeks, the present inventors examined whether the PDE10A transcript was ever expressed in the striatum of the HD mice or whether the steady-state levels of the transcript diminished in the striatum in a course that paralleled the development of the motor disorders. Wild-type and HD mice were sacrificed at 5, 7 and 8 weeks of age and their brains were prepared for *in situ* hybridization analysis using probe 1 (FIG. 5).

FIG. 5 shows the levels of PDE10A mRNA decrease in HD mice over the period of time that the HD mice develop abnormal movements and postures. *In situ* hybridization analysis of coronal and saggital sections of wild-type and HD mouse brain using oligonucleotide probe 1 which is complementary to the coding strand of PDE10A. At 5 weeks of age, before the development of motor symptoms, the HD mice express the PDE10A transcript in the same brain nuclei and at the same relative levels as wild-type mice. The steady-state level PDE10A decreases in the striatum, nucleus accumbens and olfactory tubercle from 5 to 10 weeks in the HD but not wild-type mice. By 9 weeks of age, the HD mice have abnormal

movement and posture. The numbers refer to the age in weeks of the wild-type (WT) and Huntington's (HD) transgenic mice.

None of the mice at these ages had overt motor symptoms. Sections taken throughout the rostral-caudal axis of the striatum showed that PDE10A was expressed in the 5 week-old wild-type and HD mice. The relative hybridization of probe 1 did not change in 5, 7, 8 and 10 week-old wild-type mice. The intensity of the hybridization signal appeared to decrease in the striatum, nucleus accumbens and olfactory tubercle of HD mice from 5 to 10 weeks compared to their wild-type litter mates (FIG. 5).

The levels of PDE10A were significantly reduced by 8 weeks of age in the HD mice, using two *in situ* oligonucleotide probes, one complementary to the 3' UTR, the second complementary to an internal portion of the coding region. The hybridization pattern observed in the wild-type and HD mice was the same for both the probes employed. This analysis demonstrated that there is a reduction in the complete PDE10A mRNA levels during the development of the HD phenotype and not that there was a differential reduction in the PDE10A coding region as compared to the extensive 3' UTR. Moreover, *in situ* hybridization using the PDE10A-specific probe against neurologically normal and HD human brain tissue demonstrated that there was a decrease in PDE10A levels in human HD patients.

One day old wild-type and HD mice were frozen, sectioned on a cryostat and whole mouse sections were prepared for *in situ* hybridization using probe 1. The same high stringency post-hybridization washing conditions were employed for the one day-old mouse body sections as were used for the adult mouse brain sections. Parallel *in situ* hybridization

experiments using the probe 2 were performed in order to determine the level of non-specific signal in the mouse sections. Probe 1 specifically annealed to the developing striatum (FIG. 6).

FIG. 6 demonstrates that PDE10A is expressed in the developing striatum of one day-old wild-type and HD mice. The sections on the left were subjected to *in situ* hybridization using probe 1. Following hybridization, the sections were counter-stained with cresyl violet to visualize the mouse organs. The signal outside the brain was non-specific as probe 2 and other unrelated control oligonucleotide probes all labelled these tissues.

There was no difference in the pattern of hybridization between the one day-old wild-type and HD mice demonstrating that PDE10A was expressed in the developing brain of both wild-type and HD mice.

Following *in situ* hybridization, the sections were covered in autoradiographic emulsion, left in the dark to expose for 4 weeks and then developed and viewed under dark-field microscopy or, after counter-staining the sections with cresyl violet to visualize neuronal cell bodies, under bright-field microscopy. Silver grains were observed to be concentrated in the striatum of the wild-type mice. FIG. 7 shows emulsion autoradiography of mouse brain sections following *in situ* hybridization of probe 1 demonstrated that the PDE10A transcript is expressed in neurons. PDE10A is not homogeneously distributed throughout the mouse striatum. Dark field illumination of the sections after emulsion autoradiography showed that the silver grains were clustered in specific regions of the 10 week old wild-type mouse striatum (A and C). Sections from 10 week old HD mice subjected to identical *in situ* and

emulsion autoradiographic conditions are shown in B and D. The photomicrographs shown in A and B were viewed using the 10X objective (bar represents 100  $\mu\text{m}$ ). The micrographs shown in C and D, were viewed under the 20X objective (bar represents 25  $\mu\text{m}$ ). The insert in panel C is a portion of the section in A and C counter-stained with cresyl violet to visualize the neurons, viewed using the 40X objective under bright field illumination. Note the distribution of the silver grains over some, but not all, of the striatal neurons as well as being concentrated around clusters of neurons. It appeared that the silver grains were absent from fibre tracks within the striatum. It appeared that PDE10A mRNA was not confined to regions close to the nucleus but was dispersed in cellular processes.

Huntingtin with an expanded polyglutamine tract (htt-HD) is expressed in neurons of the brain and body throughout development and during the lifetime of HD patients (The Huntington's Disease Research Collaborative, 1993; Ross, 1995). Transgenic HD mice express a portion of htt-HD and develop a phenotype with many of the symptoms of HD after a period of normal development and growth (Carter et al., 1999; Cha et al., 1998; Mangiarini et al., 1996). Using differential display RT PCR, northern blot and *in situ* hybridization, we have demonstrated that PDE10A mRNA levels decline in the striatum of HD mice. This specific member of the PDE multigene family is highly expressed in the striatum and olfactory tubercle of mice (Soderling et al., 1999) and rats (Fujishige et al., 1999) and in the caudate and putamen of humans (Fujishige et al., 1999; Loughney et al., 1999). The levels of PDE10A were the same in 5 week old wild-type and HD mice. PDE10A mRNA levels then began to decline and were almost undetectable in the striatum and olfactory tubercle by the time the mice reached 8 weeks of age. This time coincides with the onset of overt motor symptoms in the HD mice indicating that the loss of PDE10A in striatal neurons leads to

dysfunction of the nuclei that control movement. The R6/2 mice develop the HD phenotype in the absence of cell death. The decrease in PDE10A mRNA, therefore, is not due to the loss of PDE10A-expressing cells but rather a change in steady-state RNA levels that occurs due to the expression of mutant huntingtin.

The particular isoform that decreases in HD is PDE10A. PDE10A has been cloned from human lung and fetal brain cDNA libraries (Fujishige et al., 1999; Loughney et al., 1999). It appears that the presence of the expanded polyglutamine tract in huntingtin alters gene expression in the striatum, and that this is the mechanism by which only a small group of neurons in the striatum and cortex are rendered vulnerable to this ubiquitously expressed mutant protein.

#### EXAMPLE 8 - PDE10A is Highly Conserved Among Mammalian Species

The oligonucleotide (probe 1) complementary to the coding strand of the PDE10A transcript, was also used as an *in situ* hybridization probe against coronal brain sections derived from adult rats. FIG. 8 shows *in situ* hybridization analysis of adult rat brain sections using oligonucleotide probe 1 complementary to the coding-strand of PDE10A revealed that the pattern of expression of PDE10A is the same in rats and mice. The hybridization conditions used to detect the rat homologue of PDE10A in rat brain tissue differed from those used to detect the transcript in mice only in that the stringency of the post-hybridization washes were reduced.

No hybridization was observed in the rat striatum using the post-hybridization washes

employed following the *in situ* hybridization of mouse brain sections. However, when the stringency of the post-hybridization washes was lowered (2 x 60' in 1X SSC @ 42°C, 2 x 60' in 0.5X SSC @ 42°C, 2 x 60' in 0.25X SSC @ room temperature), the PDE10A oligonucleotide probe specifically labelled the adult rat striatum, nucleus accumbens and olfactory tubercle in a pattern indistinguishable from that observed in mouse brain sections. It appears, therefore, that a transcript which shares nucleotide sequence and expression pattern is present in both mice and rats. The evolutionary conservation of PDE10A suggests that it is important for normal function of the basal ganglia.

By northern blot, Fujishige et al. (1999) demonstrated that PDE10A is expressed in human fetal brain. The homology between mouse and human PDE10A is extremely high (data not shown).

#### EXAMPLE 9 - Analysis of PDE10A in Genomic DNA

Because the transgenic mice employed in this study have a copy of the human HD 5' UTR, exon 1 with expanded CAG repeat and 262 bp of the intron 1 that has been integrated into an undefined locus of the mouse genome, it was possible that the integration event disrupted the PDE10A gene preventing its expression in the HD mouse striatum. Genomic DNA was isolated from wild-type and HD mice and subjected to Southern blot analysis.

Genomic DNA was isolated from wild-type and HD mice and subjected to Southern blot analysis using pPDE10A as a hybridization probe. The size of the *Bam*HI and *Eco*RI fragments that are present in the transgenic R6/2 line that correspond to the insertion of the

human exon 1 gene fragment are 1.9 and 0.8 (*Bam*HI) and 1.9 (*Eco*RI) kb. Analysis of the size of the fragments that hybridized with pPDE10A demonstrated that there was no difference in the size of the hybridizing fragments between the wild-type and HD mice. FIG. 9 shows the genomic DNA restriction fragments that hybridized with pPDE10A were the same in wild-type and HD mice. The size of the hybridizing *Bam*HI and *Eco*RI fragments in each genomic DNA sample is approximately 8 kb and 3 kb, respectively. If the 1.9 kb *Sac*I-*Eco*RI HD gene fragment integrated into the genome within the *Bam*HI and *Eco*RI fragments that hybridized with the DHDM cDNA cloned insert, the sizes of the HD hybridizing bands would have been distinct from those of the wild-type. This Southern blot analysis indicates that the gene encoding PDE10A is present as a single-copy in the mouse genome. The numbers at the left of the blot are the relative mobility of molecular weight markers (1 kb ladder, BioRad).

The PDE10A cDNA has since been cloned using a bioinformatics search strategy involving screening of the expressed sequence tag (EST) database for novel PDE cDNA clones. Independently, the mouse PDE10A cDNA was identified after an EST search for novel PDEs with conserved cGMP binding domains (Soderling et al., 1999). The rat isoforms of PDE10A and splice variants have also been described (Fujishige et al., 1999). Human, mouse and rat PDE10A splice variants differ in their 5' untranslated and part of the 5' coding region but are identical in the coding region when the various splice variants are compared within each species. The human, mouse and rat PDE10A coding regions contain 779, 779 and 794 amino acids, respectively, encoding a protein of approximately 88.5 kDa.

**EXAMPLE 10 - Distribution of PDE10A**

In mouse, PDE10A mRNA was detected in testis and to a much lesser extent in brain but not in heart, spleen, lung, liver, skeletal muscle, kidney, ovary, pancreas, smooth muscle, eye or in total RNA isolated from 7, 11, 15 or 17 day old embryo (Soderling et al., 1999). This data agrees with the PDE10A mRNA pattern of distribution that we observed in wild-type and pre-symptomatic HD mice. In mice, two different size transcripts are detected in northern blots using the coding region as a probe. In mouse testis, the most abundant transcript is approximately 4 kb. A 9.5 kb transcript was also detected in mouse testis. It appears that the most abundant transcript in mouse brain is 9.5 k. Similarly, two sized PDE10A transcripts were observed in rats, however, it appears that, in rat, the 4 kb mRNA is expressed exclusively in testis while the 9.5 kb mRNA is expressed exclusively in brain (Fujishige et al., 1999). Within the brain, the rat PDE10A mRNA was expressed in striatum and olfactory tubercle and not cortex, cerebellum, hippocampus, midbrain or brainstem. In humans, PDE10A is expressed in the caudate, putamen and testis. As was observed in rodents, mRNAs of approximately 4 and 10 kb hybridized with the PDE10A probe. Again, it appears that, although both sized transcripts are present in brain and testis, the larger mRNA is predominant in the caudate and putamen and the smaller sized transcript is present in the testis. Each of the mouse, rat and human PDE10A sequences are not longer than 4 kb and span the coding region and parts of the 3' UTR. The difference in abundance of the short and long transcript in the testis and brain, respectively, in all three species suggest that the 3' UTR functions to provide transcript stability in the brain. As such, we present the complete sequence of the brain-specific transcript of PDE10A derived from mouse.

## EXAMPLE 11 - Modulating Activity of PDE10A Using cGMP-PDE Activity

Cyclic nucleotides are the predominant second messengers that activate cellular signaling pathways (Beavo, 1995; Conti and Jin, 1999). The concentration of intracellular cyclic nucleotides is dependent on their rate of synthesis by adenyl and guanyl synthase, the rate of efflux from the cell, and the rate of degradation. PDEs hydrolyze cAMP and cGMP limiting both the duration and amplitude of the cyclic nucleotide signal (Beavo, 1995; Conti and Jin, 1999). In mammals, PDEs are encoded by a large multigene family. The various PDE family members have tissue-specific patterns of expression (Conti and Jin, 1999). PDEs have also been described in *Caenorhabditis*, *Drosophila*, *Dictyostelium*, *Saccharomyces*, *Candida* and *Vibrio* species demonstrating that this enzyme has been conserved throughout evolution. In mammals, PDEs are encoded by at least 10 gene families, each composed of one or more genes. In addition, numerous splice variants of individual gene family members have been described. These splice variants alter the 5' domain of the protein but share identical nucleotide binding and catalytic domains. The catalytic domain, found in the carboxy-terminus of the enzyme, is ~ 275 amino acids and highly conserved in amino acid sequence in all PDEs. In total, it appears that there are ~50 PDEs expressed within the mammalian body. Some PDEs are expressed in multiple tissues while others have a very limited tissue-specific distribution (Conti and Jin, 1999).

PDE gene families differ with respect to their affinity for cAMP and cGMP and their dependence on calcium and calmodulin (Beavo, 1995). Moreover, some PDEs are inhibited or activated by binding cyclic nucleotides to a non-hydrolytic site. For example, PDE2A has a lower  $K_m$  for cGMP than cAMP although it hydrolysed both nucleotides. The binding of

cGMP to an allosteric activator site within PDE2 enhances the rate of catalysis of cAMP. PDE2 is, therefore, a cGMP-stimulated cGMP and cAMP phosphodiesterase (Beavo, 1995). Conversely, the affinity of PDE4 for cAMP is much greater than for cGMP and PDE4 activity is not affected by cGMP or calmodulin (Beavo, 1995). The differences in substrate preference, modulation of activity and tissue-specific patterns of expression suggest that subtle alterations in the relative levels of cAMP and cGMP mediated through the action of various PDEs lead to a wide range of responses to extracellular signals.

cGMP-PDE activity of compounds is measured using a one-step assay adapted from Wells et al. (Wells, J. N., Baird, C. E., Wu, Y. J. and Hardman, J. G., *Biochim. Biophys. Acta* 384:430 (1975)) and adopted by Beavo et al, U.S. Patent No. 6,037,119. The reaction medium contains 50 mM Tris-HCl, pH 7.5, 5 mM Mg-acetate, 250 ug/ml 5'-Nucleotidase, 1 mM EGTA and 0.15 uM 8-[H<sup>3</sup>] -cGMP. The enzyme used is a human recombinant PDE V (ICOS, Seattle U.S.A.).

Compounds of interest are dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

The IC<sub>50</sub> values for the compounds examined are determined from concentration-response curves using typically concentrations ranging from 10 nM to 10 uM. Tests against other PDE enzymes using standard methodology also show compounds highly selective for the cGMP specific PDE enzyme.

Rat aortic smooth muscle cells (RSMC) are prepared according to Chamley et al. in *Cell Tissue Res.* 177:503-522 (1977) and used between the 10th and 25th passage at confluence in 24-well culture dishes. Culture media is aspirated and replaced with PBS (0.5 ml) containing the compound tested at the appropriate concentration. After 30 minutes at 37° C, particulates guanylate cyclase are stimulated by addition of ANF (100 nM) for 10 minutes. At the end of incubation, the medium is withdrawn and two extractions were performed by addition of 65% ethanol (0.25 ml). The two ethanolic extracts are pooled and evaporated until dryness, using a Speed-vat system. c-GMP was measured after acetylation by scintillation proximity immunoassay (AMERSHAM). The EC<sub>50</sub> values are expressed as the dose giving half of the stimulation at saturating concentrations.

#### EXAMPLE 12 - Selected Modulators of PDE10A Activity

The catalytic domain of PDE10A is most similar in amino acid sequence to PDE5A, PDE2A, PDE6B and PDE6A. These members of the PDE family each contain a cGMP binding sequence that is not observed in other PDE family members. The non-catalytic cGMP binding sites (GAF) domains found in PDE2, 5 and 6 are also found in PDE10. At least for PDE2, this site acts as an allosteric activator for cAMP hydrolytic activity. The GAF domain of PDE10A binds other small molecules that act as allosteric activators. PDE10A is a cAMP and cAMP-inhibited cGMP PDE (Fujishige et al., 1999; Fujishige et al., 1999; Loughney et al., 1999; Soderling et al., 1999).

Attenuation of the production of cAMP, may ameliorate the symptoms of HD and positively affect gene expression. Pharmaceutically acceptable modulators of cAMP include quinpirole,

alloxan, miconazole nitrate, MDL-12330A, and tetracycline derivatives such as demeclocycline and minocycline.

Compounds which are potent and selective modulators of cGMP-specific PDE, and are useful in a variety of therapeutic areas are taught by Daugan et al, U.S. patent No. 5,981,527, PCT publication No. WO 00/15639 to Icos Corporation and PCT publication No. WO 00/15228 to Icos Corporation, which are incorporated herein by reference. Such compounds include, for example:

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,

(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and

(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione.

PDE1B1 is expressed throughout the brain and is most abundant in the striatum, nucleus accumbens and olfactory tubercle (Polli and Kincaid, 1994; Yan et al., 1994). PDE1B is a cGMP, Ca/calmodulin-dependent PDE. Therefore, PDE1B and 10A are both expressed in the majority, but not all, striatal neurons and, it is likely that both genes are co-expressed in a subset of striatal projection neurons. Selective inhibitors for PDE1 include KS-505, IC224,

and SCH 51866. Of these inhibitors, it appears that SCH 51866 has a ten-fold higher Km for PDE1 than PDE10 (Soderling et al., 1999). The non-specific PDE inhibitor IBMX is a potent inhibitor of PDE10A. Dipyridamole and SCH51866 had the highest potency of inhibitors tested on PDE10A activity. Dipyridamole was considered to be a PDE5- and PDE6-specific inhibitor, however, the Km for dipyridamole is 10 times higher for PDE10A than the other PDEs (Soderling et al., 1999). Selective inhibitors of PDE5, 2, 3 and 4 had much greater IC50 for PDE10 (Soderling et al., 1999).

#### EXAMPLE 13 - Clinical use of PDE10A Modulator

A 38 year-old female was admitted to hospital from a long-term care facility due to progressive deterioration of her physical and mental symptoms caused by Huntington's disease. The patient had been diagnosed with Huntington's disease at age 26. Prior to admission to the hospital, she had become increasingly aggressive and uncooperative. Moreover, there appeared to be an increase in the number of psychotic episodes. SPECT showed no abnormality of brain blood flow but MRI showed bilateral caudate atrophy as well as global atrophy of the cerebrum and corpus callosum.

The patient had been stable for a number of years on the antipsychotic haloperidol (3 mg/day). For the last two years, the haloperidol had been replaced by olanzapine (2.5-7.5 mg/day).

Minocycline, a tetracycline derivative, was administered at 50 mg twice daily for 7 days, followed by 100 mg twice daily for 7 days and finally 200 mg twice daily for 5 weeks. After 5 weeks of 200 mg twice daily minocycline administration, there was a mild improvement

compared to the baseline clinical global assessment made at the time of admission. The minocycline treatment was suspended for 7 days. Due to a significant increase in the number of aggressive incidence and decrease in cooperativity, minocycline (200 mg twice daily) treatment was resumed. The patient responded within 3 days to the resumed minocycline-treatment with a return to mild-improvement compared to the baseline clinical global assessment made at the time of admission. Minocycline (200 mg twice daily) treatment will continue indefinitely. The improvement in behaviour and decrease in apparent psychosis has allowed for the transfer of the patient from the acute care facility back to long-term care.

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

## Non-patent Literature Cited

- Atschul, S. F. et al.(1990), *J. Molec. Biol.* 215: 403.
- Babity, J.M., Armstrong, J.N., Plumier, J.-C., Currie, R.W., and Robertson, H.A. (1997a) A novel seizure-induced synaptotagmin gene identified by differential display. *Proc. Nat. Acad. Sci. U.S.A.* 94: 2638-2641.
- Babity, J.M., Newton, R.N., Guido, M.E. and Robertson, H.A. (1997b) The Application Of Differential Display To The Brain: Adaptations For The Study Of Heterogeneous Tissue. *Methods Mol Biol.* 85 (1997) 285-95.
- Barney (1991) in *PCR Methods and Applications*, Aug., Vol. 1(1), page 5.
- Beavo, J. (1995). Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. *Physiol. Rev.* 75, 725-748
- Beretta, S., Robertson, H. and Graybiel, A. (1992) Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. *J. Neurophysiol.* 68, 767-777
- Bennett, D. et al.,(1995) *Journal of Molecular Recognition*, Vol. 8 52-58.
- Berke, J.D., Paletzki, R.F., Aronson, G.J., Hyman, S.E. and Gerfen, C.R. (1998) A Complex Program of Striatal Gene Expression Induced by Dopaminergic Stimulation. *J. Neurosci.* 18: 5301-5310.
- Caine E.D., Hunt R.D., Weingartner H., Ebert M.H. (1978) Huntington's dementia. Clinical and neuropsychological features. *Arch-Gen-Psychiatry.* 35, 377-84.
- Carillo, H., and Lipman, D.(1988), *SIAM J. Applied Math.*, 48: 1073.
- Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnet, S. B., and Morton, A. J. (Apr. 1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. *J Neurosci* 19, 3248-57

- Cha, J.-H. J., Kosinski, C.M., Kerner, J.A., Alsdorf, S.A., Mangiarini, L., Davies, S.W., Penny, John B., Bates, G.P., Young, A.B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. *Proc. Natl. Acad. Sci. USA* 95: 6480-6485.
- Conolly, B. A. (1987) *Nucleic Acids Res.* 15:15(7): 3131.
- Conti, M., and Jin, S. L. (1999). The molecular biology of cyclic nucleotide phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* 63, 1-38
- Crino, P., Khodakhah, K., Becker, K., Ginsberg, S., Hemby, S. and Eberwine, J. (1998) Presence and phosphorylation of transcription factors in developing dendrites. *Proc. Natl. Acad. Sci. USA* 95: 2313-2318
- Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 90, 537-548.
- Davis et al., (1986) Basic Methods in Molecular Biology.
- Denovan-Wright, E.M., Newton, R.A., Armstrong, J.N., Babity, J.M., Robertson, H.A. (1998) Acute administration of cocaine, but not amphetamine, increases the level of synaptotagmin IV mRNA in the dorsal striatum of rat. *Mol. Brain Res.* 55, 350-354.
- Denovan-Wright, E.M., Gilby, K.L., Howlett, S.E. and Robertson, H.A. (1999) Cloning of differentially expressed brain cDNA. In *Differential Display - A Practical Approach*, H.A. Robertson and R.A. Leslie, Eds. Oxford University Press (in press).
- Devereux, J., et al.(1984), *Nucleic Acids Research* 12(1): 387.
- Douglass, J., McKinzie, A.A. and Couceyro, P. (1995) PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. *J.*

*Neurosci.* 15, 2471-2481.

Douglas, J. and Daoud, S. (1996) Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. *Gene* 169, 241-245

Eberwine, J. (1996) Amplification of mRNA populations using aRNA generated from immobilized oligo(dt)-T7 primed cDNA. *Biotechniques* 20: 584-589

Eberwine, J., Yeh, H., Miyashiro, K., Cao, Y., Nair, S., Finnell, R., Zettel, M., Coleman, P., (1992) Analysis of gene expression in single live neurons. *Proc. Natl. Acad. Sci. USA* 89: 3010-3014

Fujishige, K., Kotera, J., Michibata, H., Yuasa, K., Takebayashi, S., Okumura, K., and Omori, K. (June 25, 1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). *J Biol Chem* 274, 18438-45

Glass, M., Faull, R.L.M. and Dragunow, M. (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. *Neuroscience* 56: 523-527

Good et al (1977), *Nucl. Acid Res* 4:2157.

Gribskov, M. and Devereux, J., eds., *Sequence Analysis Primer*, M Stockton Press, New York, 1991.

Griffin, A. M., and Griffin, H. G., eds., *Computer Analysis of Sequence Data, Part I*, Humana Press, New Jersey, 1994.

Group THDCR (1993) A novel gene containing a trinucleotide repeat that is extended and unstable on Huntington's disease chromosomes. *Cell* 72: 971-983.

Hardy, J. and Gwinn-Hardy, K. (1998) Genetic classification of primary neurodegenerative disease. *Science* 282: 1075-1079

Hinnen et al., (1978) *PNAS USA* 75:1929-1933.

- Houbenweyl, (1987) *Methods of Organic Chemistry*, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart.
- Innis, M. A. and D. H. Gelfand (1989), PCR Protocols, A guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Shinsky and T. J. White eds, pp 3-12, Academic Press.
- Johanson, K. et al.(1995), *The Journal of Biological Chemistry*, Vol. 270, No. 16, pp 9459-9471.
- Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y. and Orr, H.T. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in *SCA1* transgenic mice. *Cell* 95: 41-53.
- Lesk, A. M., ed., *Computational Molecular Biology*, Oxford University Press, New York, 1988.
- Liang, P. and Pardee, A.B. (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science* 257: 967-971.
- Livesey, F.J., O'Brien, J.A., Li, M., Smith, A.G., Murphy, L.J. and Hunt, S.P. (1997) A Schwann cell mitogen accompanying regeneration of motor neurons. *Nature* 390: 614-618.
- Livesey, F.J. and Hunt, S.P. (1996) Identifying changes in gene expression in the nervous system: mRNA differential display. *Trends Neurosci.* 19: 84-88
- Loughney, K., Snyder, P. B., Uher, L., Rosman, G. J., Ferguson, K., and Florio, V. A. (June 1999). Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. *Gene* 234, 109-17
- Ludlow, C.L., Connor, N.P., Bassich, C.J. (1987) Speech timing in Parkinson's and Huntington's disease. *Brain-Lang*, 32, 195-214.
- Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C. Lawton,

- M., Trottier, Y., Lehrach, H., Davies, S. W. and Bates, G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87: 493-506.
- Merrifield, (1964), *J. Am. Chem. Assoc.* 85:2149-2154.
- Okano, J., (1988) *Neurochem.* 56: 560.
- Pardee, A.B. (1997) Complete genome expression monitoring: the human race. *Nat. Biotechnol.* 15: 1343-1344
- Polli, J.W., and Kincaid, R. L. (1994). Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. *J. Neurosci.* 14, 1251-1261
- Qu,-D., Ludwig,-D.S., Gammeltoft, S., Piper, M., Pelleymounter, M.A., Cullen, M.J. Mathes, W.F., Przypek, R., Kanarek, R. and Maratos-Flier, E. (1996) A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* 380: 243-247.
- Richfield, E.K. and Herkenham, M. (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. *Ann. Neurol.* 36: 577-584.
- Ross, C.A., (1997) Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? *Neuron* 19: 1147-1150.
- Saiki et al., (1986) *Nature*, 324: 163-166.
- Sambrook, et al, (1989), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear

inclusions. *Cell* 95: 55-66.

Sisodia, S.S., (1998) Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental or beneficial? *Cell* 95: 1-4.

Smith, D. W., ed., *Biocomputing: Informatics and Genome Projects*, Academic Press, New York, 1993.

Soderling, S. H., Bayuga, S. J., and Beavo. J. A. (June 1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. *Proc Natl Acad Sci U S A* 96, 7071-6

von Heinje, G., *Sequence Analysis in Molecular Biology*, Academic Press, 1987.

Yan, C., Bentley, J. K. Sonnenburg, W. K., and Beavo, J. A. (1994). Differential expression of the 61 kDa a 63 kDa calmodulin-dependent phosphodiesterase in the mouse brain. *J. Neurosci.* 14, 973-984

Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B., Ehrenkaufer, R., Jewett, D., Hichwa, R. (1986) PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. *Ann-Neurol.* 20, 296-303.

**We claim:**

1. A composition for treating a CAG repeat disorder comprising a compound which modulates PDE10A expression and a pharmaceutically acceptable carrier.
2. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of: quinpirole, alloxan, miconazole nitrate MDL-12330A, and tetracycline derivatives such as demeclocycline.
3. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of:  
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,  
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,  
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,  
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,  
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione.
4. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of: KS-505, IC224, SCH 51866, IBMX and Dipyridamole.

5. A composition as claimed in any one of claims 1 to 4, wherein said disorder is Huntington's disease.
6. The use of a composition as claimed in any one of claims 1 to 5 for treating a CAG repeat disorder comprising administering said composition to a subject in need of such treatment.
7. The use of a composition of claim 6 for treating Huntington's disease comprising administering said composition to a subject in need of such treatment.
8. A method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of:
  - (a) selecting a control animal having PDE10A and a test animal having PDE10A;
  - (b) treating said test animal using a compound; and,
  - (c) determining the relative quantity of RNA corresponding to PDE10A, as between said animals.
9. A method of claim 8, wherein said animal is a mammal.
10. A method of claim 9, wherein said mammal is a mouse.
11. A method of claim 10, wherein said mouse is R6/2 transgenic mouse.
12. A method of any one of claims 8 to 11, wherein said CAG repeat disorder is Huntington's disease.

13. A method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of:

- (a) selecting a host cell containing PDE10A;
- (b) cloning said host cell and separating said clones into a test group and a control group;
- (c) treating said test group using a compound; and
- (c) determining the relative quantity of RNA corresponding to PDE10A, as between said test group and said control group.

14. A method of claim 13, wherein said CAG repeat disorder is Huntington's disease.

15. A method for detecting the presence of or the predisposition for a CAG repeat disorder, said method comprising determining the level of expression of RNA corresponding to PDE10A in an individual relative to a predetermined control level of expression, wherein a decreased expression of said RNA as compared to said control is indicative of a CAG repeat disorder.

16. A method of claim 15, wherein said CAG repeat disorder is Huntington's disease.

17. A method of claim 15 or 16, wherein said expression is measured by in situ hybridization.

18. A method of claim 15 or 16, wherein said expression is measured using a polymerase chain reaction.

19. A method of claim 15 or 16, wherein said expression is measured using a DNA fingerprinting technique.

HD WT

1 2 3 4 5 6




Figure 1




Figure 2

Figure 3

5'                  11                  21                  31                  41

1 TGTATGGAA TAGTGTCCATATGATCTGTTGTCTGGAGTATATGCTAC  
 1 ACATACCCCTTATCACAAGGTATACTAGACAACAGACCTCATATACGATG  
probe 1

5'                  61                  71                  81                  91

51 ATGTTCATTTACTGTACAAAAACCCAGTCAGCTGATGATGCAAAGCAGT  
 51 TACAAGTAAAATGACATGTTTGCGTACGTCGACTACTACGTTCGTCA

5'                  11                  21                  31                  41

101 CTCTCTGTGTACAGTGCCCCACCTATTTAAAAATCACG TACTTGCCA  
 GAGAGAGACACATGTCACGGGGTGGATAAA TTTTAGTGCATGAACGGGT

5'                  61                  71                  81                  91

151 GAACACTGTGAAACACTTAA CATAAGAACAAACGCAGCGTCTGGATTCTT  
 151 CTTGTGACACTTGTGAATTGTATTCTTGTGCGTCCAGACCTAACAGAA

5'                  11    probe 2    21                  31                  41

201 TCCAAGGAGAGCAGCTTCTCCACAGGAACACAGTAACAAAAGAGGTCCG  
 201 AGGTTCTCTCGTCGAAAGAGGTGTCCTTGTGTCATTGTTCTCCAGGC

5'                  61                  71                  81                  91

251 CCGCCATCCAACCCCAGCCAAGACACCTCAGAGGCCATAGGGACAAACCTC  
 251 GGCGGTAGGTGTGGGTCGGTTCTGTGGAGTCTCCGGTATCCCTGTTGGAG

5'                  11                  21                  31                  41

301 CTTGCTGGCCAACACCTGCTGGAGCAGGGG CACAGGTCCCAGCAACTGAT  
 301 GAACGACCGGTTGTGGACGACCTCGTCCCCGTGTCAGGGTCGTTGACTA

5'                  61                  71                  81                  91


351 CCTCAGTGGATGGGTCTGCAGCCAAAGCCTTAATGGGCTCTCTTTGAAG  
 351 GGAGTCACCTACCCAGACGT CGGTTTCGGAATTACCCGAGAGAAAACCTC

5'                  11                  21                  31                  41

401 GGGAAAGAAAAGAATTCAAGCTTATGATATCCAATATTATTATAGTTGAT  
 401 CCCTTTCTTCTTAAAGTTCGAATACTATAAGTTATAATAATCAACTA

5'                  61                  71                  81                  91

451 GAGTTAGTAAATTCCAAAAAA  
 451 CTCATCATTAAAGTTTTTTTT



WT      HD

Figure 4




Figure 5




Figure 6




Figure 7



Figure 8




Figure 9

Figure 10

5'                  11                  21                  31                  41

1 CACTGAAGCTGGTCCACGTCTATAAACAGGTGACACTGGCTGCAGCAAA  
1 GTGACTTCGACCAGGTGCAGATATTGTCCACTGTGACCGACGTCGTTT

5'                  61                  71                  81                  91

51 AGCCATTGATCCACACAAAATTGATCTTCTATCATCTGGAAATCTGAATT  
51 TCGGTAAGCTAGGTGTGTTAACTAGAAGATAGTAGAACCTAGACTTAA

5'                  11                  21                  31                  41

101 GCAGGGAGGAGCAGTATGTAAGACGACCGTTAACATTCAAGGCATTCCGAAG  
101 CGTCCCTCCTCGTCATACATTCTGCTGGCAAATTAAAGTCCGTAAGGCTTC

5'                  61                  71                  81                  91

151 GCATGAGCGCATGGATTCTGTCACCAAGCGTATAAAAGGACCCCTGGCATT  
151 CGTACTCGCGTACCTAACAGACAGTGGTCGCATATTTCCTGGGACCGTAA

5'                  11                  21                  31                  41

201 GGGAAACCTATGACGGACTGTTTTGCTGTAGAAGTAGGGATTTACAGA  
201 CCCTTGGAATACTGCCTGACAAAAACGACATCTTCATCCCTAAAATGTCT

5'                  61                  71                  81                  91

251 AGTCTCCTTGAATTGCCCCTGCCTGGGCAAGTTTGCTGAGAGGAACCTGCC  
251 TCAGAGGAACCTAACCGGGACGGACCCCGTCAAAACGTCTCCTGGACGG

5'                  11                  21                  31                  41

301 AGAGATTATTTGGCTGGTCAGTCTCTTGTGAAATAGTATCATGTGAGAAA  
301 TCTCTAAATAACCGACCAAGTCAGAGAACACTTTATCATAGTACACTCTT

5'                  61                  71                  81                  91

351 CAGTTGTAGAAAAAAACTATACCTGGGAGACCTTGCAACATTGTTCC  
351 GTCAAACATCTTTTGATATGGACCCCTCTGGAAACGTTGTAACAAGG

5'                  11                  21                  31                  41

401 TTCCATGGGCCAAGACTCAGTTAGGAGGCAAAATCTGCCCGGAATAAAC  
401 AAGGTACCCGGTTCTGAGTCATCCTCCGTATTTAGACGGGCCTTATTG

5'                  61                  71                  81                  91

451 TAGGCCAGGATACAGCCATGTTAGTTAATAATTGGTTTAGAATTAC  
451 ATCCGGTCCTATGTCGGTACAAATCAATTAAACCAAAATCTAAGTG

5'                  11                  21                  31                  41

501 ACAGGCAGGATTGGTTTTTGTGTCTTGGCAAGTGGAGCATATTTAAC  
501 TGTCGGTCCTAACCAAAAAACAGAACCGTTACCTCGTATAAATTGT

5'                  61                  71                  81                  91

551 TACAGGCATGGGAATCCTGCCCTCTTAGCTTTCCCACCCCTTGTCTCAC  
551 ATGTCCGTACCCCTTAGGACGGAGAATCGAAAAGGGTGGGAGAACAGAGTG

5'                  11                  21                  31                  41

601 CAAGTTTTCTCTCCAAAGGTTCCAGGAATTCTCATTAATGGCTGAT  
601 GTTCAAAAAGAGAGGTTCCAAAGGTCTTAAAGAGTAATTACCGACTA

Figure 10 continued

5'                    61                    71                    81                    91

51 GCAAACCTAGTGAATAATAAATGAATATAAAACAATGCTCACCTCACCAAAAA  
651 CGTTGAATCACTTATTATTACTTATTTGTACGAGTGGAGTGGTTTT

5'                    11                    21                    31                    41

51 TTATATTATTGTCAGTCATTGTGATAACACAAATTATCGCAATGGTT  
701 AATATAATAAACGTCACTAAACACTATTGTGTTAAAATAGCGTTACCAA

5'                    61                    71                    81                    91

51 ATTATTTAATTGTGCCACACACTGTGGTTATCTTTGTTGTGGTTGTT  
751 TAATAAATTAAACACCGGTGTGTGACACCAATAGAAAACAACACCAAACAA

5'                    11                    21                    31                    41

51 TCTGAGAAAATGTTCTTGGATATGTAAGTGCCAATACCAGTGTGAAGTAT  
801 AGACTCTTACAAGAACCTATACATTACGGTTATGGTCACACTTCATA

5'                    61                    71                    81                    91

51 TGATCCCGGGCAGCAAAATA CAGCCTAAGGTTGTAAACATCAATTCTAT  
851 ACTAGGGCCCGTCGTTTATGCGGATCCAAACATTGTAGTTAAGATA

5'                    11                    21                    31                    41

51 CTCAGTTCATCAGAGGGCCTGAGAAGCTGCAGTGTAAAGTAAAGT  
901 GAGTCAGTAGTCTCCGGACTCTCGACGCCGTCACATTTCATTCA

5'                    61                    71                    81                    91

51 ATGCTGGGCTGGTGGTGGTCAGCCTCCCGCTGAAGAGTGAACAGTGTG  
951 TACGACCCGACCACCAACAGTCGGAGGGCGGACTTCTCACTGGTCACGAC

5'                    11                    21                    31                    41

51 GCCCGACGGA TCGCTGAGATATTCTCCATAATGGAAAAAAATAGGCAG  
1001 CGGGCTGCCTAGCGACTCTATAAGAGGGTATTACCGTTTTTATCCGTC

5'                    61                    71                    81                    91

51 TTTGATGTGACCTGTTAGTGTGGCTCTCTCTTTGAGCATGTGTTAGC  
1051 AAACTACACTGGACAAATCACACCGAGAGGAGAAAACCTCGTACACAATCG

5'                    11                    21                    31                    41

51 ATTTTTATTTATACATCCAGTGAACCTGCTCTTCCAAGTGTGTTCA  
1101 TAAAAATAAAATATGAGTAGGTCACTTGAGACGAGAAGGTTACACACAAGT

5'                    61                    71                    81                    91

51 TGTATGTGCTAGATATATTAGCACAGCCTGCCTCTGCTGCACACGCCT  
1151 ACATACACGATCTATATAATCGTGGACGGAAAGACGACGTGTGCGGA

5'                    11                    21                    31                    41

51 TAGAGACCCGGCCTTCAATGAGCTTAGCTTGTGCTCTGTTCTGCTCTC  
1201 ATCTCTGGGCCGGAAAGTTACTCGAACACGAGACAAAGACGAGAG

5'                    61                    71                    81                    91

51 TTAGGTCTAAACTATGGTGT CAGTTTAATAGAACAAAAGTATGCATCTT  
1251 AATCCAGATTGATACCAACAGTCAAAATTATCTTGTTCATAACGTAGAA

## Figure 10 continued

5'                  11                  21                  31                  41

1301 GCCTTGGCTTGAGCCTTTCTGTTTCATGCTGACTTCTCCCTTCT  
CGAACCGAACTCGAAAAGCAAAAGTTACGACTGAAGAGGGGAAGAGA

5'                  61                  71                  81                  91

1351 CCTGTGCTCACCTTACCTTCCAGAGTGTAAAGGGACAACTTTAAGGAGG  
GGACACGAGTGGAAATGGAAAGGTCTCACATTCCCTGTTGAAAATTCCCTCC

5'                  11                  21                  31                  41

1401 CGTGTCCCTGGTAGGGCATCCCTGTTCAC CAGGTGCCTGTCATCACCCCC  
GCACAGGGACCACATCCCCTAGGGACAAGTGGTCCACGGACAGTAGTAGTGGGG

5'                  61                  71                  81                  91

1451 ACTTGACTGACATCTACCCCTGGTACTATGGGTTCTTGTGTTAGGG  
TGAAC TGACTGTAGATGGGACCACTGATAACCAAGGAGAACAAACATCCC

5'                  11                  21                  31                  41

1501 AACGGTGGCTCCAGGTGGAGGCATCAATCTGTTGGGTTCTGGTCCCGGC  
TTGCCACCGAGGTCCACCTCCGTAGTTAGACAACCCAAGACCAAGGGCCG

5'                  61                  71                  81                  91

1551 TGCCTTTGGTTTGAAAGTCTCTCTGTATATTCTAC CCTGCATTG  
ACGGAAACCAAAACTTCAGAGAGACATATAAGGATGGACGTAAAC

5'                  11                  21                  31                  41

1601 CTTTGTGTGGTGCTGATGCTGTGCGCAGTAGGATTCTGGATGACTCTCC  
GAAACACACCACGACTACGACACGCGTCATCCTAAGAACCTACTGAGAGG

5'                  61                  71                  81                  91

1651 ATCAGTCACAGACTCCCCCTGTTGCAAAGTGTCAAGGCTGACTCGACAGTC  
TAGTCAGTGTCTGAGGGGGACAACGTTCAAGTCCGACTGAGCTGTCAG

5'                  11                  21                  31                  41

1701 ACCGTAAAATCTGAGTCAGTCACACACAGGCTGTCAGGCCACGGCTTCCAC  
TGGCATTAGACTCAGTCAGTGTGTCCGACAGTCGGTGCCGAAGGTG

5'                  61                  71                  81                  91

1751 TTGCATGGCTATTCTATTTCACACGTGAGTTCTGTTGCTGGCTGGCTG  
AACGTACCGATAAGATAAAAGTGTGCACTCAAAGACAACGACCGACCGAC

5'                  11                  21                  31                  41

1801 ACTGGCATTATCTATGCTAAGTGAAATCAGGAGTGCACGGCCAGCAGAGCCCA  
TGACCGTAATAGATACGATTCAACTTAGTCCTCACGGGTGCTCGGGT

5'                  61                  71                  81                  91

1851 TCATTCTCACTGTCTTGAAACAAAGCTGTACGGTTTGATCGATGAACGT  
AGTAAGAGTGACAGAAACTTGTGTTGACATGCCAAACTAGCTACTTGCA

5'                  11                  21                  31                  41

1901 ATTTAAAGCATTTCATGCAA TGACAAAGTGTCACTAGTGGAAAGGCAGGC  
TAAATTCGTAAAGTACGTTACTGTTCACGAGTCATCACCTCCGTCCG

Figure 10 continued

5'                  61                  71                  81                  91

1951 TGTGACCAGT CTGCCTGCTC CCTTA CTTACTATAA TTGTGAGGAT TTGTTACTGG  
ACACTGGTCAGACGGACGAGGAATGATATTAAACACTCCTAAACAATGACC

5'                  11                  21                  31                  41

2001 AACAGTACATGGAGGCCCTGACCTTGTGGGG GCACAGGGTGGAACCTTAGC  
TTGTCATGTACCTCCGGACTGGAACACCCCCCGTGTCCCACCTTGGAAATCG

5'                  61                  71                  81                  91

2051 TGAATATAGT GTGTGTCTCAAGAGGAAGTCAGGGTACTAG CTCAGTGCTC  
ACTTATATCACACACAGTTCTCCTTCAGTCCCATGATCGAGTCACGAG

5'                  11                  21                  31                  41

2101 AATCTCCAGG TACTATATACATTGCCC GTTTATCTCTAATGTGAAA  
TTAGAGGTCCATGATATATGTAAACGGG CAAAATAGAGATTACACTTT

5'                  61                  71                  81                  91

2151 TAAATCCCCAACACTTGT TATCGTGTAG CGTACCTAAAAGACTATTCT  
ATTTAGGGTTTGTGAACAAATAGCACATCGCATGGATTTCTGATAAGA

5'                  11                  21                  31                  41

2201 ATTATGGGTGTCCCCACTTTCTGGTTGGTCACCCCCGAT CCCCCGGTCT  
TAATACCCACAGGGTGAAAGAACCAAACCAAGTGGGCTAGGGGCCAGA

5'                  61                  71                  81                  91

2251 TCTGCTGTATCTAGAACAGTGACTATAAATGATGTATGGGAATAGTGT  
AGACGACATAGATCTGTCACTGATATTACTACATACCCCTATCACAAA

5'                  11                  21                  31                  41

2301 CCATATGATCTGTTGTCTGGAGTATATGCTACATGTTCAATTACTGTACA  
GGTATACTAGACAAACAGACCTCATATACGA TGTACAAGTTAATGACATGT

5'                  61                  71                  81                  91

2351 AAAACCCAGTGCAGCTGATGATGCAAAGCAGTCTCTCTGTGTACAGTG  
TTTGGGTCA CGTCGACTACTACGTTCGT CAGAGAGAGAACATGTCAC

5'                  11                  21                  31                  41

2401 CCCCCACCTATTAAAAATCACGTACAASCC CAGAACACTGTGAAACACTT  
GGGGTGGATAAAATTAGTGCATGTTGGGTCTTGTGACACTTTGTGAA

5'                  61                  71                  81                  91

2451 AACATAAGAACAAACGCAGCGTCTGGATCTTCCAAGGAGAGCAGCTT  
TTGTATTCTGTTGCGTCG CAGACCTAAGAAAGGTTCCCTCGTCGAAA

5'                  11                  21                  31                  41

2501 CTCCACAGGAACACAGTAACAAAAGAGGTCCGCCCATCCACACCCAGC  
GAGGTGTCCCTGTGTCAATTGTTTCTCCAGGCGGGTAGGTGTGGTCG

5'                  61                  71                  81                  91

2551 CAAGACACCTCAGAGGCCATAGGGACAACCTCCTTGCTGGCCAACACCTG  
GTTCTGTGGAGTCTCCGGTATCCCTGTTGGAGGAACGACCGGTTGTGGAC

Figure 10 continued

5'                    11                21                31                41  
 2601 CTGGAGCAGGGCACAGGTCCCCAGCACTGATCCTCAGTGGATGGGTCCG  
 GACCTCGTCCCCGTCCAGGGTCGTTGACTAGGAGTCACCTACCCAGGC

5'                    61                71                81                91  
 2651 CAGTCAAAGCCTAATGGGCTCTCTTTGAAGGGGAAAGAAAGAATTCA  
 GTCAGTTCGGAATTACCGAGAGAAAACCTCCCCTTCTTTCTAAAGT

5'                    11                21                31                41  
 2701 AGCTTATGATATCCAACATTATTATAGTTGATGAGTTAGTAATTCCAAA  
 TCGAATACTATAGGTTGTAATAATATCAACTACTCAATTAAAGGTTT

5'                    61                71                81                91  
 2751 AAAAAAGATGATTTATATGTATGACATAAAAAAAATCTTGTAAAGTG  
 TTTTTTCTACTAAATATACTACTGTATTTTTAGAACATTTCAC

5'                    11                21                31                41  
 2801 CGCAAGTGCAATAATTAAAGAGGTCTTATCTTGCAATTATAATTATA  
 GCGTTCACGTTATTAAATTCTCCAGAATAGAACGTAAATTAAAT

5'                    61                71                81                91  
 2851 AATATTGTACATGTGTGTAATTTCATGTATTCAATTGCAGTCTTGTA  
 TTATAACATGACACACATTAAAAGTACAATAGAACGTCAAGAACAT

5'                    11                21                31                41  
 2901 TTTAAAAAAACTTACTGTTATGTTGTATAATAGAACATTAAATCATTAA  
 AAATTTTTGAAATGACAATACAAACATAATTATCTGTAATTAGTAAAT

5'                    61                71                81                91  
 2951 TTATAACTCAGACAAGGTGAAATAATTCAATTCAAACAGCCAGTAT  
 AATATTGAGTCTGTTCCACATTATTAAAGTATTAGTTGTCGGTCATA

5'                    11                21                31                41  
 3001 ATATGCATATATGGGTGTTACATTGCAAAATCTCTATCTTGTCTATT  
 TATACGTATATACCCACAATGTAACGTTTAGAGATAGAACAGATAA

5'                    61                71                81                91  
 3051 CACATGCTTAAAGAAGTAAGAAATCTTTGTTGGATATGTAATTACATA  
 GTGTACGAATTCTTCATTCTTAGAAAACACCTACATTAATATGTAT

5'                    11                21                31                41  
 3101 TAAAGTATATATATGTATGATACATGAAATATATTAGAAATGTTCAT  
 ATTTCATATATATACATACTATGTAATTATAAATCTTACAAGTA

5'                    61                71                81                91  
 3151 AATTTTAATGGATATTCTTGGTGTGAATAATTGAATACAAACATTAA  
 TTAAAATTACCTATAAGAAACCACACTTAACTTATGTTGTAAGGAA

5'                    11                21                31                41  
 3201 AATGAAAAAAAAAAAAAAACAAAAAA  
 TTACTTT




Figure 11  
3236 bp

Figure 12

5'                    11                    21                    31                    41

1 AAGTGTAAATAAAATAACATCTAATAAAAAAAATTACATACCATAGAGG  
1 TTCACATTTATTTATTTGTAGATTATTTTTAATGTATGGTATCTCC

5'                    61                    71                    81                    91

51 AACAAAGATAATACTGCCAACCTCATACCCTCCAGCGTATAGTGGTGA  
51 TTGTTCTATTAAAGACGGGTGAAAGTATGGGAGGTGCGATATCACAACTC

5'                    11                    21                    31                    41

101 GTTTGGTCTGTTGCTGTATTGTAATGTAATGTTAAATTCTCTACCTGA  
CAAACCAGACAAACGACACATAACATTACATTACAATTAAAGAGATGGACT

5'                    61                    71                    81                    91

151 AGGTCTAGGCCTACAAGTGAATTCTCATGTTTATAGAGTTTGTTGTGCA  
151 TCCAGATCCGATGTTCACTTAAGAGTACAAATATCTCAAAACACACGT

5'                    11                    21                    31                    41

201 AACCTTGTTCTTAATTAAAACTATGGTTAAAAAACAAAACAAAACACTGG  
201 TTGGAACAAAGGAATTAAATTGGATACCAATTGGTTTGTTTGACC

5'                    61                    71                    81                    91

251 CTACAGCCAACTAACTGAAGGGGGTACCTTGTGAAGGGGTGGAAAAGAG  
251 GATGTCGGTTATTGACTTCCCCAATGGAACAACCTCCCCACCTTTCTC

5'                    11                    21                    31                    41

301 AGAGGAGGAAGGAAGGGAGTTCAAGAGAAGGAGAAGAACAAAGGGAGAGGA  
301 TCTCCTCCTCTTCCCTCAAGTTCTCTTGTCTCCTCTCCT

5'                    61                    71                    81                    91

351 GGAAGCTGCCACGAGGGGAGATGGGCCATGAGAACTTGGCCAGGAGAAAT  
351 CCTTCGACGGTGCTCCCTACTACCCGGTACTCTTGAACCGGTCTCTTA

5'                    11                    21                    31                    41

401 AGCCAGTATCTGGAGTACACCACTGAGGAGGTAGCCAGGCTAGCAGTTAG  
401 TCGGTCACTAGACCTCATGTTGACTCCTCCATCGGTCCATCGTCAATC

5'                    61                    71                    81                    91

451 AAGAGTAGATTAGGGTTATTTCCTCCACTCCACATAGTTATCAAAGC  
451 TTCTCATCTAATCCCCAATAAAAGGGGTGAGGTGTATCAATAGTTCG

5'                    11                    21                    31                    41

501 CAAATAAAATAACCATAGTCTGAGTCTCATCTATTTGTAAGCTAGTTGGG  
501 GTTTATTTATGGTATCAGACTCAGAGTAGATAAACATTGATCAACCC

5'                    61                    71                    81                    91

551 TATAAGATTAATTGGCTGTACTACAGTTAGATTCTAACATAGGAACCT  
551 ATATTCTAAATTAAACCGACATGATGTCAAATCTAAAGATTGTATCCTGAA

5'                    11                    21                    31                    41

601 ATCAAAAAACTTGCTCAAACAAGAACATGCTGACAATATTAAAGATTGATT  
601 TAGTTTTGAACGAGTTGTTCTGTACGACTGTATAAAATTACTAA

Figure 12 continued

5'                    61                    71                    81                    91

651 ATTTATATTGTTGCACTTCTAAAGTTCTCTAAATGTTCCATGGTCA  
      TAAATATAACAAACGTGAAAGATTCAAAGAAGATTACAAGGTACCAAGT

5'                    11                    21                    31                    41

701 AATTAaaaaaaTATACATATTGGCTATTAAAATCGTCTAAGTGGGGCTGGA  
      TTAATTTTTATATGTATAACCGATAATTAAAGCAGATTCACCCCCGACCT

5'                    61                    71                    81                    91

751 GAGATAGCTCAGAGGTTAACAGCACTGACTGCTCTCCAGAGGTCTGAG  
      CTCTATCGAGTCTCCAATTCTCGTACTGACGAGAAGGTCTCCAGGACTC

5'                    11                    21                    31                    41

801 TTCAATTCCCAGCGACCACATGGTGGCTCACAGCCATCTGTAATAGATAG  
      AAGTTAAGGGTCGCTGGTGTACCACCGAGTGTGGTAGACATTATCTATC

5'                    61                    71                    81                    91

851 GATCTGACGCCCTCTTCTGGAGTGTCTGAAGACAGCTACAATGTACTCAT  
      CTAGACTGCGGGAGAACCTCACAGACTCTGTCGATGTTACATGAGTA

5'                    11                    21                    31                    41

901 ATATATTAAAATAATAATATTAGAAAATTCTCTAAGTGTATCATTATA  
      TATATAATTATTATTATAATCTTTAAGAAGATTACATAGTAAATAT

5'                    61                    71                    81                    91

951 GAATATTAAATATATAAGTAAATGCCTCAGGAAATATAAACTTGGAATT  
      CTTATAAAATTATATATTCAATTACGGAGTCCTTATATTGAACCTTAA

5'                    11                    21                    31                    41

1001 AAATCAAAGAACATTGAGTAGTGGGCCACAAAAAATGTGTACCAAGGGG  
      TTTAGTTCTTGAAGTACTCATCACCCGGTGTACACATGGTCCCC

5'                    61                    71                    81                    91

1051 AAGACCGGAGGGAGGGGAGAAGGAAGGGATGGAGATAGAATTGGCCTCT  
      TTCTGGCCTCCCTCCCTCTTCCTCCCTACCTCTATCTAAAACGGAGA

5'                    11                    21                    31                    41

1101 GCATTCTGGCTGGCACAGGTATAATGCTGTGGGAATTGGGAAACTAC  
      CGTAAGGAACCCGACCGTGTCCATATTACGACACCCCTAACCCGGATG

5'                    61                    71                    81                    91

1151 AAGGAAGCTGCAAAGCTGGCGGAACTCGTTCCGCAAGCTGGGCTCATC  
      TTCCTTCGACGTTGACCCGCCTTGAGCAAAGGCGTTGACCGAGTAG

5'                    11                    21                    31                    41

1201 TAAGTGTCCATGCATGGCTGCCACACTGCGAGTGAACTTAAAACATTGT  
      ATTACACAGGTACGTACCGACGGTGTGACGTCACTTGAAATTGTAAACA

5'                    61                    71                    81                    91

1251 GTTCCAGAGATGTAGAGATGCTCACAATAGTACAAAGGCGGGAGGG  
      CAAGGTCTACATCTACGAGTGTATCATGTTCCGCCCTCCCTCCA

Figure 12 continued

5'                  11                  21                  31                  41

1301 ATTTCCAGACTAAGAGGAAGAAAAACCATTGCTGATTAAAACATCTGCATA  
TAAAGGTCTGATTCTCCTCTTTGGTAACGACTAATTGTAGACGTAT

5'                  61                  71                  81                  91

1351 TGAGCGCCCCCACCTCCATACACACACACAACACACACACACACACACA  
ACTCGCGGGGGTGGAGGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT

5'                  11                  21                  31                  41

1401 CAACCAAACAGAACAAATACACATGCATGTCTACAGCCTGCAGGAACAAA  
GTTGGTTGTCTGTTATGTGTACGTACAGATGTCGGACGTCCCTGTT

5'                  61                  71                  81                  91

1451 ATGGTATGTCTGTGAGGAACCAGGAGATGCACAGGTCTAACCTCTGTCT  
TACCATACAGACACTCCTGGCCTCTACGTGTCCAGGATTGGAGACAGA

5'                  11                  21                  31                  41

1501 CCTACAAAGCCCTGAAGTCTGGTCAGGGTCAAATGTACAAAAGCAGGCTAA  
GGATGTTCGGGACTTCAGACCAAGTCCCAGTTACATGTTCGTCCGATT

5'                  61                  71                  81                  91

1551 GGAAGCTGTTAGTGAAAGATTTTTTCTTCAACTCTAGGAACAAACCTAT  
CCTTCGACAAATCACTTCTAAAAAAAGAAGTTGAGATCCTGTTGGATA

5'                  11                  21                  31                  41

1601 TTCTAGGATTGGAGAGTCTCAGGAGGAAACATTCAAGAACACTGATGC  
AAGGATCCTAAACCTCTCACGAGTCCTCTTGTAAAGTCTGTTGACTACG

5'                  61                  71                  81                  91

1651 TCTCTGTGTACCCCAGATTCAAGGTATTGGGGTAGTTAGTTGTGCTCATGT  
AGAGACACATGGGGTCTAAGTCCATAACCCCATCAATCAAACCGAGTACA

5'                  11                  21                  31                  41

1701 ATGTGCTAGATATATTAGCAAGCCTGCCTCTGCTGCACAAACGCCTAG  
TACACGATCTATATAATCGTGTGGACCGAAGACGACGTGTTGGAAATC

5'                  61                  71                  81                  91

1751 AGACCCGGCCCTTCAATGAGCTTAGCTTGTGCTCTGTTCTGCTCTCTTA  
TCTGGGCCGGAAAGTTACTCGAATCGAACACGAGACAAAGACGAGAGAAAT

5'                  11                  21                  31                  41

1801 GGTCTAAACTATGGTGTCAAGTTTAATAGAACAAAAGTATGCATCTGCC  
CCAGATTGA TACCACAGTCAAAATTATCTGTTTCATA CGTAGAACGG

5'                  61                  71                  81                  91

1851 TTGGCTTGAGCCTTTCTGTTCAATGCTGACTCTCCCTTCTCTCCT  
AACCGAAACTCGGAAAAGCAAAAGTTACGACTGAAGAGGGAAAGAGAGGA

5'                  11                  21                  31                  41

1901 GTGCTCACCTACCTTCCAGAGTGTAAAGGGACAACCTTTAAGGAGGGCGT  
CACGAGTGGAAATGGAAAGGTCTCACATTCCCTGTTGAAAATTCCTCCGCA

Figure 12 continued

5' 61 71 81 91  
 1951 GTCCCTGGTAGGGCATCCCTGTTACCAAGGTGCCTGTCATCACCCCCACT  
 CAGGGACCATCCCCGTAGGGACAAGTGGTCACGGACAGTAGTGGGTGA

5' 11 21 31 41  
 2001 TGACTGACATCTACCCCTGGTGACTATGGGTTCCTCTGTTGTAGGGAAC  
 ACTGACTGTAGATGGGACCACTGATAACCCAAGGAGAACAAACATCCCTG

5' 61 71 81 91  
 2051 GGTGGCTCCAGGTGGAGGCATCAATCTGTTGGTTCTGGTTCCCGGCTGC  
 CCACCGAGGTCCACCTCCGTAGTTAGACAAACCAAGACCAAGGGCCGACG

5' 11 21 31 41  
 2101 CTTTGGTTTGAAAGTCTCTCTCTGTATAATTCCTACCCCTGCATTGCTT  
 GAAACCAAAACTTCAGAGAAGAGACATATAAGGATGGGACGTAAACGAA

5' 61 71 81 91  
 2151 TGTGTGGTGTGATGCTGTGCGCAGCAGGAATTCTGGATGACTCTCCATC  
 ACACACCACGACTACGACACGCGTCGTCTAACAGAACCTACTTGAGAGGTAG

5' 11 21 31 41  
 2201 AGTCACAGACTCCCCCTGTTGCAAAGTGTCAAGGCTGACTCGACAGTCACC  
 TCAGTGTCTGAGGGGGACAACGTTCACAGTCCGACTGAGCTGTCAGTGG

5' 61 71 81 91  
 2251 GTAAAATCTGAGTCAGTCACACACAGGCTGTCAGGCCACGGCTTCCACTTG  
 CATTAGACTCAGTCAGTGTGTCCGACAGTCGGTGCAGGTAAC

5' 11 21 31 41  
 2301 CATGGCTATTCTATTTCACACGTGAGTTCTGTTGCTGGCTGGCTGACT  
 GTACCGATAAGATAAAAGTGTGCACTCAAAAGACAAACGACCGACCGACTGA

5' 61 71 81 91  
 2351 GGCATTATCTATGCTAAGTTGAAATCAGGGGTGCCAGCAGAGCCCACATCA  
 CCGTAATAGATACGATTCAACTTTAGTCCCACGGGTGCTCTGGGTAGT

5' 11 21 31 41  
 2401 TTCTCACTGTCTTGAAACAAAGCTGTACGGTTGATCGATGAACGTATT  
 AAGAGTGCAGAAACTTTGTTCGACATGCAAACACTAGCTACTTGCATAA

5' 61 71 81 91  
 2451 TAAAGCATTCTATGCAATGACAAAGTGTCAAGTAGTGGAGGCAGGGCTGT  
 ATTCGTAAGTACGTTACTGTTCACGAGTCATCACCTTCCGTCCGACA

5' 11 21 31 41  
 2501 GACCAGTCTGCCTGCTCCTTACTATAATTGTGAGGATTGTTACTGGAAC  
 CTGGTCAGACGGACGAGGAATGATATTAAACACTCCTAAACATGACCTG

5' 61 71 81 91  
 2551 AGTACATGGAGGCCTGACCTTGTGGGGGCA CAGGGTGGAACCTTAGCTGA  
 TCATGTACCTCCGGACTGGAACACCCCCGTGTCCCACCTTGGAAATCGACT

## Figure 12 continued

5'                  11                  21                  31                  41

ATATAGTGTG TGTCTCAAGAGGAAGTCAGGGTACTAGCTCAGTGCTCAAT  
2601 TATATCACACACAGAGTTCTCCTTCAGTCCCATGATCGAGTCACGAGTTA

5'                  61                  71                  81                  91

CTCCAGGTACTATATATACATTGCCCGTTTATCTCTAA TGTGAAATAA  
2651 GAGGTCCATGATATATATGTAAACGGGAAAATAGAGATTACACTTTATT

5'                  11                  21                  31                  41

ATCCCCAACACTGTTATCGTGTAGCGTACCTAAAAGACTATTCTATT  
2701 TAGGGGTTTG TGAACAAATAGCACATCGCATGGATTTCTGATAAGATAA

5'                  61                  71                  81                  91

ATGGGTGTCCCCACTTCTGGTTGGTCACCCCGATCCC CCGGTCTTCT  
2751 TACCCACAGGGGTGAAAGAACAAACCAGTGGGGCTAGGGGGCCAGAAGA

5'                  11                  21                  31                  41

GCTGTATCTAGAACAGTGACTATAAATGATGTATGGGAATAGTGTTC  
2801 CGACATAGATCTGTCACTGATATTACTACATACCCCTATCACAAAGGT

5'                  61                  71                  81                  91

TATGATCTGTTGTCTGGAGTATATGCTACATGTTCTTA CTGTACAAAAA  
2851 ATACTAGACAACAGACCTCA TATACGATGTACAAGTAAATGACATGTTT

5'                  11                  21                  31                  41

ACCCAGTGCAGCTGATGATGCAAAGCAGTCCTCTCTGTG TACAGTGCC  
2901 TGGGTACGT CGACTACTACGTTCGTAGAGAGAGACACATGTCACGGG

5'                  61                  71                  81                  91

CACCTATTTAAAAATCACGTACTTGCCCAGAACACTGTGAAACACTTAAC  
2951 GTGGATAAAATTAGTGCATGAACGGGTCTTGTGACACTTTGTGAATTG

5'                  11                  21                  31                  41

ATAAGAACAAACGCAGCGCTGGATTCTTCCAAGGAGAG CAGCTTCTC  
3001 TATTCTGTTGCGTCGCAGACCTAACGAAAGGTCCTCTCGTCGAAAGAG

5'                  61                  71                  81                  91

CACAGGAACACAGTAACAAAAGAGGTCCGC CGCCATCCACACCCAGCCAA  
3051 GTGTCCTTGTGTCATTGTTCTCCAGGCGCGGTAGGTG TGGGTGGTT

5'                  11                  21                  31                  41

GACACCTCAGAGGCCATAGGGACAAACCTCCTGCTGGCCAACACCTGCTG  
3101 CTGTGGAGTCTCCGGTATCCCTGTTGGAGGAACGACCGTTGTGGACGAC

5'                  61                  71                  81                  91

GAGCAGGGGCACAGGTCCAGCAACTGATCCTCAGTGGATGGGTCTGCAG  
3151 CTCGTCCCCGTGTCAGGGTCTGACTAGGAGTCACCTACCCAGACGTC

5'                  11                  21                  31                  41

CCAAAGCCTTAATGGGCTCTTTGAAGGGGAAAGAAAGAATTCAAGC  
3201 GGTTTCGGAATTACCGAGAGAAAACCTCCCTTCTTCTAAAGTCG

Figure 12 continued

5' 61 71 81 91  
 TTATGATATC CAATATTATTAGTTGATGAGTTAGTAAATTCCAAAAAA  
 3251 AATACTATAGGTATAATAATATCAACTACTCAATCATTAAAGGTTTTT  
 5' 11 21 31 41  
 AAAAGATGATTTATATGTA TGACATAAAAAAAATCTTG TAAAGTGC  
 3301 TTTCTACTAAAATACATACACTGTATTTTTAGAACATTTCACGCG  
 5' 61 71 81 91  
 AAGTGCAATAATTAAAGAGGTCTTATCTTG CATTATAAATTATAAAT  
 3351 TTCACGTTATTAAATTCTCCAGAATAGAAACGTAAATTAAATTTA  
 5' 11 21 31 41  
 ATTGTACATGTGTAAATTTTCATGTATT CATTGCAGTCTTG TATT  
 3401 TAACATGTACACACATTAAAAGTACATAAGTAAACGTCA  
 5' 61 71 81 91  
 AAAAAAACTTACTGTTATG TTTGTATAATAGAACATTAACTATT  
 3451 TTTTTTGAAATGACAATACAAACATATT CTTGTAAATTAGTAAATAAT  
 5' 11 21 31 41  
 TAACTCAGACAAAGGTGAAATTCAAACAGCCAGTATA  
 3501 ATTGAGTCTGTTCCACATTATTAAAGTATTAAAGTTGTCGGTC  
 5' 61 71 81 91  
 TGCATATATGGTGTACATTGCAAAATCTCATCTTGTTCTATT  
 3551 ACGTATATACCCACAATGTAACGTTTAGAGATAGAAACAAGATAAGT  
 5' 11 21 31 41  
 ATGCTTAAAGAAGTAAGAAATCTTTGTGGATATGTAATTACATATAA  
 3601 TACGAATTCTTCATTCTTAGAAAACACCTATAACATTAAATGT  
 5' 61 71 81 91  
 AGTATATATATATGTATGATACATGAAATAATTAGAAAATGTT  
 3651 TCATATATATACATACTATGTACTTATATAAATCTTACAAGTATT  
 5' 11 21 31 41  
 TTTAATGGATATTCTTGGTGTGAATAATTGAATACACATTAAAAT  
 3701 AAATTACCTATAAGAAACCAACTTATTAACTTATGTTAAAATTTA  
 5' 61 71 81 91  
 AAAAAAAAAAAAAAAAAAAAAAAATTTTTTTTTTTTTTTTT  
 3751 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
 5' 11 21 31 41  
 TTATTCAGAGATTAAAGACACTAGATCTTAAACCTTGAA GGGCAGGCAA  
 3801 AATAAGGTCTTAATTCTGTGATCTAGAAATTGGAACCTTCCC  
 5' 61 71 81 91  
 GAGGTGGCAATGCTGCAA CATAGAAGTCAGGGACCATT  
 3851 CTCCAGCCGTTACGACAGTTGTATCTCAGTCCCTGGTAAAGAAGAACT

Figure 12 continued

5'                    11                    21                    31                    41

3901 ACATGCAGTCACTTCCCTGATTGCTCTTCACATCCTCAAGGCTCCGGAAAT  
TGTACGTCAGTGAAAGGACTAACGAGAAGTAGGAGTTCCGAGGCCTTA

5'                    61                    71                    81                    91

3951 TCCGGGGGTGTTGGGGCTTGATCTCAGGACTCTGGAGGCAGAAGCAGG  
AGGCCACACCCACCCGAAACTAGAGTCCTGAGACCTCCGTCTCGTCC

5'                    11                    21                    31                    41

4001 CAGATCTCTGTGAATATGAGGCCAGCCTGCACACAGAGCTCCAGACC  
GTCTAGAGACACTTATACTCCGGTCGGACGTGATGTGTCTCGAGGTCTGG

5'                    61                    71                    81                    91

4051 AGTCATGGCTACATCATGAAACCTGTCTCAAAAAGAAAAATAAAACTGT  
TCAGTACCGATGTAGTACTTGGGACAGAGTTTTCTTTATTTTGACA

5'                    11                    21                    31                    41

4101 TGTGTTCTACCATAGTGTAAACTCAGAGTCTGAGTAATGTCGGGCTGA  
ACACAAAGATGGTATCACATTGAGTCTCAGACTCATTACAGCCCCACT

5'                    61                    71                    81                    91

4151 CATGCTCGGGTGTTAACATACCTTCAGCTTGACGAGGCCTGAACAGT  
GTACGAGCCCACAAATTGTATGGAAGTCGAAACTGCTCCCGACTTGTCA

5'                    11                    21                    31                    41

4201 CAAAGTCTGGCCTGGGAGCGGTGGCTGTGTTGTGCTCAAGTCCACCG  
GTTTCAGACCGGAACCCCTCGCCACCGACAACACAGAGTTCAGGTGGC

5'                    61                    71                    81                    91

4251 TGAAATCCTGATTGTGAATTGGACAACCGTGTCTTCTTCTTGTGCT  
ACTTTAGGACTAACACTAAACCTGTTGGCACAGGAAGAACCGGAAG

5'                    11                    21                    31                    41

4301 CATGCAACCTCCAACCTCATGTTGGTCATTGTTGCAAAACACTGTGTGAT  
GTACGTTGGAGGTTGAAGTACAACCGTAAACAGTTTGACACACTA

5'                    61                    71                    81                    91

4351 GTTTTATCAATATACTGCCATTCCACATATGTAGAGATGTAGTCTGCCT  
CAAAAATAGTTATATGACGGTAAGGTGTACATCTACATCAGACGGA

5'                    11                    21                    31                    41

4401 GGCTTCCTTCTTTAGCCAATCGAATGCTCTGATCATGCCCTCAATC  
CCGAAAGGAAAGAAATCGGTTAGCTACGAGAACTAGTACGGGAGTTAG

5'                    61                    71                    81                    91

4451 TCATCTCTAGCTTTATCACGTCTCTGCTAATTCCCTGAAACCTGAATCGA  
AGTAGAGATCGAAAATAGTCAGAGACGATTAAGGACTTGAACCTAGCT

5'                    11                    21                    31                    41

4501 AGTTTCTCTGGGTCATCTCAATGGTGTGTTCAAGTCCCTTCTGAATCT  
TCAAAAGAACCAAGTAGAGTTACCACTACAAGTCAAGGAAGACTTACA

Figure 12 continued

5'                  61                  71                  81                  91

4551 CATTCAAGTTTCTCGTACTCCTCCATGTCAAAGTCACTGACACACTCATCG  
GTAAGTCAAAGAGCATGAGGAGGTACAGTTCACTGACTGTGTGAGTAGC

5'                  11                  21                  31                  41

4601 TCATTGGTGTAGGAAAGCTGCTCTTGGTAATCAGTCCTTAGGCCAGGA  
AGTAACCACATCCTTCGACGAGAACCATAGTCAAGGAAATCGGTCC

5'                  61                  71                  81                  91

4651 GATTGTTTGTTCACACTGTCTACCCCTGAACCACATACCTGGAAAAGCTG  
CTAACAAAACAAGTGTGACAGATGGGACTGGTGTATGGACCTTTGAC

5'                  11                  21                  31                  41

4701 TGTGCTCTATTTCTTTCCAAAACCAGGGTGTCTTTGGGGAAAGCT  
ACACGAGATAAAAGAAAAGGTTGGTCCCACAAGAAAAACCCCTTCGA

5'                  61                  71                  81                  91

4751 TGCTTGGGAAAGCCAAGAAAGGCTAAAGAGAAAATGGAAAATTAATGTTCA  
ACGAACCCCTTCGGTTCTTCCGATTCCTTACCTTAATTACAAAG

5'                  11                  21                  31                  41

4801 TTTTACTCCCTTCAACATCAAGGTTAGGAATATGTATTCATAAAAGCTA  
AAAATGAGGGAAAGTTGTAGTTCCATCCTTACATAAAGTATTTCGAT

5'                  61                  71                  81                  91

4851 ACAACTCACAGGCAATCTTAGACATCACTGACTGCTGGCAGGCGACTGC  
TGTTGAGTGTCCGTTAGAATCTGTAGTGACTGACGAACCGTCCGCTGACG

5'                  11                  21                  31                  41

4901 TTGGGGGGAGCTGGAGAGCCTTCTCTTTCTTCATGTTGTCTGAAAAAAA  
AACCCCCCTCGACCTCTCGGAAGAGAAAAGTACAACAGCATTTC

5'                  61                  71                  81                  91

4951 TTGCAGAATA TGGGGCTGGAAGATAACAACTTAACCTCTTCACAGCCT  
AACGTCTTACCCGACCTCTATTGTTGAAATTGAGAGAAGTGTGCGGA

5'                  11                  21                  31                  41

5001 GCACTGATTTTTCTGGACAAATTCTCAAATGGCATCTAT TATCGCTTT  
CGTACTAAAAAGACCTGTTAACAGTTACCGTAGATAATAGCGAAA

5'                  61                  71                  81                  91

5051 GCTACTACGTTGGGTCTGTTGAGCATTCTTCACAGGACAACTCGTAAAGGAAGTTTTGTTTCG  
CGATGATGCAAACCCAGGACAACTCGTAAAGGAAGTTTTGTTTCG

5'                  11                  21                  31                  41

5101 ACATTTTAAAGTCAGGTTAACAGATCCA CCTGAAAAAGCTGCAA  
TGTAAAAATTTCAGTTCAAATTCTAGGTGGACGTTTTTCGACGTT

5'                  61                  71                  81                  91

5151 TATAAGCGAGGAATTCTAGTTGTCAACAGGAAATAAAAATG TCTGTTCCA  
ATATTGCTCCTTAAGATCAACAGTGTCCATTACAGACAAGGGT

Figure 12 continued

5'                    11                    21                    31                    41  
 5201 CTATAATCAA TGTAGACTGATAATATTATGCCAGCAAATAGTTTGAACT  
 GATATTAGTTACATCTGACTATTATAATACGGTCGTTATCAAAACTTCA

5'                    61                    71                    81                    91  
 5251 CCTAGGCACAGTGGGAGGAGTTTGTCCACGCTGTTCAAAAGCCAATA  
 GGATCCGTGT CACCCTCCTCCAAAACAAGGTGCGACAAGTATTGGTTAT

5'                    11                    21                    31                    41  
 5301 CCCCAGCAAAAGACCTAAAGGACAAC TTGTAATTGGGACATTACACATC  
 GGGGTCGTTTCTGGAATT CCTGTTGAACATTAAACCTGTAAGTGTAG

5'                    61                    71                    81                    91  
 5351 TGTCCCTTTCATCTGATCTGGCTCCAGTGTCACTCTCTAACACGGTCCT  
 ACAGGAGAAGTAGACTAGACCGAGGGTCACAGTGAGAGATTGTGCCAGGA

5'                    11                    21                    31                    41  
 5401 TAGAGGGACAATTATCCCTGCCTCTGCTTGATCTTATGCATGTATCTGT  
 ATCTCCCTGTTAAATAGGGACGGAGACGAACTAGAATACGTACATAGACA

5'                    61                    71                    81                    91  
 5451 ATTCTTCAGCCATCCCTGGCGACCTGATTCTAAGGCACCCAAAACT  
 TAAGAAGGTCGGTAGGGACCGCTGGACTAAAAAGATTCCGTGGTTTGA

5'                    11                    21                    31                    41  
 5501 GTAAGCTACTTCTTATAATCTATAATTCTGAGCATATTAGTTAGCCTGAG  
 CATTGATGAAGAATATTAGATATTAGACTCGTATAATCAATCGGACTC

5'                    61                    71                    81                    91  
 5551 CCTCCAGGGATATCTTCTCCCTATACTCAGTCCAGTTTAGCTGCCAG  
 GGAGGTCCTATAGAAAGAGGGATATGAGTCAGGTCAAAATCGACGGGTC

5'                    11                    21                    31                    41  
 5601 AAGGATTCAAAGCTGATCTACGAGTAGATCACTCCTGTCTACAGCTTGT  
 TTCCTAAGTTTCGACTAGATGCTCATCTAGTGAGGACAGATGTGAAACAA

5'                    61                    71                    81                    91  
 5651 CCAGATCTGTTCTCAAGGCCCTGGAAGCCATCAGCCAGGTAAAGATTGTA  
 GGTCTAGAACAAAGAGTTGGGACCTTCGGTAGTCGGTCCATTCTAACAT

5'                    11                    21                    31                    41  
 5701 AAACAATCCC TTCTAATCATGGGTGTGGCCCAAAGTGAATGGCCGGAAT  
 TTTGTTAGGGAAAGATTAGTACCCACACCGGGTTCACTTACCGGCCTTA

5'                    61                    71                    81                    91  
 5751 TC  
 AG




Figure 13  
5752 bp




Figure 14

## Figure 15

PDE10a and RACEs compiled

1 CGCCCGGGCA GGTCTGTTGG AGGGCAGTTG GTCAACCTGA CCAGAGAGAG CTGAGCTGGA  
 61 GCGGGCCCGT CCAGACAACC TCCCCTCAAC CAGTTGGACT GGTCTCTCTC GACTCGACCT  
 121 AGACCCCACT GATGGTGTC TGCCCTTCAG TCCAGGAAGA AAGAAAGGAA GGATTCTGAG  
 TCTGGGGTGA CTACCAACACG ACGGAAAGTC AGGTCTTCT TTCTTTCTT CCTAAGACTC  
 181 GATTGGGCA AAGCCACATT CCTGGAGAAG TCTGTATACT GATGCCAAC CCAAGAGCTG  
 CTAAACCGT TTCGGTGTAA GGACCTCTTC AGACATATGA CTACGGTTG GGTTCTCGAC  
 241 AGCTGCTGAT GAGGCCAGG GAGTAGCCCCA CGCGCCCTGA GCTGTTGGCT AGCAAGGCCT  
 TCGACGACTA CTCCGGGTCC CTCATGGGT GCGCGGGACT CGACAAACCGA TCGTTCCGGA  
 301 TCCCTGCTCCA TGTGGCATGG AAAAATTATA TGGTTTGACG GATGAAAAGG TGAAGGCCTA  
 AGGACGAGGT ACACCGTACC TTTTAATAT ACCAAACTGC CTACTTTCC ACTTCCGGAT  
 361 TCTTCTCTC CATCCCCAGG TATTAGATGA ATTGTTTCT GAAAGTGTAA GTGCAGAGAC  
 AGAAAGAGAG GTAGGGGTCC ATAATCTACT TAAACAAAGA CTTTCACAAAT CACGCTCTG  
 421 TGTGGAAAAG TGGCTGAAGA GGAAAACCAA CAAAGAAAAA GATGAACCAT CTOCCAAGGA  
 ACACCTTTTC ACCGACTTCT CTTTTGGTT GTTCGTTTCT TACTTGGTA GAGGGTTCC  
 481 AGTCAGCAGG TACCAAGATA CGAATATGCA GGGAGTCGTG TACGAGCTGA ACAGCTACAT  
 TCAGTCGTCC ATGGTCCTAT GCTTATACTG CCCTCAGCAC ATGTCGACT TGTGATGTA  
 541 AGAGCAGCGC CTGGACACGG GCGGGGACAA CCACCTGCTC CTCTATGAGC TCAGCAGCGAT  
 TCTCGTGCAG GACCTGTGCC CGCCCCCTGTT GTGGGACGAG GAGATACTCG AGTCGTCGTA  
 601 CATCAGGATA GCCACAAAAG CCGACGGATT TGCACGTGAA TTGTTGGAG AGTGCATAAA  
 GTAGTCCTAT CGGTGTTTTC GGCTGCCTAA ACGTGACATG AAGGAACCTC TCACGTTATT  
 661 TAGGCTGTGT GTGTTCATAC CACCOGGGAT GAAGGAAGGC CAACCCCGGC TCATCCCTGC  
 ATCGGACACA CACAAGTATG GTGGGCCTA CTTCTTCCG GTGGGGCCG AGTAGGGACG  
 ....  
 721 GTTGGTAGAG GATATCCTTG GGGATGAGCG ATTCTCGA GGTACTGGCC TGGAAATCAGG  
 CAACCATCTC CTATAGGAAC CCCTACTCGC TAAAGGAGCT CCATGACCGG ACCTTAGTCC  
 781 AACCCGCATC CAGTCTGTT TTTGCTGCT CATTGTCACT GCCATTGGAG ACTTGATTGG  
 TTGGCGTAG GTCAAGACAAG AAACGAACGG GTAACAGTGA CGGTAACCTC TGAACTAACC  
 841 CATCCTGAA CTGTACAGGC ACTGGGGCAA AGAGGCCTTC TGCCTCAGCC ATCAGGAGGT  
 GTAGGAACCT GACATGTCCG TGACCCCGTT TCTCCGGAAAG ACGGAGTCGG TAGTCCTCCA  
 901 TGCACAGGCC AATCTTGCTT GGGCTTCCGT AGCAATACAC CAGGTGCAGG TGTGAGAGG  
 ACGTTGCGG TTAGAACGAA CCCGAAGGCA TGTGTTATGTG GTCCACCGTCC ACACATCTCC  
 961 TCTCGCCAAA CAGACCGAAC TGAATGACTT CCTACTCGAC GTATCAAAGA CATACTTTGA  
 AGAGCGGTTT GTCTGGCTTG ACTTACTGAA GGATGAGCTG CATACTTTCT GTATGAAACT  
 1021 TAACATAGTT GCCATAGACT CTCTACTTGA ACACATCATG ATATATGCAA AAAATCTAGT  
 ATTGTATCAA CGGTATCTGA GAGATGAAC TGTGAGTAC TATATACGTT TTTAGATCA  
 1081 GAACGCCGAC CGCTGCGCGC TCTTCCAGGT GGACCCACAAG AACAGGAGC TGTACTCGGA  
 CTTGCGGCTG CGCAAGCGCGC AGAAGGTCCA CCTGGTGTTC TTGTTCTCG ACATGAGCCT  
 1141 CCTGTTGAC ATTGGGGAGG AGAAGGAGGG GAAGCCCATC TTCAAGAAGA CCAAGGAGAT  
 GGACAAACTG TAACCCCTCC TCTTCCCTCC CTTGGGGTAG AAGTTCTTCT GGTCCCTCTA  
 1201 CAGATTTC C ATTGAGAAAG GGATTGCTGG TCAAGTGGCA AGAACAGGGC AAGTCTTGAA  
 GTCTAAAGG TAATCTTTT CCTAACGACC AGTTCACCGT TCTTGTCCGC TTCAGAACTT  
 1261 CATTCCCGAT GCCTACCGGG ACCCTCGCTT TAACAGGGAG GTGGACCTGT ACACAGGGCTA  
 GTAAGGGCTA CGGATGCGCC TGGGAGCGAA ATTGTCCCTC CACCTGGACA TGTGTCCGAT  
 1321 CACCCACGGG AACATTCTGT GTATGCCAT AGTGAGCCGA GGCAGCGTGA TTGGCGTGGT  
 GTGGTGCCTCC TTGTAAGACA CATACTGGCT CGTGCAGACT AACCGCACCA

Figure 15 (con't)

PDE10a and RACEs compiled

1381 GCAGATGGTG AACAAGATCA GCGGTAGCGC CTTCTCCAAG ACAGACGAGA ACAACTTCAR  
CGTCTACCAAC TTGTTCTAGT CGCCATCGCG GAAGAGGTT TGTCCTCT TGTTGAAGTT

1441 GATGTTGCT GTCTTCTGCG CACTGGCCTT GCACGTGCT AACATGTACC ACAGGATCCG  
CTACAAACGA CAGAAGACGC GTGACCGAA CGTGACACGA TTGTACATGG TGTCCTAGGC

1501 CGACTCAGAA TGCATCTACA GGGTTACCAT GGAGAACGTT TCCTACCA GCATCTGCAC  
GGTAGAGCTT ACGTAGATGT CCCAATGGTA CCTCTTCGAA AGGATGGTT CGTAGACGTG

1561 CTCGGAGGAG TGGCAAGGCC TCATGCGCTT CAACCTACCA GCACGCATCT GCGGGACAT

1621 GAGGCTCTC ACGTTCCGG AGTACCGGAA GTGGATGGT CGTGGTARGA CGGCCTGTA

1681 CGAGCTATTIC CACTTGACA TTGGTCTTT CGAGAACATG TGGCCTGGGA TCTTGTCTA  
GCTCGATAAG GTGAAACTGT AACCAGGAAA GCTCTTGAC ACCGGACCT AGAAACAGAT

1741 CATGATCCAT CGGTCTTGIG GGACATCTG ITTGAACCT GAAAAATTGT GCGGTTTAT  
GTACTAGGTG GCCAGAACAC CCTGTAGGAC ARAACTTGA CTTTTAACCA CGGCAAAATA

1801 CATGTCGTG AAGAAGAACT ATGGCGGGT TCCTTACAC AACGGAAAGC ATGCACTCAC  
GTACAGACAC TTCTCTTGA TAGCGGCGCA AGGAATGGTG TTGACCTCG TACGTCACTG

1861 GGTGGCACAC TGCATGTATG CCATACTTC AAACAACAT GGCCTCTCA CAGAOctOGA  
CCACCGTGTG ACGTACATAC GGTATGAAGT TTGTTGTTA CGGGAGAAGT GTCTGGAGCT

1921 CGCTAATTG CGTGTCTG CGATGACCTG GACCACAGGG GCTTCAGTAA

1981 GCGCAAGGC CTGCTAATTG CGTGTCTG CGATGACCTG GACCACAGGG GCTTCAGTAA  
CGCGTTCCG GACGATTAAC GCACAGACAC GGTACTGGAC CTGGTGTCCC CGARGTCATT

2041 CAGCTAATTG CAGAAGTTG ACCACCCCCCT GGCGGOGCTG TACTCCACCT CCACCATGGA  
GTGCGATGGAC GTCTTCAGC TGGGGGGGA CGCGCGCGAC ATGAGGTGGA GTGGTACCT

2101 GCAACACCCAC TTCTCCAGA CGGTGTGAC CCTTCAGCTG GAAGGGCACCA ATATCTTCTC  
CGTTGTGGTG AAGAGGGTCT GGCACAGGTA GGAAGTCGAC CTTCCCGTGT TATAGAAGAG

2161 CACCCCTGAGC TCCAGCGAGT ACGAGCAGGT GCTGGAGATC ATCCGCAAG CCATCATCGC  
GTGGGACTCG AGGTGCGTCA TGCTGTOCA CGACCTCTAG TAGGOGTTC GGTAGTAGCG

2221 CACCGACCTC GGCCTATACT TTGGGAACAG GAGCGATGT GAGGAGAAGT ACCAGACAGG  
GTGGCTGGAG CGGGATATGA ARCCCTGTC TTCTGTCAC CTCCTCTACA TGGCTGTCC

2281 ATATGCAGAA TTCTGGGCTG AGGGTGATGA GATGAAGAAG CTGGGCATAC AGCCCATTCC  
TATACGTCTT AAGACCCGAC TCCCACACT CTACTCTTC GACCCGTATG TCGGGTAAGG

2341 TATGATGGAC AGAGACAAGC GAGATGAAGT CCTCTAAGGG CAGCTCGGAT TCTACAATGC  
ATACTACCTG TCTCTGTCTG CTCTACTTC GGGAGTTCCC GTGAGGCTA AGATGTTACG

2401 TGTGGCATT CCCTGCTATA CCACCTGAC GCAGATCTC CCACCCACAG AGCCTCTGCT

2461 ACACGGTAA GGAGCGATAT GGTGGAAACTG CGTCTAGGAG GGTGGGTGTC TCGGAGACGA  
GAAGGGCTGC AGGGATAACC TCAATCAGTG GGAGAAGGTA ATTGGCGGGG AAGAGACAGC

2521 AATGTGGATT TCAGGGCCAG GCGGGCGCC TAGCAAGAGC ACACCTGAGA AGCTGAACGT  
TTACACCTAA AGTCCGGGTC CGGGCGCGGG ATCGTTCTCG TGTGGACTCT TCGACTTGCA

2581 GAAGGGTGAA GACTGATCTT GAAAGTGAAGT CCTGATGTCT GCCCAGCAAC CGACTCAACC  
CTTCCAACTT CTGACTAGGA TTGACTGCA GGACTACAGA CGGGTCGTG GCTGAGTTGG

2641 TGCTCTGTG ACTTOGTTCT TTTGTTTCA AAGGGGTGAA AACCCCTGT CAGAAGGTAC  
ACGAAGACAC TGAAGCAAG AAAACAAAAG TTCCCCACTT TTGGGGACA GTCTTCCATG

Figure 15 (con't)

PDE10a and RACEs compiled

2701 CGTCGCATAT CCATGTGAAG CAGACGACTC CCTGCTTGC GCACACACCT CGGACAGTGA  
 GCAGCGTATA GGTACACTTC GTCTGCTGAG GGACGAACGG CGTGTTGGA GCCTGTCACT  
 2761 GCAACCCAGG CTCTGCCGTG TTCAGACGTC GGCTACTCCG TGGCTCCACC TGACCTCCGA  
 CGTTGGTCC GAGACGGCAC AAGTCTGCAG CCGATGAGGC ACCGAGGTGG ACTGGAGGCT  
 2821 ATGCTATTTG CTCCCAGGCC AGCACTGCAC TGCTGGAGG GGGCAGAGAC CACAGGAGAG  
 TACGATAAAC GAGGGTCCGG TCGTGACGTG ACAGACCTCC CCCGTCTCTG GTGTCCTCTC  
 2881 GTTCTGCCT GCATCCTCCC ATGAGGGTGT GGCCAGTTCC CTAGTTCTGT GCCATGCTGC  
 CAAGAACGGA CGTAGGAGGG TACTCCACA CCGGTCAAGG GATCAAGACA CGGTACGACG  
 2941 TGCTTGGTGG CATTGGTTAG GAATGGGACA CACGCCCTT GTTGTGAAGT TTACATGTGA  
 ACGAACACCAC GTAACCAATC CTTACCTGT GTGGGGGAA CAACACTTCA AATGTACACT  
 3001 CCTTCTTATA GGTAACTGA GTTTGTGGCC TGGACACATG TAATGAAGGT CACAGTCCAC  
 GGAAGAATAT CCAATTGACT CAAACACCGG ACCTGTGTAC ATTACTTCCA GTGTCAGGTG  
 3061 AGGTGACAGA GAAATCCAAA CTGTTGATTA CAGGTGCACT ACAGGTATGC TCTTCAGTC  
 TCCACTGTCT CTTAGGTTT GACAACATAAT GTCCACGTGA TGTCCATACG AGAAAGTCAG  
 3121 TATCTGGGG CACATAGGTG AGTCTGCTCC ACTCAGAANN AAGCATACCT CTGCCCTCAT  
 ATAGACCCCCC GTGTATCCAC TCAGACGAGG TGAGTCTNN TTCTGTATGGA GACGGGAGTA  
 3181 CCAGGGGACA CAGGGTACAT CCCAGGCATC GGGGAACCTGA AGCTCTCACT TCAAACCATG  
 GGTCCCCCTGT GTCCCATGTA GGGTCCGTAG CCCCTTGACT TOGAGAGTGA AGTTGGTAC  
 3241 TCAAAGAATT AAAACACCTC CCCTCCCCCT CACTGTAGCC TTGACACAAT GCGCCAATCC  
 AGTTCTTAA TTTTGTGGAG GGGAGGGGA GTGACATCGG AAGCTGTTGA CGCGGTTAGG  
 3301 CTTTATACAA AGAAAATAAA AGTAAGGCAT ATAATTTCC TCCAGCAAGC AAATCTTGTG  
 GAAATATGTT TCTTTATTT TCATTCCGTAT TATTTAAAGG AGGTCTTCG TTTAGAACAC  
 3361 GGTAAAAAAA ARGCATGTGA ATNNATAACAA CNCTANANT NTCNCNGNAT GTTATGGCAG  
 . CCATTTTTT TTCGTACACT TANNATTGTT GNAGATNTNA NAGNGNCNTA CAATACCGTC  
 3421 AATTTAGTC ACGTCCAAA CAAAAGATT ATTCAGAAG ATACCTCATC CTATGCTGA  
 TTAAATCAG TCGAGGTTT GTTTCTAA TAAGGTCTTC TATGGAGTAG GATAACGGACT  
 3481 AAGGCTCCAC AGCATGGCGT CGGTCTCCCA GGGTTCTGAT CCGTCTCCTC ACGGTGCAAT  
 TTCCGAGGTG TCGTACCGCA GGCAGAGGGT CCAAGACTA GGCAGAGGGAG TGCCACGTTA  
 3541 CAGGCAGGAC AGAGAGGAGG GCTGCCGGC TACCACATTG ACCCAGAAGG TATCTCCTCT  
 GTCCGTCCTG TCTCTCCTC CGACGTCCCG ATGGTGTAAAC TGGGTCTTCC ATAGAGGAGA  
 3601 CACCAATTCAAG ACATCCATAA GGAATGCCAA ATGCTGTATT GAATAGTTCT CTGTGTGACT  
 GTGGTAAGTC TGTAGGTATT CCTTACGGTT TACGACATAA CTTATCAAGA GACACACTGAA  
 ....  
 3661 TTCTAGAGAA CCCAGGACAC CCTGAGCCTT TCCNGGGAA CTCTAAGGGAG TCACAGGTTG  
 AAGATCTCTT CGGTCTCTGTG GGACTCGGAA AGGNCCCTT GAGATTCTCTC AGTGTCCAAQ  
 3721 ACACCGTGGG GATTTTCAGG ATAGCATGGA GACAGAGATC CGGTCTGTG TCTCACTCGT  
 TGTGGCACCC CTAAAAGTC TATCGTACCT CTGTCTCTAG GCCAGCAACA AGAGTGAGCA  
 3781 GAGCCTTGAG AAGGAGAGAC TGACCAAGAA CACTCACTCA GCACTCTGCA GGAGCAGGGAG  
 CTCGGAACTC TTCTCTCTG ACTGGTCTT GTGAGTGAGT CGTGAGACGT CCTCGTCCTC  
 3841 AAGATACTT AAGATGAATC TTGGATAGAT TTGATACAC CCAATACCAT ACACACAGGA  
 TTCTATGAAA TTCTACTTAG AACCTATCTA AACTATGTG GGTTATGGTA TGTGTGCTCT  
 3901 GCTTGGCATT TGCAAAGTCT ATTCAAGTTT CTTCCGCGCT CTGACCCACG GTTGTAGCGG  
 CGAACCGTAA ACAGTTTCAGA TAAGTCAAAG GAAGGCGCGA GACTGGGTGC CAACATCGCC  
 3961 AGTGGGCTGA ACACTGTAAAC ACTGTACATG CGATTTCCCCC ATGGGTTCTT AAAATGTAC  
 TCACCCGACT TGTGACATTG TGACATGTAC GCTAAAGGGG TACCCGAAGA TTTACAGTG  
 4021 CATCTCCCTC CCTGCTGTGT CCTACTCCAT TTACTGGTTA CAAGGTGATG TCAACAAAGAG  
 GTAGAGGAGG GGACGACACA GGATGAGGTAA ATGACCAAT GTTCCACTAC AGTTGTCTC

Figure 15 (con't)

PDE10a and RACEs compiled

4081 AAGCTATCAC AACACCAGGG CTGTGCACAC GTGCACACAC ATGTATGCAC AAGCACACAG  
 TTGATAGTG TTGTTGTCAC GACACGTGTG CACGTGTG TACATACGTG TTGTTGTCAC  
 4141 ATGTATGTAC AGCACACACA CACACACACA CCCAAAAGG AGAGAAAAGG AAGAAAACAT  
 TACATACATG TCGTGTGTGT GTGTTGTCAC GGGGTTTCC TCTCTTTCC TTGTTGTCAC  
 4201 TTATAAAAAG CGACAGCTAC CCCATATCAA AATAGTCTT CCTGTAGGAA ACAGGAGCTC  
 AATATTTTC GCTGTCGATG GGGTATAGTT TTATCAGAAA GGACATCCTT TGTCCTCGAG  
 4261 TCCATAAGGA ATTATCATGA GTGTTGTCAC CCATCAGTGC ACTCTCCCAG GGGTGTCTC  
 AGGTATTCT TAATAGTACT CACACAAGAG GGTAGTCACG TGAGAGGGTC CCCACGAGTG  
 4321 TGAAGCTGGT CCACRTCTAT AAACAGGTGA CACTGGCTGC AGCAAAAAGC CATTGATCC  
 ACTTCGACCA GGTGRAGATA TTGTCACACT GTGACCGACG TCGTTTTCG GTAAGCTAGG  
 4381 ACACAAATTG ATCTTCTATC ATCTTGAAT CTGAATTGCA GGGAGGAGCA GYATGTAAGA  
 TGTGTTAAC TAGAAGATAG TAGAACCTTA GACTTAACGT CCCTCCTCGT CYTACATTCT  
 4441 CGACCGTTA ATTCAAGGCAT TCCGAAGGCA TGAGCGCATG GATTCTRTCA CCAAGCGTAT  
 GCTGGCAAAT TAAGTCCGTA AGGCTTCGT ACTCGCGTAC CTAAGARAGT GGTCGCTATA  
 4501 AAAAGGACCC TGGCATTGGG AAACCTATGA CGGACTGTGT TTGCTGTAGA AGTAGGGATT  
 TTTCCCTGGG ACCGTAACCC TTTGGATACT GCCTGACAAA AACGACATCT TCATCCCTAA  
 4561 TTACAGAAGT CTCTTGRAT TTGCCCTGCC TGGGGCAGTT TTGAGAGGA ACCTGCCAGA  
 AATGTCCTCA GAGGAACRTA AACGGGACGG ACCCGTCAA AACGTCCTT TGGACGGTCT  
 4621 GATTTATTGG CTGGTCAGTC TCTTGTAAA TAGTATCATG TGAGAACAG TTTGTAGAAA  
 CTAATAAAC GACCACTCAG AGAACACTT ATCATAGTAC ACTCTTGTG AAACATCTT  
 4681 AAAACTATAC CTGGGAAGAC CTTTGCACAA TTGTTCTTC CATGGCCAA GACTCAGTTA  
 TTTTGATATG GACCCCTCTG GAAACGTGT AACRAGGAAG GTACCCGGTT CTGAGTCATT  
 4741 GGAGGCATAA ATCTGCCCGG AATAAAACTAG GCCAGGATAC AGCCATGTT AGTTAATAAT  
 CCTCCGTATT TAGACGGGCC TTATTTGATC CGGTCTATG TCGGTACAAA TCAATTATTA  
  
 4801 TTGGTTTAG AATTACACACA GGCAGGATTG GTTTTTTGT GTCTGGCAA GTGGAGCATA  
 AACCAAATC TTAAGTGTGT CCGTCCTAAC CAAAAAAACA CAGAACCGTT CACCTCGTAT  
 4861 TTTAACATAC AGGCATGGGA ATCCGTGTC TTAGCTTTG CCACCCCTTT GTCTCACCAA  
 AAATTGTATG TCCGTACCT TAGGACGGAG AATCGAAAAG GGTGGGAGAA CAGAGTGGTT  
 4921 GTTTTCTC TCCAAAGGTT TCCAGGAATT TCTCATTAAT GGCTGATGCA AACTTGTGA  
 CAAAAAAGAG AGGTTCCAA AGGTCTTAA AGAGTAATTA CCGACTACGT TTGATCACT  
 4981 ATAATAATGA ATATAAACAA TGCTCACCTC ACCAAAATTA TATTATTG AGTCATTG  
 TATTATTACT TATATTGTT ACGAGTGGAG TGGTTTAAT ATAATAAACG TCAGTAAACA  
 5041 GATAACACAA ATTTATCGC AATGGTTATT ATTAATTG TGCCACACAA CTGTTGTTAT  
 CTATTGTGTT TAAAATAGCG TTACCAATAA TAAATTAAAC ACCGGTGTGT GACACCAATA  
 5101 CTTTTGTTGT GGTGTTTCT GAGAAAATGT TCTGGATAT GAAAGTGCCTAATCCTAAGGT  
 GAAAACAACA CCAACAAAGA CTCTTTACAA AGAACCTATA CATTCACTGGT TATGGTCACA  
 5161 GAAGTATTGA TCCCGGGCAG CAAAATACAG CCTAAGGTTT GTAAACATCA ATTCTATCTC  
 CTTCATAACT AGGGCCCCGTC GTTTTATGTC GGATTCCAAA CATTGTAGT TAAGATAGAG  
 5221 AGTTCATCACAG AGGGCCTGAG AAGCTGCCGG GCAGTGTAAA GTAAAGTATG CTGGGCTGGT  
 TCAAGTAGTC TCCCGGACTC TTGACGCCCGT CGTCACATTT CATTTCATAC GACCCGACCA  
 5281 GGTGGTCAGC CTCCCCCTGCAAGAAGAGA GCAATTGAAT CCTGTCCCCA GCTCCCTCCA  
 CCACCACTCG GAGGGGAACG GTTCTTCTCT CGTAACTTA GGACAGGGGT CGAGGGAGGT  
 5341 CGCCTGAAGA GTGACCAAGTG CTGGCCGAC GGATCGCTGA GATATTCTCC CATAATGGCA  
 GCGGACTTCT CACTGGTCAC GACCGGGCTG CCTAGCGACT CTATAAGAGG GTATTACCGT  
 5401 AAAAAATAGG CAGTTGATG TGACCTGTT AGTGTGGCTC TCCCTTTG AGCATGTGTT  
 TTTTTATCC GTCAAACTAC ACTGGACAAA TCACACCGAG AGGAGAAAAC TCGTACACAA

Figure 15 (con't)

PDE10a and RACEs compiled

5461 AGCATTATA TTTTATACTC ATCCAGTGAA CTCTGCTCTT CCAAGTGTGT TCATGTATGT  
 TCGTAAAAAT AAAATATGAG TAGGTCACTT GAGACGAGAA GGTTCACACA AGTACATACA  
 5521 GCTAGATATA TTAGCACAGC CTGCCTCTG CTGCACAAACG CCTTAGAGAC CGGGCCTTC  
 CGATCTATAT AATCGTGTG GACGGAAGAC GACGTGTTGC GGAATCTCTG GGCGGAAAG  
 5581 AATGAGCTA GCTTGTC GCTTGTC TGTTCTGCT CTCTTAGGTC TAAACTATGG TGTCAGTTT  
 TTACTCGAAT CGAACACGAG ACAAAAGACGA GAGAACCCAG ATTGATACCC ACAGTCAAA  
 5641 AATAGAACAA AAGTATGCAT CTTGCCCTGG CTTGAGCCTT TTGCTTTCA ATGCTGACTT  
 TTATCTTGTGTT TCATACGTA GAACGGAACC GAACTCGGAA AAGCAAAGT TACGACTGAA  
 5701 CTCCTCTTC TCTCCGTGTC TCACCTTACCC TTTCCAGAGT GTAAGGGACA ACTTTAAGG  
 GAGGGGAAG AGAGGACACG AGTGGATGG AAAGGTCTCA CATTCCCTGT TGAAAATTCC  
 5761 AGGCCTGTCC CTGGTAGGGG CATCCCTGTT CACCAAGTGC CTGTACATCAC CCCACTTGAC  
 TCCGCACAGG GACCATCCCC GTAGGGACAA GTGGTCCACG GACAGTAGTG GGGTGAACG  
 5821 TGACATCTAC CCTGGTGAAT ATGGGTTCTT CTTGTTGTA GGGAACGGTG GCTCCAGGTG  
 ACTGTAGATG GGACCACTGA TACCCAAAGGA GAAACAAACAT CCCTTGCCAC CGAGGTCCAC  
 5881 GAGGCATCAA TCTGTTGGGT TCTGGTCCC GGCTGCCTT GTTTTGAAA GTCTCTCTC  
 CTCCGTAGTT AGACAAACCA AGACCAAGGG CCGACGGAAA CCAAAACTTT CAGAGAAGAG  
 5941 TGTATATTC TACCCCTGCAT TTGCTTTGTG TGGTGTGAT GCTGTGGCAG TAGGATCTTG  
 ACATATAAGG ATGGGACGTA AACGAAACAC ACCACGACTA CGACACCGTC ATCCTAGAAC  
 6001 GATGACTCTC CATCAGTCAC AGACTCCCCC TGTGCAAAG TGTCAAGCTG ACTCGACAGT  
 CTACTGAGAG GTAGTCAGTG TCTGAGGGG ACAACGTTT ACAGTCCGAC TGAGCTGTCA  
 6061 CACCGTAAAA TCTGAGTCAG TCACACACAG GCTGTCAGCC ACGGCTTCCA CTTGCATGGC  
 GTGGCATTAGT AGACTCAGTC AGTGTGTGTC CGACAGTCGG TGCCGAAGGT GAACTACCG  
 6121 TATTCTATTT TCACACGTGA GTTCTGTG CTGGCTGGCT GACTGGCAAT ATCTATGCTA  
 ATAAGATAAA AGTGTGCACT CAAAGACAAAC GACCGACCGA CTGACCGTAA TAGATACGAT  
 6181 AGTTGAAATC AGGAGTGTGC CCAGCAGAGC CCATCATTCT CACTGTCTT GAAACAAAGC  
 TCAACTTTAG TCCTCACAGC GGTCGTCTCG GGTAGTAAGA GTGACAGAAA CTTTGTTCG  
 6241 TGTACGGTTT GATCGATGAA CGTATTTAA GCATTCATG CAATGACAAA GTGCTCAGTA  
 ACATGCCAAA CTAGTACTT GCATAAATT CGTAAAGTAC GTTACTGTGTT CACGAGTCAT  
 6301 GTGGAAGGCA GGCTGTGACC AGTCTGCTG CTCCCTACTA TAATTGTGAG GATTGTTAC  
 CACCTTCCGT CCGACACTGG TCAGACGGAC GAGGAATGAT ATTAACACTC CTAACAAATG  
 6361 TGGAACAGTA CATGGAGGCC TGACCTGTG GGGGCACAGG GTGGAACCTT AGCTGAAATAT  
 ACCTTGTCA GTACCTCCGG ACTGGAACAC CCCCCTGTCC CACCTTGGAA TCGACTTATA  
 6421 AGTGTGTGTC TCAAGAGGAA GTCAGGGTAC TAGTCAGTG CTCAATCTCC AGGTACTATA  
 TCACACACAG AGTTCTCCTT CAGTCCCATG ATCGAGTCAC GAGTTAGAGG TCCATGATAT  
 6481 TATACATTTG CCGGTTTAT CTCTAATGTG AAATAAAATCC CCAAAACACTT GTTATCGTG  
 ATATGTAAC GGGAAAATA GAGATTACAC TTTATTTAGG GGTTTGTGAA CAAATAGCAC  
 6541 TAGCGTACCT AAAAGACTAT TCTATTATGG GTGTCCCCAC TTTCTGGTT TGGTCACCCCC  
 ATCGCATGGA TTTCTGATA AGATAATACC CACAGGGTG AAAGAACCAA ACCAGTGGGG  
 6601 GATCCCCCGG TCTCTGCTG TATCTAGAAC AGTGAAC TATGATGTAT GGGAAATAGTG  
 CTAGGGGGCC AGAACAGAC ATAGATCTG TCACTGATAT TTACTACATA CCCTTATCAC  
 6661 TTTCATATG ATCTGTTGTC TGGAGTATAT GCTACATGTT CATTACTGT ACAAAAACCC  
 AAAGGTATAC TAGACAAACAG ACCTCATATA CGATGTACAA GTAAATGACA TGTTTTGGG  
 6721 AGTGCAGCTG ATGATGCAA GCAGTCTCTC TCTGTGTACA GTGCCCCAC TATTAAAAA  
 TCACGTGAC TACTACGTT CGTCAGAGAG AGACACATGT CACGGGGTGG ATAAATTTT  
 6781 TCACGTACAA NCCAGAACAA CTGTGAAACA CTTAACATAA GAAACAAACG CAGCGTCTGG  
 AGTGCATGTT NGGGTCTGT GACACTTTGT GAATTGTATT CTTGTGTTGC GTGCGAGACC

Figure 15 (con't)

PDE10a and RACEs compiled

|      |   |        |       |
|------|---|--------|-------|
| 6841 | ATTCTTCCA AGGAGAGCAG CTTTCTCCAC AGGAACACAG TAACAAAAGA GGTCCGCCGC<br>TAAGAAAGGT TCCTCTCGTC GAAAGAGGTG TCCTGTGTC ATTGTTTCT CCAGGCAGCG     | HindII | EcoRV |
| 6901 | CATCCACACC CAGCCAAGAC ACCTCAGAGG CCATAGGGAC AACCTCCTG CTGGCCAACA<br>GTAGGTGTGG GTCGGTTCTG TGGAGTCTCC GGTATCCCTG TTGGAGGAAC GACCGGTTGT   |        |       |
| 6961 | CCTGCTGGAG CAGGGCACAG GTCCCAGCAA CTGATCCTCA GTGGATGGGT CCGCAGTCAA<br>GGACGACCTC GTCCCGTGTG CAGGGTCGTT GACTAGGAGT CACCTACCCA GGCGTCAGTT  |        |       |
| 7021 | AGCCTTAATG GGCTCTCTTT TGAAGGGAA AGAAAANNTT CAAGCTTATG ATATCCAACA<br>TCGGAATTAC CCGAGAGAAA ACTTCCCCCTT TCTTNNAAA GTTCGAATAC TATAGGTTGT   |        |       |
| 7081 | TTATTATAGT TGATGAGTTA GTAAAATCCG AAAAAAAAAG ATGATTTAT ATGTATGACA<br>ATAAATATCA ACTACTCAAT CATTAAAGC TTTTTTTTC TACTAAAAATA TACATACTGT    |        |       |
| 7141 | AAAAAAAAAT CTTGTAAAG TGCGCAAGTG CAATAATTAA AAGAGGTCTT ATCTTGCAT<br>ATTTTTTTA GAAACATTTC ACGCGTTACG GTTATTAAT TTCTCCAGAA TAGAACGTA       |        |       |
| 7201 | TTATAAATTA TAAATATTGT ACATGTGTGT AATTTTTCAT GTATTCAATT GCAGTCTTG<br>AATATTAAAT ATTATAACA TGTACACACA TTAAAAAGTA CATAAGTAAA CGTCAGAAC     |        |       |
| 7261 | TATTTAAAAA AACTTACTG TTATGTTGT ATAATAGAAC ATTAATCATT TATTATAACT<br>ATAAATTTTT TTGAAATGAC AATACAAACA TATTATCTG TAATTAGTAA ATAATATTGA     |        |       |
| 7321 | CAGACAAGGT GTAAAATAAT TCATAATTCA AACAGCCAGT ATATATGCAT ATATGGGTGT<br>GTCTGTTCCA CATTATTTA AGTATTAAGT TTGTCGGTCA TATATACGTA TATACCCACA   |        |       |
| 7381 | TACATTGCAA AAATCTCTAT CTTTGTCTA TTACACATGCT TAAAGAAGTA AGAAATCTTT<br>ATGTAACGTT TTAGAGATA GAAACAGAT AAGTGTACGA ATTTCTTCAT TCTTAGAAA     |        |       |
| 7441 | TGTGGATATG TAATTATACA TATAAAGTAT ATATATATGT ATGATACATG AAATATATTT<br>ACACCTATAC ATTAATATGT ATATTTCTATA TATATATACA TACTATGTAC TTTATATAAA |        |       |
| 7501 | AGAAATGTTC ATAATTTAA TGGATATTCT TTGGTGTGAA TAATTGAATA AACATTTTT<br>TCTTTACAAG TATTAATTTAC ACCTATAAGA AACCAACATT ATTAACCTAT GTTGTAAAAA   |        |       |
| 7561 | AAAAATGAAAA AAAAAGAAAA C<br>TTTACTTTT TTTTTTTTT G   |        |       |

Figure 16




Figure 17

PDE10A compiled - coding sequence and features





Figure 18

PDE10A compiled - restriction sites



## Figure 19

PDE10A compiled

1 CGCCCAGGCA GGTCTGTTGG AGGGCAGTTG GTCAACCTGA CCAGAGAGAG CTGAGCTGGA  
 GCGGGCCCGT CCAGACAACC TCCCGTCAAC CAGTTGGACT GGTCTCTCTC GACTCGACCT  
 61 AGACCCCACT GATGGTGTGC TGCCCTTCAG TCCAGGAAGA AAGAAAGGAA GGATTCTGAG  
 TCTGGGGTGA CTACCACACG ACGGAAAGTC AGGTCTTCT TTCTTCCTT CCTAAGACTC  
 121 GATTGGGCA AAGCCACATT CCTGGAGAAG TCTGTATACT GATGCCAAC CCAAGAGCTG  
 CTAAACCCGT TTCGGTGTAA GGACCTCTTC AGACATATGA CTACGGTTG GTTCTCGAC  
 181 AGCTGCTGAT GAGGCCAGG GAGTAGCCCA CGGCCCTGA GCTGTTGGCT AGCAAGGCCT  
 TCGACGACTA CTCCGGTCC CTCATCGGGT GCGCGGGACT CGACAACCGA TCGTTCCGGA  
 241 TCCTGCTCCA TGTTGCATGG AAAAATTATA TGTTTGACG GATGAAAAGG TGAAGGCCTA  
 AGGACGAGGT ACACCGTAC TTTTAATAT ACCAAACTGC CTACTTTCC ACTTCCGGAT  
 301 TCTTCTCTC CATCCCCAGG TATTAGATGA ATTGTTCT GAAAGTGTG GTGCAGAGAC  
 AGAAAGAGAG GTAGGGGTCC ATAATCTACT TAAACAAAGA CTTCACAAAT CACGTCTCTG  
 361 TGTGGAAAAG TGGCTGAAGA GGAAACCAA CAAAGAAAA GATGAACCAT CTCCCAAGGA  
 ACACCTTTC ACCGACTTCT CCTTTGGTT GTTCGTTT CTACTGGTA GAGGGTTCT  
 421 AGTCAGCAGG TACCAAGATA CGAATATGCA GGGAGTCGTG TACGAGCTGA ACAGCTACAT  
 TCAGTCGTCC ATGGTCCTAT GCTTATACGT CCCTCAGCAC ATGCTCGACT TGTCGATGTA  
 481 AGAGCAGCGC CTGGACACGG GCGGGACAA CCACCTGCTC CTCTATGAGC TCAGCAGCAT  
 TCTCGCGC GACCTGTGCG CGCCCGTGT GGTGGACGAG GAGATACTCG AGTCGTCGTA  
 541 CATCAGGATA GCCACAAAAG CCGACGGATT TGCACGTAC TTCTGGAG AGTGAATAA  
 GTAGTCCTAT CGGTGTTTC GGCTGCCAA ACGTGACATG AAGGAACCTC TCACGTTATT  
 601 TAGCCTGTGT GTGTTCATAC CACCCGGAT GAAGGAAGGC CAACCCCGGC TCATCCCTGC  
 ATCGGACACA CACAAGTATG GTGGGCCCTA CTTCCTTCCG GTTGGGGCCG AGTAGGGACG  
 661 AGGGCCATC ACCCAGGGTA CCACCATCTC TGCCTACGTG GCCAAGTCTA GGAAGACGTT  
 TCCCAGGTAG TGGGTCCCAT GGTGGTAGAG ACGGATGCAC CGGTTCAAGAT CCTCTGCAA  
 721 GTTGGTAGAG GATATCCTTG GGGATGAGCG ATTTCCTCGA GGTACTGGCC TGAATCAGG  
 CAACCATCTC CTATAGGAAC CCCTACTCGC TAAAGGAGCT CCATGACCGG ACCTTAGTCC  
 781 AACCCGCATC CAGTCTGTT TTTGCTTGCC CATTGTCACT GGCATTGGAG ACTTGATTGG  
 TTGGCGTAG GTCAGACAAG AAACGAACGG GTAACAGTGA CGGTAACCTC TGAACTAACC  
 841 CATCCTTGAA CTGTACAGGC ACTGGGGCAA AGAGGCCCTC TGCCTCAGCC ATCAGGAGGT  
 GTAGGAACCTT GACATGTCCG TGACCCCGTT TCTCCGGAAAG ACGGAGTCGG TAGTCCTCCA  
 901 TGCAACAGCC AATCTTGCTT GGGCTCCGT AGCAATACAC CAGGTGCAGG TGTGTAGAGG  
 ACGTTGTCGG TTAGAACGAA CCCGAAGGCA TCGTTATGTG GTCCACGTCC ACACATCTCC  
 961 TCTGCCAAA CAGACCGAAC TGAATGACTT CCTACTCGAC GTATCAAAGA CATACTTGA  
 AGAGCGGTTT GTCTGGCTG ACTTACTGAA GGATGAGCTG CATACTTCT GTATGAAACT  
 1021 TAACATAGTT GCCATAGACT CTCTACTTGA ACACATCATG ATATATGCAA AAAATCTAGT  
 ATTGTATCAA CGGTATCTGA GAGATGAACT TGTGTAGTAC TATATACGTT TTTTAGATCA  
 1081 GAACGCCAC CGCTGCCGC TCTTCAGGT GGACCCACAAG AACAAAGGAGC TGTACTCGGA  
 CTTGCCGCTG GCGACGCCGG AGAAGGTCCA CCTGGTGTTC TTGTTCCCTCG ACATGAGCCT  
 1141 CCTGTTGAC ATTGGGGAGG AGAAGGAGGG GAAGGCCATC TTCAAGAAGA CCAAGGAGAT  
 GGACAAACTG TAACCCCTCC TCTTCCTCCC TTGCGGGTAG AAGTCTTCT GTTCCCTCTA  
 1201 CAGATTTCC ATTGAGAAAG GGATTGCTGG TCAAGTGGCA AGAACAGGCG AAGTCTTGA  
 GTCTAAAAGG TAACCTCTTC CCTAACGACC AGTCACCGT TCTTGTCCGC TTCAGAACTT  
 1261 CATTCCCGAT GCCTACGGG ACCCTCGCTT TAACAGGGAG GTGGACCTGT ACACAGGCTA  
 GTAAGGGCTA CGGATGCCGG TGGGAGCGAA ATTGTCCCTC CACCTGGACA TGTGTCCGAT  
 1321 CACCACGAGG AACATTCTGT GTATGCCAT AGTGAACCGA GGCAGCGTGA TTGGCGTGGT  
 GTGGTGTCC TTGTAAGACA CATACGGGT AACTCGGCT CCGTCGCACT AACCGCACCA

Figure 19 (con't)

PDE10A compiled

1381 GCAGATGGTG AACAAGATCA GCGGTAGCGC CTTCTCCAAG ACAGACGAGA ACAACTTCAA  
 CGTCTACCAC TTGTTCTAGT CGCCATCGCG GAAGAGGTTC TGCTGCTCT TGTGAAAGTT  
 1441 GATGTTGCT GTCTCTGCG CACTGGCCTT GCACTGTGCT AACATGTACC ACAGGATCG  
 CTACAAACGA CAGAAGACGC GTGACCGAA CGTGACACGA TTGTACATGG TGTCCTAGGC  
 1501 CCACTCAGAA TGCACTACA GGGTTACCAT GGAGAAGCTT TCCTACCACA GCATCTGCAC  
 GGTGAGTCTT ACGTAGATGT CCCAATGGTA CCTCTTCGAA AGGATGGTGT CGTAGACGTG  
 1561 CTCCGAGGAG TGGCAAGGCC TCATGCGCTT CAACCTACCA GCACGCATCT GCCGGGACAT  
 GAGGCTCCTC ACCGTTCCGG AGTACGCGAA GTTGGATGGT CGTGCCTAGA CGGCCCTGTA  
 1621 CGAGCTATTG CACTTGACA TTGGTCCTT CGAGAACATG TGGCCTGGGA TCTTGTCTA  
 GCTCGATAAG GTGAAACTGT AACCAGGAAA GCTCTTGTAC ACCGGACCCCT AGAAACAGAT  
 1681 CATGATCCAT CGGTCTTGTG GGACATCCTG TTTGAACTT GAAAAATTGT GCCGTTTAT  
 GTACTAGGTA GCCAGAACAC CCTGTAGGAC AAAACTTGAA CTTTTAAACA CGGCAAAATA  
 1741 CATGTCGTG AAGAAGAACT ATCGGCGGGT TCCTTACACC AACTGGAAGC ATGCACTCAC  
 GTACAGACAC TTCTTCTGTA TAGCCGCCA AGGAATGGTG TTGACCTCG TAGTCAGTG  
 1801 GGTGGCACAC TGCACTGTATG CCATACTTCA AAACAACAAT GGCCTCTCA CAGACCTCGA  
 CCACCGTGTG ACCTACATAC GGTATGAAGT TTGTTGTTA CCGGAGAAGT GTCTGGAGCT  
 1861 GCGCAAAGGC CTGCTAATTG CGTGTCTGTG CCATGACCTG GACCACAGGG GCTTCAGTAA  
 CGCGTTCCG GACGATTAAC GCACAGACAC GGTACTGGAC CTGGTGTCCC CGAAGTCATT  
 1921 CAGCTACCTG CAGAAGTTCG ACCACCCCT GGCAGCGCTG TACTCCACCT CCACCATGGA  
 GTCGATGGAC GTCTTCAAGC TGGTGGGGGA CCGCCGCGAC ATGAGGTGGA GGTGGTACCT  
 1981 GCAACACCAAC TTCTCCAGA CGGTGTCCAT CCTTCAGCTG GAAGGGCACA ATATCTCTC  
 CGTTGTGGTG AAGAGGGTCT GCCACAGGT GGAAGTCGAC CTTCCCGTGT TATAGAAGAG  
 2041 CACCCGTGAGC TCCAGCGAGT ACGAGCAGGT GCTGGAGATC ATCCGCAAAG CCATCATCG  
 GTGGGACTCG AGGTGCTCA TGCTCGTCCA CGACCTCTAG TAGGCGTTTC GGTAGTAGCG  
 2101 CACCGACCTC GCCCTATACT TTGGGAACAG GAAGCAGTTG GAGGAGATGT ACCAGACAGG  
 GTGGCTGGAG CGGGATATGA AACCTTGTG CTCGTCAC CCTCTCTACA TGGTCTGTCC  
 2161 GTCGCTGAAC CTCCACAAAC AGTCCCCTCG AGACCGTGT ATCGGTTGA TGATGACTGC  
 CAGCGACTTG GAGGTGTTGG TCAGGGTAGC TCTGGCACAG TAGCCAACT ACTACTGACG  
 2221 CTGTGATCTT TGCTCTGTGA CCAAACATAG GCCAGTTACA AAATTGACAG CGAATGATAT  
 GACACTAGAA ACCAGACACT GGTGGATAC CGGTCAATGT TTTAACTGTC GCTTACTATA  
 2281 ATATGCAGAA TTCTGGCTG AGGGTGTGA GATGAAGAAG CTGGGCATAC AGCCCATTCC  
 TATACGTCTT AAGACCCGAC TCCCACACT CTACTTCTTC GACCCGTATG TCGGGTAAGG  
 2341 TATGATGGAC AGAGACAAGC GAGATGAAGT CCCTCAAGGG CAGCTGGAT TCTACAATGC  
 ATACTACCTG TCTCTGTTCG CTCTACTTCA GGGAGTTCCC GTGAGCCTA AGATGTTACG  
 2401 TGTGGCCATT CCCTGCTATA CCACCTTGAC GCAGATCCTC CCACCCACAG AGCCTCTGCT  
 ACACCGTAA GGGACGATAT GGTGGAACTG CGTCTAGGAG GGTGGGTGTC TCGGAGACGA  
 2461 GAAGGCCATT AGGGATAACC TCAATCAGTG GGAGAAGGTAA ATTGGCGGGG AAGAGACAGC  
 CTTCCGGACG TCCCTATTGG AGTTAGTCAC CCTCTTCCAT TAAGCGCCCC TTCTCTGTG  
 2521 AATGTGGATT TCAGGCCAG GCCCCGGCGCC TAGCAAGAGC ACACCTGAGA AGCTGAACGT  
 TTACACCTAA AGTCCGGGTG CGGGCCGGCGG ATCGTTCTCG TGTGGACTCT TCGACTTGCA  
 2581 GAAGGGTGAAG GACTGATCCT GAAGTGCAGT CCTGATGCT GCCCAGCAAC CGACTCAACC  
 CTTCCAACCTT CTGACTAGGA CTTCACTGCA GGACTACAGA CGGGTCGTTG GCTGAGTTGG  
 2641 TGCTTCTGTG ACTTCGTTCT TTTGTTTC AAGGGGTGAA AACCCCTGT CAGAAGGTAC  
 ACGAAGACAC TGAAGCAAG AAAACAAAAG TTCCCCACTT TTGGGGGACA GTCTTCCATG  
 2701 CGTCGCATAT CCATGTGAAG CAGACGACTC CCTGCTTGGC GCACACACCT CGGACAGTGA  
 GCAGCGTATA GGTACACTTC GTCTGCTGAG GGACGAACGG CGTGTGTGGA GCCTGTCACT

Figure 19 (con't)

PDE10A compiled

2761 GCAACCCAGG CTCTGCCGTG TTCAGACGTC GGCTACTCCG TGGCTCCACC TGACCTCCGA  
 CGTTGGTCC GAGACGGCAC AAGTCTGCAG CCGATGAGGC ACCGAGGTGG ACTGGAGGCT  
 2821 ATGCTATTG CTCCCAGGCC AGCACTGCAC TGCTGGAGG GGGCAGAGAC CACAGGAGAG  
 TACGATAAAC GAGGGTCCGG TCGTGACGTG ACAGACCTCC CCCGTCTCTG GTGCTCTCTC  
 2881 GTTCTGCCT GCATCCTCCC ATGAGGGTGT GGCCAGTTCC CTAGTTCTGT GCCATGCTGC  
 CAAGAACGGA CGTAGGAGGG TACTCCCCACA CCGGTCAAGG GATCAAGACA CGGTACGACG  
 2941 TGCTTGGTGG CATTGGTTAG GAATGGACA CACGCCCCTT GTTGTAAAGT TTACATGTGA  
 ACGAACCAACC GTAACCAATC CTTACCCCTGT GTGCGGGGAA CAACACTCA AATGTACACT  
 3001 CCTCTTATA GGTTAACTGA GTTGTGGCC TGGGACACAT GTAATGAAGG TCACAGTCCA  
 GGAAGAATAT CCAATTGACT CAAACACCGG ACCCTGTGTA CATTACTTCC AGTGTCAAGGT  
 3061 CAGGTGACAG AGAAATCCAA ACTGTTGATT ACAGGTGCAC TACAGGTATG CTCTTCAGT  
 GTCCACTGTC TCTTAGGTT TGACAACCAA TGTCACCGT ATGTCCATAC GAGAAAGTCA  
 3121 CTATCTGGGG GCACATAGGT GAGTCTGCTC CACTCAGAAG GAGCATAACC TCTCCCTCA  
 GATAGACCCCC CGTGTATCCA CTCAGACGAG GTGAGTCTTC CTTCGTATGG AGASGGGAGT  
 3181 TCCAGGGGAC ACAGGGTACA TCCCAGGCAT CGGGGAACTG AAGCTCTAC TTCAAACCAT  
 AGGTCCCTG TGTCCTCATGT AGGGTCCGTA GCCCCTTGAC TTGAGAGTG AAGTTGGTA  
 3241 GTCAAAGAAT TAAAACACCT CCCCTCCCCC TCACTGTAGC CTTCGGCAAC TGCGCCAATC  
 CAGTTCTTA ATTTGTGGA GGGGAGGGGG AGTGCACATCG GAAAGCCGTTG ACCGGGTTAG  
 3301 CCTTTATACA AAGAAAATAT AAGTAAGGCA TATAAATTTC CTCCAGCAAG CAAATCTTGT  
 GGAAATATGT TTCTTTATA TTCATCCGT ATATTTAAAG GAGGTCTTC GTTTAGAACAA  
 3361 GGGTAAAAAA AAAAATGTG AATTTAACAA ACCTCTATAT TTTCACTGTA TGTATGGCA  
 CCCATTTCCTT TTTTTACAC TTAAAATTGT TGGAGATATA AAAGTACAT ACAATACCGT  
 3421 GAATTTAGT CACGTCCAAA ACAAAAGATT ATTCCAGAAG ATACCTCATC CTATGCCTGA  
 CTTAAAATCA GTGCAGGTTT TGTTTCTAA TAAGGTCTTC TATGGAGTAG GATACTGGACT  
 3481 AAGCTCCACA GCATGGCGTC CGTCTCCCAG GTTCTGATC CGTCTCCTCA CGGTGCAATC  
 TTGAGGTGT CGTACCGCAG GCAGAGGGTC CCAAGACTAG GCAGAGGAGT GCCACGTTAG  
 3541 AGGCAGGACA GGAGGAGGTG CAGGGCTTAC ACATTGACCC AGATGGTATC TCTCTCACC  
 TCCGTCTGT CCTCCTCCAC GTCCCGATGG TGAACTGGG TCTACCATAG AGGAGAGTGG  
 3601 ATTCAAGACAT CCATAAGGAA TGCAAATGC TGTTATTGAAT AGTTCTCTG TGTGACTTT  
 TAAGTCTGTA GGTATTCTT ACGGTTACG ACATAACTTA TCAAGAGGAC ACACGTAAAG  
 3661 TAGAGAAGCC AGGACACCCC TGAGCCTTTC CTGGGAACCTC CTAAGGAAGT CACAGGTTCA  
 ATCTCTCGG TCCGTGGGG ACTCGGAAAG GACCCTTGAG GATTCCCTCA GTGTCCAAGT  
 3721 CACCGTGGGG ATTTTCAGGA TAGCATGGAG ACCAGAGAAAT CCCGGTCCGG TTGTTCTCAC  
 GTGGCACCCC TAAAAGTCCT ATCGTACCTC TGTTCTCTTA GGGCCAAGCC AACAAAGAGTGG  
 3781 TCGGTGAGCC TTGAGAAGGA AGAGACTGAC CAGAAACACT CACTCAGCAC TCTGGCAGGA  
 AGCCACTCGG AACTCTTCCT TCTCTGACTG GTCTTGTGA GTGAGTCGTG AGACCGTCC  
 3841 GCAGGAGAAG ATACTTTAAG ATGAATCTT GGGATAGATT TTGATACACC CAAATACCAT  
 CGTCCTCTTC TATGAAATTTC TACTTAGAA CCCTATCTAA AACTATGTGG GTATGGTAT  
 3901 CACACAGGAG CTGGCATTG GCAAAGTCTA TTCAGTTCC TTCCACACTC TGACCCACGG  
 GTGTCTCTC GAACCGTAAA CGTTTCAGAT AAGTCAAAGG AAGGTGTGAG ACTGGGTGCC  
 3961 TTGTAGCGGA GTGGGCTGAA CACTGTAACA CTGTACATGC GATTTCCCA TGGGCTTCTA  
 AACATCGCCT CACCCGACTT GTGACATTGT GACATGTAGC CTAAGGGGT ACCCGAAGAT  
 4021 AAATGTCACC ATCTCTCTCC CTGCTGTGTC CTACTCCATT TACTGTTAC AAGGTGTGATGT  
 TTTACAGTGG TAGAGGAGGG GACGACACAG GATGAGGTAA ATGACCAATG TTCCACTACA  
 4081 CAACAAGAGA AGCTATCACA ACACCAAGGGC TGTGCACAGC TGCACACACA TGATGCACA  
 GTGTTCTCT TCGATAGTGT TGTGGTCCCG ACACGTGTGC ACGTGTGTGT ACATACGTGT

Figure 19 (con't)

PDE10A compiled

4141 AGCACACAGA TGTATGTACA GCACACACAC ACACACACAC CCCAAAAGGA GAGAAAAGGA  
 TCGTGTGCT ACATACATGT CGTGTGTG TGTTGTTG GGGTTTCCT CTCTTTCC  
 4201 AGAAAACATT TATAAAAAGC GACAGCTACC CCCATATTCA AAAATAGTTC TTTTCCCTGT  
 TCTTTGTAA ATATTTTCG CTGTCGATGG GGGTATAAGT TTTTATCAAG AAAAGGGACA  
 4261 AGGGAAACAG GTAGCTCTCC ATAAGGAAAT TATCATGAGT GTGTTCTCCC ATCAGTGAC  
 TCCCTTGTC CATCGAGAGG TATTCCCTTA ATAGTACTCA CACAAGAGGG TAGTCACGTG  
 4321 TTCTCCCAGG GGTGCTCACT GAAGCTGGTC CACGTCTATA AACAGGTGAC ACTGGCTGCA  
 AAGAGGGTCC CCACGAGTGA CTTCGACAG GTGCAGATAT TTGTCCACTG TGACCGACGT  
 4381 GCAAAAAGCC ATTCGATCCA CACAAATTGA TCTTCTATCA TCTTGAATC TGAATTGCAG  
 CGTTTTCGG TAAGCTAGGT GTGTTAACT AGAAGATAGT AGAACCTTAG ACTTAACGTC  
 4441 GGAGGAGCAG CATGTAAGAC GACCGTTAA TTCAGGCATT CCGAAGGCAT GAGCGCATGG  
 CCTCCTCGTC GTACATTCTG CTGGCAAATT AAGTCCGTAA GGCTTCCGTA CTCGCGTACC  
 4501 ATTCTGTAC CAAGCGTATA AAAGGACCT GGCATTGGGA AACCTATGAC GGACTGTTT  
 TAAGACAGTG GTTCGCATAT TTTCCTGGGA CCGTAACCTT TTGGATACTG OCTGACAAA  
 4561 TGCTGTAGAA GTAGGGATT TACAGAAGTC TCCTTGGATT TGCCCTGCCT GGGGCAGTTT  
 ACGACATCTT CATCCCTAAA ATGTCTTCAG AGGAACCTAA ACGGGACGGA CCCCCGTCAAA  
 4621 TGCAGAGGAA CCTGCCAGAG ATTTATTGGC TGGTCAGTCT CTTGTGAAAT AGTATCATGT  
 ACGTCTCCTT GGACGGTCTC TAAATAACCG ACCAGTCAGA GAACACTTTA TCATAGTACA  
 4681 GAGAAACAGT TTGTAGAAAA AAACATATACC TGGGAAGACC TTTGCAACAT TGTTCCCTCC  
 CTCTTGTCA AACATCTTT TTGATATGG ACCCTTCTGG AAACGTTGTA ACAAGGAAGG  
 4741 ATGGGCCAAG ACTCAGTTAG GAGGCATAAA TCTGCCCGGA ATAAACTAGG CCAGGATACA  
 TACCGGTTTC TGAGTCAATC CTCCGTATTT AGACGGGCCT TATTGATCC GGTCTATGT  
 4801 GCCATTTA GTTAATAATT TGGTTTAGA ATTACACACAG GCAGGATTGG TTTTTTGTG  
 CCGTACAAT CAATTATTAA ACCAAATCT TAAGTGTGTC CGTCCTAAC AAAAAAACAC  
 4861 TCTTGCAAG TGGAGCATAT TAAACATACA GGCACTGGGA TCCTGCCTCT TAGCTTTCC  
 AGAACCGTTC ACCTCGTATA AATTGTATGT CCGTACCCCT AGGACGGAGA ATCGAAAAGG  
 4921 CACCCCTTG TCTCACCAAG TTTTCTCT CCRAAGGTTT CCAGGAATTTC CTCATTAATG  
 GTGGGAGAAC AGAGTGGTC AAAAAAGAGA GTTTCAAA GGTCTTAAA GAGTAATTAC  
 4981 GCTGATGCAA ACTTAGTGA TAATAATGAA TATAAACAT GCTCACCTCA CCAAAATTAT  
 CGACTACGTT TGAATCATT ATTATTACTT ATTTTGTTA CGAGTGGAGT GTTTTAA  
 5041 ATTATTTGCA GTCATTTGTG ATACACAAA TTTTATGCA ATGGTTATTA TTTAATTGT  
 TAATAAACGT CAGTAAACAC TATTGTGTT AAAATAGCGT TACCAATAAT AAATTAAACA  
 5101 GGCCACACAC TGTGGTTATC TTTTGTG TGTTGTTCTG AGAAAATGTT CTTGGATATG  
 CCGGTGTG ACACCAATAG AAAACAACAC CAACAAAGAC TCTTTACAA GAACCTATAC  
 5161 TAAGTGCCAA TACCAAGTGTG AAGTATTGAT CCCGGGCAGC AAAATACAGC CTAAGGTTG  
 ATTACCGTT ATGGTCACAC TTCATAACTA GGGCCCGTGC TTTTATGTG GATTCCAAAC  
 5221 TAAACATCAA TTCTATCTCA GTTCATCAGA GGGCCTGAGA AGCTGCGGGG CAGTGTAAAG  
 ATTTGTAGTT AAGATAGAGT CAAGTAGTCT CCCGGACTCT TCGACGCCCC GTCACATTTC  
 5281 TAAAGTATGC TGGGCTGGTG GTGGTCAGCC TCCCCTGCC AAGAAGAGAG CAATTGAATC  
 ATTCATACG ACCCGACCAAC CACCAAGTCGG AGGGGAACGG TTCTCTCTC GTTAACTTAG  
 5341 CTGCCCCAG CTCCCTCCAC GCCTGAAGAG TGACCAAGTGC TGGCCCGACG GATCGCTGAG  
 GACAGGGTCA GAGGGAGGTG CGGACTTCTC ACTGGTCACG ACCGGGCTGC CTAGCGACTC  
 5401 ATATTCTCCC ATAATGGCAA AAAATAGGC AGTTTGATGT GACCTGTTA GTGTGGCTCT  
 TATAAGAGGG TATTACCGTT TTTTATCCG TCAAACTACA CTGGACAAAT CACACCGAGA  
 5461 CCTCTTTGA GCATGTGTTA GCATTTAT TTTTATCTCA TCCAGTGAAC TCTGCTCTTC  
 GGAGAAAAACT CGTACACAAAT CGTAAAAATA AAATATGAGT AGGTCACTTG AGACGAGAAG

## Figure 19 (con't)

PDE10A compiled

5521 CAAGTGTGTT CATGTATGTG CTAGATATAT TAGCACAGCC TGCCTCTGC TGCACAACGC  
 GTTCACACAA GTACATACAC GATCTATATA ATCGTGTGCG ACGGAAGACG ACGTGTGCG  
 5581 CTTAGAGACC CGGCCTTCA ATGAGCTTAG CTTGTGCTCT GTTTCTGCTC TCTTAGGTCT  
 GAATCTCTGG GCCGAAAGT TACTCGAAC GAAACACGAGA CAAAGACGAG AGAATCCAGA  
 5641 AAACATATGGT GTCAGTTTA ATAGAACAAA AGTATGCATC TTGCCTTGGC TTGAGCCTT  
 TTTGATACCA CAGTCAAAT TATCTTGTGTT TCATACGTAG AACGGAACCG AACTCGGAAA  
 5701 TCGTTTCAA TGCTGACTTC TCCCCTTCT CTCCCTGTGCT CACCTTACCT TTCCAGAGTG  
 AGCAAAAGTT ACAGACTGAAG AGGGGAAAGA GAGGACACGA GTGGAATGGA AAGGTCTCAC  
 5761 TAAGGACAA CTTTAAGGA GGCGTGTCCC TGGTAGGGGC ATCCCTGTC ACCAGGTGCC  
 ATTCCCTGTT GAAAATTCCCT CCGCACAGGG ACCATCCCCG TAGGGACAAG TGGTCCACGG  
 5821 TGTCACTACC CCACATTGACT GACATCTACC CTGGTGAECT TGGGTTCTC TTGTTTGAG  
 ACAGTAGTGG GGTGAACCTGA CTGTAGATGG GACCACTGAT ACCCAAGGGAG AACAAACATC  
 5881 GGAACGGTGG CTCCAGGTGG AGGCATCAAT CTGTTGGGTT CTGGTCCCG GCTGCCTTG  
 CCTTGCCACC GAGGTCCACC TCCGTAGTT GACAACCCAA GACCAAGGGC CGACGGAAAC  
 5941 GTTTGAAAG TCTCTCTCT GTATATTCTC ACCCTGCATT TGCTTGTGT GGTGCTGATG  
 CAAAACCTTC AGAGAACAGA CATATAAGGA TGGGACGTAAC GCAACACACA CCACGACTAC  
 6001 CTGTGGCAGT AGGATCTTGG ATGACTCTCC ATCAGTCACA GACTCCCCCT GTGCAAAGT  
 GACACCGTCA TCCTAGAAC TACTGAGAGG TAGTCAGTGT CTGAGGGGA CAACGTTCA  
 6061 GTCAGGCTGA CTCGACAGTC ACCGTAAT CTGAGTCAGT CACACACAGG CTGTCAGCCA  
 CAGTCGACT GAGCTGTCA TGCGATTTA GACTCAGTC GGTGTTGTC GACAGTCGGT  
 6121 CGGCTCCAC TTGCATGGCT ATTCTATTT CACACGTGAG TTTCTGTTGC TGGCTGGCTG  
 GCCGAAGGTG AACGTACCGA TAAGATAAAA GTGTGCACTC AAAGACAACG ACCGACCGAC  
 6181 ACTGGCATT TCTATGCTAA GTTGAATCA GGAGTGTGCC CAGCAGAGCC CATCATTCTC  
 TGACCGTAAT AGATACGATT CAACTTAGT CCTCACACGG GTCGTCTCGG GTAGTAAGAG  
 6241 ACTGTCTTG AAACAAAGCT GTACGTTG ATCGATGAA GTATTAAAG CATTTCATGC  
 TGACAGAAAC TTGTTTCGA CATGCCAAC TAGCTACTTG CATAAAATTTC GTAAAGTACG  
 6301 AATGACAAAG TGCTCAGTAG TGGAAAGGCG GCTGTGACCA GTCTGCCTGC TCCTTACTAT  
 TTACTGTTTC ACGAGTCATC ACCTCCGTC CGACACTGGT CAGACGGACG AGGAATGATA  
 6361 AATTGTGAGG ATTGTTACT GGAACAGTAC ATGGAGGCCT GACCTTGTGG GGGCACAGGG  
 TTAACACTCC TAAACAATGA CCTTGTCAATG TACCTCCGGA CTGGAACACC CCCGTGTCCC  
 6421 TGGAACCTTA GCTGAATATA GTGTGTGTCT CAAAGAGGAAG TCAGGGTACT AGCTCAGTGC  
 ACCTTGAAT CGACTTATAT CACACACAGA GTTCTCCTTC AGTCCCATGA TCGAGTCACG  
 6481 TCAATCTCCA GGTACTATAT ATACATTGCG CCGTTTATC TCTAATGTGA AATAAAATCCC  
 AGTTAGAGGT CCATGATATA TATGTAACG GGCAAAATAG AGATTACACT TTATTTAGGG  
 6541 CAAACACTTG TTTATCGTGT AGCGTACCTA AAAGACTATT CTATTATGGG TGTCCCCACT  
 GTTGTGAAAC AAATAGCACA TCGCATGGAT TTTCTGATAA GATAATACCC ACAGGGGTGA  
 6601 TTCTGGTTT GGTACCCCCG ATCCCCCGGT CTTCTGCTGT ATCTAGAAC GTGACTATAA  
 AAGAACCAAA CCAGTGGGGC TAGGGGGCCA GAAGACGACA TAGATTTGT CACTGATATT  
 6661 ATGATGTATG GGAATAGTGT TTCCATATGA TCTGTGTCT GGAGTATATG CTACATGTC  
 TACTACATAC CCTTATCACA AAGGTATACT AGACAACAGA CCTCATATAC GATGTACAAG  
 6721 ATTTACTGTA CAAAAACCA GTGCAGCTGA TGATGAAAG CAGTCCTCT CTGTGTACAG  
 TAAATGACAT GTTTTGGGT CACGTCGACT ACTACGTTTC GTCAAGAGAGA GACACATGTC  
 6781 TGCCCCACCT ATTTAAAAAT CACGTACAAN CCCAGAACAC TGTGAAACAC TTAACATAAG  
 ACGGGGTGA TAAATTTTA GTGCATGTTN GGGTCTGTG AACTTTGTG AATTGTATT  
 6841 AAACAAACGC AGCGTCTGGA TTCTTCCAA GGAGAGCAGC TTTCTCCACA GGAACACAGT  
 TTTGTTGCG TCGCAGACCT AAGAAAGGTT CCTCTCGTCG AAAGAGGTGT CCTTGTGTCA

## Figure 19 (con't)

PDE10A compiled

6901 AACAAAAGAG GTCCGCCGCC ATCCACACCC AGCCAAGACA CCTCAGAGGC CATAGGGACA  
 TTGTTTCTC CAGGCCGG TAGGTGTGGG TCGGTTCTGT GGAGTCTCCG GTATCCCTGT  
 6961 ACCTCCTTGC TGGCCAACAC CTGCTGGAGC AGGGCACAGG TCCCAGCAAC TGATCCTCAG  
 TGGAGGAACG ACCGGTTGTG GACGACCTCG TCCCGTGTCC AGGGTCGTTG ACTAGGAGTC  
 7021 TGGATGGGTC CGCAGTCAAA GCCTTAATGG GCTCTTTT GAAGGGGAAA GAAANNTTC  
 ACCTACCCAG GCGTCAGTTT CGGAATTACC CGAGAGAAAA CTTCCCTTT CTTTNNAAG  
 7081 AAGCTTATGA TATCCAACAT TATTATAGTT GATGAGTTAG TAAATTCCGA AAAAAAAAGA  
 TTCGAATACT ATAGGTTGTG ATAATATCAA CTACTCAATC ATTTAAGGCT TTTTTTCT  
 7141 TGATTTATA TGATGACAT AAAAAAAATC TTTGAAAGT GCGCAAGTGC AATAATTTAA  
 ACTAAAATAT ACATACTGTG TTTTTTTAG AAACATTCA CGCGTTCACG TTATTAATT  
 7201 AGAGGTCTTA TCTTGCATT TATAAATTAT AAATATTGTG CATGTGTGTA ATTTTCATG  
 TCTCCAGAAT AGAAACGTAA ATATTTATA TTTATAACAT GTACACACAT TAAAAGTAC  
 7261 TATTCATTG CAGCTTTGT ATTTAAAAAA ACTTTACTGT TATGTTGTG TAATAGAAC  
 ATAAGTAAAC GTCAGAAACA TAAATTTTT TGAAATGACA ATACAAACAT ATTATCTTGT  
 7321 TTAATCATTT ATTATAACTC AGACAAGGTG TAAATAAATT CATAATTCAA ACAGCCAGTA  
 AATTAGTAA TAATATTGAG TCTGTTCCAC ATTTATTTAA GTATTAAGTT TGTCCGTAT  
 7381 TATATGCATA TATGGGTGTT ACATTGCAA AATCTCTATC TTTGTTCTAT TCACATGCTT  
 ATATACGTAT ATACCCACAA TGTAACGTT TTAGAGATAG AAACAAGATA AGTGTACGAA  
 7441 AAAGAAGTAA GAAATCTTT GTGGATATGT AATTATACAT ATAAAGTATA TATATATGTA  
 TTTCTTCATT CTTTAGAAAA CACCTATACA TTAATATGTG TATTCATAT ATATATACAT  
 7501 TGATACATGA AATATATTTA GAAATGTTCA TAATTTAAT GGATATTCTT TGGTGTGAAT  
 ACTATGTACT TTATATAAT CTTTACAAGT ATTAAGGTTA CCTATAAGAA ACCACACTTA  
 7561 AATTGAATAC AACATTTTA AAATGAAAA AAAAAAAA AAAAAAAA AAAAAAAA  
 TTAACCTTATG TTGTAAGGTT TTTACTTTT TTTTTTTTT TTTTTTTT TTTTTTTT

## SEQUENCE LISTING

<110> ROBERTSON, Harold  
DENOVAN-WRIGHT, Eileen  
NOVANEURON, INC.

<120> GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND  
COMPOUNDS FOR MODULATING SAME

<130> 36541-0005

<140>  
<141>

<150> US60/158,043

<151> 1999-10-07

<150> US60/217,765

<151> 2000-07-12

<160> 12

<170> PatentIn Ver. 2.0

<210> 1  
<211> 3236  
<212> DNA  
<213> mouse

<400> 1  
cactgaagct ggtccacgtc tataaacagg tgacactggc tgcagcaaaa agccattcga 60  
tcccacacaaa ttgatcttct atcatcttgg aatctgaatt gcagggagga gcagtatgtta 120  
agacgaccgt ttaattcagg cattccgaag gcatgagcgc atggattctg tcaccaagcg 180  
tataaaagga ccctggcatt gggaaaccta tgacggactg ttttgctgt agaagttaggg 240  
attttacaga agtctccttg aatttgcctt gcctggggca gttttgcaga ggaacctgcc 300  
agagatttat tggctggtca gtctcttgta aaatagtatc atgtgagaaa cagttttag 360  
aaaaaaaaacta tacctggaa gaccttgca acattgttcc ttccatggc caagactcag 420  
ttaggaggca taaatctgcc cggaataaac taggccagga tacagccatg ttttagttaat 480

aatttggttt tagaattcac acaggcagga ttgggttttt tgcgtcttgg caagtggagc 540  
 atattnaca tacaggcatg gaaatccgc ctcttagctt ttcccaccct cttgtctcac 600  
 caagttttt ctctccaaag gtttccagga atttcattt aatggctgat gcaaacttag 660  
 tgaataataa tgaatataaa caatgctcac ctcaccaaaa ttatattatt tgcaagtctt 720  
 tgtgataaca caaatttat cgcaatgggtt attattnat ttgtggccac acactgtgg 780  
 tatctttgt tgcgtttgtt tctgagaaaa tgcgtttggta tatgtaaatg ccaataccag 840  
 tgtgaagtat tgatccccggg cagcaaaaata cagcctaagg tttgtaaaca tcaattctat 900  
 ctcagttcat cagagggcct gagaagctgc ggggcagtgt aaagtaaagt atgctggct 960  
 ggtggtggtc agcctccgc ctgaagagtg accagtctg gccgcacggta tcgctgagat 1020  
 attctccat aatggcaaaa aaataggcag tttgtatgtga cctgttttagt gtggctctcc 1080  
 tctttgagc atgtgttagc atttttat tataactcatc cagtgaactc tgctcttcca 1140  
 agtgtgttca tgcgtgtct agatataat gcacagctg cctctgtc cacaacgcct 1200  
 tagagacccg gccttcaat gagcttagt tgcgtctgt ttctgtctc ttaggtctaa 1260  
 actatgggtt cagtttaat agaacaaaag tatcatctt gccttggctt gagcctttc 1320  
 gtttcaatg ctgacttctc cccttctct cctgtgtca ccttacctt ccagagtgt 1380  
 agggacaact tttaaggagg cgtgtccctg gtagggcat ccctgttac caggtgcctg 1440  
 tcatcaccctt acttgactga catctaccct ggtgactatg gtttccctt gttttaggg 1500  
 aacggtggtt ccaggtggag gcatcaatct gttgggttct gtttcccgcc tgctttgg 1560  
 tttgaaatgc tcttctctgt atattcctac cctgcatttgc ctttgtgtgg tgctgtatgt 1620  
 gtgcgcagta ggattcttgg atgactctcc atcagtcaca gactccccctt gttgcaaaatg 1680  
 gtcaggctga ctgcacagtc accgtaaaat ctgagtcagt cacacacagg ctgtcagcca 1740  
 cggcttccac ttgcattggctt attctat ttttgcatttgc tggctggctg 1800  
 actggcatta tctatgtcaa gttgaaatca ggagtgccttca gcaagaccca tcattctcac 1860  
 tgcgtttgaa acaaagctgt acggtttgcat cgatgaacgt atttaaagca tttcatgcaa 1920  
 tgacaaatgc tctagtagt gaaaggcaggc tgcgttgcctt cttactataa 1980  
 ttgtgaggat ttgttactgg aacagtacat ggaggcctga cttgtgggg gcacagggtg 2040  
 gaaccttagc tgaatataatgt gtgtgtctca agaggaagtc agggtactatg ctcagtgctc 2100  
 aatctccagg tactatataat acatttgcctt gtttctctc taatgtgaaa taaatccccca 2160  
 aacacttgcattt ttcgtgttag cgtacctaaa agactattctt attatgggttgc tccccacttt 2220  
 cttggtttgg tcaaaaaatgc cccccggctt cttactgtat ctgcatttgc gactataat 2280  
 gatgtatggg aatagtgtttt ccatatgtatc tgcgttgcctt agtataatgtt acatgttcaa 2340  
 ttactgtaca aaaacccagt gcaagctgtatg atgcaaaatgc gtctctctt gtgtacagt 2400  
 cccccactt taaaaatgc cgtacaascc cagaacactg tgaaacactt aacataagaa 2460  
 caaacgcagc gtctggattc tttccaagga gagcagctt cttccacagga acacagtaac 2520  
 aaaagaggcgc cggccgcattc cacacccaggc caagacacctt cagaggccat aggacaacc 2580  
 tccctgtgg ccaacacactg ctggagcagg ggcacaggc ccagcaactg atcctcagtg 2640  
 gatgggtccg cagtcaaagc cttatgggc tcttttgc ttttgc ttttgc ttttgc ttttgc 2700  
 agcttatgtt atccaaacattt attatgttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2760  
 gatgtatgggg ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2820

gaggtcttat cttgcattt ataaattata aatattgtac atgtgtgtaa ttttcatgt 2880  
attcatttgc agtctttgtta tttaaaaaaa ctttactgtt atgtttgtat aatagaacat 2940  
taatcattta ttataactca gacaagggtgt aaataaaattc ataattcaaa cagccagtgat 3000  
atatgcatat atgggtgtta cattgcaaaa atctctatct ttgttctatt cacatgctta 3060  
aagaagtaag aaatcttttg tggatatgtta attatacata taaagtatata atatatgtat 3120  
gatacatgaa atatatttag aaatgttcat aattttaatg gatattctt ggtgtgaata 3180  
attqaataaca acatTTTaa aatgaaaaaaaaaaaaaaaaaaaaaaa aaaaaaaa 3236

<210> 2

<211> 5752

<212> DNA

<213> mouse

<400> 2

aagtgtaaaat aaaataaaaca tctaataaaa aaaattacat accatagagg aacaagataa 60  
tttctgccc aacctcatacc ctccagcgta tagtgttag gtttggctcg ttgtgtgt 120  
ttgtaatgtat atgttaaatt ctctacctga aggtcttaggc ctacaagtga attctcatgt 180  
ttatagagtt ttgttgca aaccttggc cttaaattaa aactatggtt aaaaaacaaa 240  
acaacaaactgg ctacagccaa taactgaagg gggttacctt gttgaagggg tggaaaagag 300  
agaggagggaa gaaggaggtt caagagaagg agaagaacaa gaggagagga ggaagctgcc 360  
acgaggggag atgggcccattt agaacttggc caggagaaat agccagtatc tggagtacac 420  
caactgaggag gtagccaggc tagcagttag aagagtagat taggggttat tttccccca 480  
ctccacatag ttatcaaagc caaataaaat aaccatagtc tgagtctcat ctattgtaa 540  
gctagttggg tataagatta atttggctgt actacagttt agattctaa cataggaact 600  
atcaaaaaact tgctcaaaca agaacatgct gacaatattt taaaatgatt atttatattt 660  
tttgcacttt ctaaagttt tcctaaatgt tccatggtca aattaaaaaa tatacatatt 720  
ggcttataaa ttctgtctaaag tggggctgga gagatagctc agaggttaag agcactgact 780  
gctctccag aggtcctgag ttcaattccc agcgaccaca tggtggtca cagccatctg 840  
taatagatag gatctgacgc cctcttctgg agtgtctgaa gacagctaca atgtactcat 900  
atataattaaa taaataatataat tagaaaaattt tcctaaatgtt atcatttata gaatattttaa 960  
tatataaaatgtt aaatgcctca gggaaatataa acttggaaattt aaatcaaaga acttcatgag 1020  
tagtgggcca caaaaaatgt gtaccagggg aagaccggag ggaggggaga aggaaggat 1080  
ggagatagaa ttttgcctct gcattccttgc ggctggcaca ggtataatgc tgtggaaattt 1140  
ggggaaactac aaggaagctg caaagctggg cggaaactcgt ttccgcaagc tgggctcatc 1200  
taagtgtcca tgcattggctg ccacactgca gtgaactttt aaacatttgtt gttccagaga 1260  
tgttagagatg ctcacaatag tacaaaggcg ggagggaggtt atttccagac taagaggaag 1320  
aaaaaccatt gctgattttt catctgcata tgagcgcccc cacctccata cacacacacaca 1380  
cacacacacaca cacacacacaca caaccaaaca gaacaaatac acatgcattt ctacagcctg 1440  
caggaacaaa atggtatgtc tgtgaggaac caggagatgc acaggtccta acctctgtct 1500

cctacaagcc ctgaagtctg gtcagggtca aatgtacaaa agcaggctaa ggaagctgtt 1560  
tagtgaaaga ttttttctt caactctagg aacaacctat ttccttaggat ttggagagtg 1620  
ctcaggagga aacattcaga caactgatgc tctctgtgt ccccagattc aggtattggg 1680  
gtagtttgtt gtgctcatgt atgtgctaga tatattagca cagcctgcct tctgctgcac 1740  
aacgccttag agacccggcc tttcaatgag cttagctgt gctctgttc tgctcttta 1800  
ggtctaaact atgggtgtcag tttaataga acaaaagtat gcatcttgcc ttggcttgag 1860  
cctttcggtt ttcaatgctg acttctcccc tttctctcct gtgctcacct tacctttcca 1920  
gagtgttaagg gacaactttt aaggaggcgt gtcctggta ggggcattccc tgttcaccag 1980  
gtgcctgtca tcaccccaact tgactgacat ctaccctggt gactatggg tcctcttgg 2040  
tgttagggAAC ggtggctcca ggtggaggca tcaatctgtt gggttctggt tcccgctgc 2100  
ctttgggttt gaaagtctct tctctgtata ttcctaccct gcatttgctt tgtgtggc 2160  
tgatgctgtg cgccagcaggta ttcttggatg actctccatc agtcacagac tccccctgtt 2220  
gcaaagtgtc aggctgactc gacagtcacc gtaaaatctg agtcagtcac acacaggctg 2280  
tcagccacgg cttccacttg catggctatt ctatttcac acgtgagttt ctgttgcgg 2340  
ctggctgact ggcatttatct atgctaagtt gaaatcaggg gtgcccagca gagcccatca 2400  
ttctcactgt ctggaaaca aagctgtacg gtttgcgtt tgaacgtatt taaagcattt 2460  
catgcaatga caaagtgtc agtagtgaa ggcaggctgt gaccagtctg cctgctcctt 2520  
actataattt tgaggatttg ttactggaa acgtacatgaa ggcctgaccc tggggggca 2580  
cagggtggaa ccttagctga atatagtgtg tgtctcaaga ggaagtcagg gtactagctc 2640  
agtgctcaat ctccaggtac tatatatatac tttggccgtt ttatctctaa tgtgaaataa 2700  
atccccaaac acttggattt cgtgtacgt acctaaaaga ctattctatt atgggtgtcc 2760  
ccactttctt gggttggta ccccgatccc ccggcttctt gctgtatcta gaacagtgac 2820  
tataaatgat gtatggaaat agtggatcca tatgatctgt tgtctggagt atatgctaca 2880  
tgttcattta ctgtacaaaa acccagtgcac gctgatgatg caaagcagtc tctctctgtg 2940  
tacagtgtccc cacattatc aaaatcacgt acttgcggcag aacactgtga aacacttaac 3000  
ataagaacaa acgcagcgac tggattctt ccaaggagag cagcttctc cacaggaaca 3060  
cagtaacaaa agaggtccgc cgccatccac acccagccaa gacacctcag aggcattagg 3120  
gacaacctcc ttgctggcca acacctgctg gagcaggggc acaggtccca gcaactgatc 3180  
ctcagtggat gggctgtcag ccaaagcctt aatgggtctt cttttgaagg ggaaagaaag 3240  
aatttcaagc ttatgatatc caatattatt atagttgatg agtttagaaa ttccaaaaaa 3300  
aaaagatgat ttatatgtt tgacataaaa aaaatctttt taaagtgcgc aagtgcata 3360  
attnaaagag gtcttatctt tgcatttata aattataaat attgtacatg tgtgtatctt 3420  
ttcatgtatt catttgcagt ctttgttatt aaaaaactt tactgttatg tttgtataat 3480  
agaacattaa tcatttata taactcagac aaggtgtaaa taaattcata attcaaacag 3540  
ccagttatata tgcattatatg ggtgttacat tgcaaaaatc tctatcttgc ttctattcac 3600  
atgcttaaag aagtaagaaa tctttgtgg atatgtatt atacatataa agtataatata 3660  
tatgtatgtat acatgaaata tatttagaaa tggcataat ttatggat attctttgg 3720  
gtgaataattt gaatacaaca tttttaaaat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3780  
aaaatttttt ttatccaga gattaaagac actagatctt taaccttgaa 3840

gggcaggcaa gaggtcggca atgctgtcaa catagaagtc agggaccatt ttcttcttga 3900  
 acatgcagtc actttcttga ttgctttca catcctaag gctccggaat tccgggggtg 3960  
 tggtggcctt tgatctcagg actctggagg cagaagcagg cagatctcg tgaatatgag 4020  
 gccagcctgc actacacaga gctccagacc agtcatggct acatcatgaa accctgtctc 4080  
 aaaaagaaaaaaa taaaaactgt tgtgtttcta ccatagtgtt aaactcagag tctgagtaat 4140  
 gtcgggctga catgctcggg tggtaacat accttcagct ttgacgaggc gctgaacagt 4200  
 caaagtctgg cttggggag cggtggctgt gtttgctc aagtccaccc tgaaatcctg 4260  
 atttgtaatt tggacaaccg tggccctt cttggccttc catgcaacct ccaacttcat 4320  
 gttggtcatt ttgtcaaaac actgtgtgat gtttttatca atatactgcc attccacata 4380  
 tgttagagatg tagtctgcct ggctttcctt ttctttagcc aatcgaatgc tcttgatcat 4440  
 gcccctaattc tcatactctag cttttatcac gtctctgcta attcctgaaa cttgaatcga 4500  
 agtttcttc tggttcatct caatggtgat gttcagttcc ttctgaatct cattcagttt 4560  
 ctctgactcc tccatgtcaa agtcaactgac acactcatcg tcattgggtt aggaaagctg 4620  
 ctcttggta atcagttcct ttagccagga gattgttttgc ttccacactgt ctacccctga 4680  
 accacataacc tggaaaactg tgtgctctat ttcttttcc aaaaccaggg tggttttttt 4740  
 gggggaaagct tgcttggaa agccaagaaa ggctaaagag aaaatggaaa ttaatgtttc 4800  
 ttttactccc ttcaacatca aggttaggaa tatgtatttc ataaaagcta acaactcaca 4860  
 ggcaatctta gacatcaactg actgcttggc aggcaactgc ttggggggag ctggagagcc 4920  
 ttctctttctt ttcatgttgt cgtaaaaaaa ttgcagaata tggggctgga agataacaac 4980  
 tttaactctc ttccacagcct gcactgattt ttctggaca aattcttcaa tggcatctat 5040  
 tatcgctttt gctactacgt ttgggtcctg ttgagcattt cttcaaaaaa caaaaaaagc 5100  
 acattttaa aaagtcaagg ttaagatcca cctgcaaaaaa aaagctgcaa tataagcgg 5160  
 gaattcttagt tgtcacagga aataaaaaatg tctgttccca ctataatcaa ttagactga 5220  
 taatattatg ccagcaata gtttgaagt cctaggcaca gtgggaggag gtttggcc 5280  
 acgctgttca taagccaata ccccagcaaa agacctaaa ggacaacttg taatttggga 5340  
 cattcacatc tgtccttttc atctgatctg gctccagtg tcactctcta acacggcct 5400  
 tagagggaca atttatccct gcctctgctt gatcttgc atgtatctgt attcttccag 5460  
 ccatccctgg cgacctgatt ttcttaaggc accaaaaact gtaagctact tcttataatc 5520  
 tataattctg agcatattag ttagcctgag cctccaggat atcttttttc cctataactca 5580  
 gtccagttt agctgcccag aaggattcaa agctgatcta cgagtagatc actcctgtct 5640  
 acagcttgtt ccagatcttgc ttctcaagc cctggaagcc atcagccagg taagattgta 5700  
 aaacaatccc ttctaatca tgggtgtggc ccaaagtgaa tggccggaaat tc 5752

&lt;210&gt; 3

&lt;211&gt; 475

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 3

tgtatggaa tagtgttcc atatgatctg ttgtctggag tatatgcac atgttcattt 60  
actgtacaaa aaccaggcgc agctgatgtat gcaaaggcagt ctctctctgt gtacagtgcc 120  
ccacacctttt aaaaatcacg tacttgccca gaacactgtg aaacacttaa cataagaaca 180  
aacgcagcgt ctggattctt tccaaggaga gcagctttct ccacaggaac acagtaacaa 240  
aagaggtccg ccgccccatcca cacccagcca agacacctca gaggccatag ggacaacctc 300  
cttgctggcc aacacctgct ggagcagggg cacaggtccc agcaactgat cctcagtgg 360  
tgggtctgca gccaaagcct taatgggctc tctttgaag gggaaagaaa gaatttcaag 420  
cttatgatat ccaatattat tatagttgtat gagtttagtaa attccaaaaaaa aaaaaa 475

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 4

agggctgtca atcatgctgg

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 5

aaactcacgg tcgggtgcagc

20

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 6  
at~~ta~~accctc actaaatgct gtat

24

<210> 7  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:probe

<400> 7  
cattatgctg agtgat~~at~~tct tttttt~~t~~tcg

30

<210> 8  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:probe

<400> 8  
gaacatgtag c~~a~~tatactcc agacaacaga tc~~a~~tatgg

38

<210> 9  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:probe

<400> 9  
cag~~tt~~ctcc acag~~gg~~aacac agtaacaaag ag

32

<210> .10  
<211> 35  
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

ctatccaca agagactgac cagccaataa atctc

35

<210> 11

<211> 7581

<212> DNA

<213> Unknown

<400> 11

cgccccggca ggtctgttgg agggcagttg gtcaacctga ccagagagag ctgagctgga 60  
agaccccact gatggtgtgc tgccttcag tccaggaaga aagaaaggaa ggattcttag 120  
gatttggca aagccacatt cctggagaag tctgtatact gatgccaaac ccaagagctg 180  
agctgctgat gaggcccagg gagtagccca cgccctgta gctgttgct agcaaggcct 240  
tcctgctcca tgtggcatgg aaaaattata tggtttgacg gatgaaaagg tgaaggccta 300  
tctttctctc catccccagg tattagatga atttgttct gaaagtgtta gtgcagagac 360  
tgtggaaaag tggctgaaga gaaaaaccaa caaagcaaaa gatgaaccat ctcccaagga 420  
agtcagcagg taccaggata cgaatatgca gggagtcgtg tacgagctga acagctacat 480  
agagcagcgc ctggacacgg gcggggacaa ccacctgctc ctctatgagc tcagcagcat 540  
catcaggata gccacaaaag ccgacggatt tgcactgtac ttcccttggag agtgcataaa 600  
tagcctgtgt gtgttcatac cacccggat gaaggaaggc caacccggc tcatccctgc 660  
agggccatc acccaggta ccaccatctc tgcctacgtg gccaagtcta ggaagacgtt 720  
gttggtagag gatatccttgc gggatgagcg atttcctcgat ggtactggcc tggaaatcagg 780  
aaccgcac tgcgttgc tttgcttgcc cattgtcaact gccattggag acttgattgg 840  
catccttgcac ctgtacaggc actggggcaa agaggccttc tgcctcagcc atcaggaggt 900  
tgcaacagcc aatcttgcatt gggcttcgt agcaatacac caggtgcagg tgtgttagagg 960  
tctcgccaaa cagaccgaac tgaatgactt cctactcgac gtatcaaaga catacttga 1020  
taacatagtt gcccataact ctctacttgc acacatcatg atatatgc当地 aaaaatctagt 1080  
gaacgcccac cgctgcgcgc tcttccaggt ggaccacaag aacaaggagc tgtactcgga 1140  
cctgtttgac attggggagg agaaggaggg gaagccatc ttcaagaaga ccaaggagat 1200  
cagatttcc attgagaaag ggattgtgg tcaagtggca agaacaggcg aagtcttgc当地 1260  
cattcccgat gcctacgcgg accctcgctt taacaggag gtggacctgt acacaggcta 1320  
caccacgagg aacattctgt gtatgcccatt agtgcgcga ggcagcgtga ttggcgtggt 1380  
gcagatggtg aacaagatca gcggttagcgc cttctccaag acagacgaga acaacttcaa 1440  
gatgtttgct gtcttctgcg cactggcctt gcactgtgct aacatgtacc acaggatccg 1500

ccactcagaa tgcacatctaca gggttaccat ggagaagctt tcctaccaca gcatctgcac 1560  
ctccgaggag tggcaaggcc tcacatgcgtt caacccatcca gcacgcacatc gccgggacat 1620  
cgagctatttc cactttgaca ttggtcctt cgagaacatg tggcctggga tctttgtcta 1680  
catgatccat cggtcttgtg ggacatcctg ttttgaacctt gaaaaattgt gccgttttat 1740  
catgtctgtg aagaagaact atcggcgggt tccttaccac aactggaagc atgcagtcac 1800  
ggtggcacac tgcacatgtatc ccatacttca aaacaacaat ggcctttca cagacatcga 1860  
gcfgcaaaggc ctgctaatttgc cgtgtctgtg ccatgacactg gaccacaggg gcttcagtaa 1920  
cagctacactg cagaagttcg accacccctt ggcggcgctg tactccacccatccaccatgga 1980  
gcaacaccac ttctcccaga cgggttccat cttcagctg gaagggcaca atatcttctc 2040  
caccctgagc tccagcgttgc acgagcaggt gctggagatc atccgcaaaag ccacatcgc 2100  
caccgaccc tcacatgtatc ttgggaacag gaagcagttg gaggagatgt accagacagg 2160  
gtcgctgaac ctccacaacc agtcccacatcg agaccgtgtc atccgcttgc tgatgactgc 2220  
ctgtatctt tgctctgtga ccaaactatg gccagttaca aaattgacag cgaatgatata 2280  
atatgcagaa ttctgggctg agggtgatga gatgaaagaag ctgggcatac agccattcc 2340  
tatgtggac agagacaagc gagatgaagt ccctcaaggg cagctcgat tctacaatgc 2400  
tgtggccatt ccctgctata ccaccttgc acgatcctc ccacccacag agcctctgt 2460  
gaaggcctgc agggataacc tcaatcagtg ggagaaggta attcgcgggg aagagacagc 2520  
aatgtggatt tcaggcccag gcccggcgcc tagcaagagc acacctgaga agctgaacgt 2580  
gaagggttgc gactgatcctt gaagtgcgtt cctgatgtct gcccagcaac cgactcaacc 2640  
tgcttctgtg acttcgttctt ttttggggaa aacccctgt cagaaggtac 2700  
cgctcgatata ccatgtgaag cagacgactc cctgcttgc gcacacacccatc cggacagtga 2760  
gcaacccagg ctctgccgtg ttcagacgtc ggctactccg tggctccacc tgacccatcc 2820  
atgctatttgc ctccaggcc agcaactgcac tgtctggagg gggcagagac cacaggagag 2880  
gttcttgctt gcacatccc atgagggtgt ggccagttcc ctatgttgc gcatgctgc 2940  
tgcttgggg cattgggttag gaatgggaca cacggccctt gttgtgaagt ttacatgtga 3000  
ccttcttata ggttaactga gtttgtggcc tggacacatg taatgaaggt cacagtccac 3060  
aggtgacaga gaaatccaaa ctgttgatta caggtgcact acaggtatgc tcttcagtc 3120  
tatctggggg cacatagggtg agtctgcctt actcagaann aagcataacct ctggccatcat 3180  
ccaggggaca caggttacat cccaggcatc ggggaactga agctctact tcaaaccatg 3240  
tcaaagaatt aaaacacactc ccctccccctt cactgttagcc ttgcacaact gcgccaaatcc 3300  
ctttatacaa agaaaataaa agtaaggcat ataaaattcc tccagcaagc aaatcttgc 3360  
ggtaaaaaaaa aagcatgtga atnntaaca cntctanant ntcncngnat gttatggcag 3420  
aatttttagtc acgtccaaaa caaaaagatt attccagaag atacctcattc ctatgcctga 3480  
aaggctccac agcatggcgt ccgtctccca ggggtctgtat ccgtctccctc acgggtcaat 3540  
caggcaggac agagaggagg gctgcaggcc taccacatttgc acccagaagg tatctccctt 3600  
caccatttcac acatccataa ggaatgcacaa atgctgtattt gaatagttct ctgtgtgact 3660  
ttcttagagaa gccaggacac cctgagcctt tccngggaa ctctaaggag tcacagggttc 3720  
acaccgtggg gattttcagg atagcatggaa gacagagatc cggtcggttgc tctcaactcgt 3780  
gagccttgcag aaggagagac tgaccagaaa cactcaactca gcaactctgcac ggagcaggag 3840

aagatactt aagatgaatc ttggatagat tttgatacac ccaataccat acacacagga 3900  
gcttggcatt tgcaaagtct attcagttc cttccgcgt ctgacccacg gtttagcgg 3960  
agtgggctga acactgtaac actgtacatg cgattcccc atgggcttct aaaatgtcac 4020  
catctcctcc cctgctgtgt cctactccat ttactggta caaggtgatg tcaacaagag 4080  
aagctatcac aacaccaggg ctgtgcacac gtgcacacac atgtatgcac agcacacag 4140  
atgtatgtac agcacacaca cacacacaca ccccaaaagg agagaaaagg aagaaaacat 4200  
ttataaaaag cgacagctac cccatatcaa aatagtctt cctgttagaa acaggagctc 4260  
tccataagga attatcatga gtgtgttctc ccacatcgtgc actctccag gggtgctcac 4320  
tgaagctggt ccacrtctat aaacaggtga cactggctgc agcaaaaagc cattcgatcc 4380  
acacaaatg atcttctatc atcttggaat ctgaattgca gggaggagca gyatgtaaga 4440  
cgaccgtta attcaggcat tccgaaggca tgagcgcatalog gattctrca ccaagcgtat 4500  
aaaaggaccc tggcattggg aaacctatga cgactgttt ttgctgtaga agtagggatt 4560  
ttacagaagt ctccttgrat ttgccctgcc tggggcagtt ttgcagagga acctgccaga 4620  
gatttattgg ctggtcagtc tcttgtaaaa tagtatcatg tgagaaacag tttgtagaaa 4680  
aaaactatac ctgggaagac ctttgcaca ttgttccttc catggccaa gactcagtt 4740  
ggaggcataa atctgcccgg aataaactag gccaggatac agccatgttt agttaataat 4800  
ttggtttag aattcacaca ggcaggattg gttttttgt gtcttggcaa gtggagcata 4860  
ttaacatac aggcatggg atcctgcctc ttagctttc ccacccttctt gtctcaccaa 4920  
gtttttctc tccaaagggtt tccaggaatt tctcattaat ggctgatgca aacttagtga 4980  
ataataatga atataaacaa tgctcacctc accaaaatta tattatttgc agtcatttgc 5040  
gataacacaa attttatcgc aatggttatt attaatttg tggccacaca ctgtggttat 5100  
cttttggtagt ggtgtttct gagaaaaatgt tcttgatat gtaagtgcca ataccagtgt 5160  
gaagtattga tccccggcag caaaatacag cctaagggtt gtaaacatca attctatctc 5220  
agttcatcag agggcctgag aagctgcggg gcagtgtaaa gtaaagtatg ctgggctgg 5280  
ggtggtcage ctccccttgc caagaagaga gcaattgaat cctgtccccca gctccctcca 5340  
cgccctgaaga gtgaccagtg ctggcccgac ggatcgctga gatattctcc cataatggca 5400  
aaaaaatagg cagtttgatg tgacctgttt agtgtggctc tcctcttttgc agcatgtgtt 5460  
agcattttta ttttatactc atccagtgaa ctctgcttctt ccaagtgtgt tcatgtatgt 5520  
gctagatata ttagcacage ctgccttctg ctgcacaacg ccttagagac cccgccttcc 5580  
aatgagctt gcttgcctc tgtttctgt ctcttaggtc taaactatgg tgtcagtttt 5640  
aatagaacaa aagtatgcat cttgccttgg cttgagcctt ttcgtttca atgctgactt 5700  
ctcccccttcc tctccctgtgc tcaccttacc tttccagagt gtaaggagaca acttttaagg 5760  
aggcgtgtcc ctggtagggg catccctgtt caccagggtgc ctgtcatcac cccacttgc 5820  
tgacatctac cctgggtact atgggttccct cttgtttgt gggAACGGTG gctccagggtg 5880  
gaggcatcaa tctgttgggt tctgggtcccc ggctgccttt ggtttgaaa gtctcttctc 5940  
tgttatattcc taccctgcat ttgctttgtg tgggtgtat gctgtggcag taggatcttgc 6000  
gatgactctc catcagtcac agactcccc tggtaaaag tggcaggctg actcgacagt 6060  
caccgtaaaa tctgagtcag tcacacacag gctgtcagcc acggcttcca ctgcacggc 6120  
tattctattt tcacacgtga gtttctgttgc ctggctggct gactggcatt atctatgcta 6180

agttgaaatc aggagtgtgc ccagcagagc ccatcattct cactgtctt gaaacaaagc 6240  
 tgtacggttt gatcgatgaa cgtatTTaaa gcatttcatg caatgacaaa gtgctcagta 6300  
 gtggaggca ggctgtgacc agtctgcctg ctccTTacta taattgttag gattgttac 6360  
 tggAACAGTA catggaggcc tgacCTTGTG gggcacagg gtggAACCTT agctgaatat 6420  
 agtgtgtgtc tcaagaggaa gtcagggtac tagctcagtg ctcaatctcc aggtactata 6480  
 tatacatttgc cccgttttat ctctaattgtg aaataaatcc ccaaACACTT gtttATCGTG 6540  
 tagcgtacctt aaaagactat tctattatgg gtgtccccac tttcttggtt tggTCACCCCC 6600  
 gatccccccgg tcttctgctg tatctagaac agtactata aatgatgtat gggAAATAGTG 6660  
 tttccatATG atctgttgc tggagtatact gctacatgtt catttactgt acaaaaaACCC 6720  
 agtgcagctg atgatgcaaa gcagtctc tcgtgtaca gtgccccacc tattttaaaa 6780  
 tcacgtacaa ncccagaaca ctgtgaaaca cttaacataa gaaacaaacg cagcgtctgg 6840  
 attctttcca aggagagcag ctttctccac aggaacacag taacaaaaga ggtccgcccgc 6900  
 catccacacc cagccaagac acctcagagg ccataggac aacctccttgc ctggccaaca 6960  
 cctgctggag cagggcacag gtcccagcaa ctgatcctca gtggatgggt ccgcagtcaa 7020  
 agcctaatttgc ggctctttt tgaaggggaa agaaannttt caagctttagt atatccaaca 7080  
 ttattatagt ttagttagtta gtaaattccg aaaaaaaaaaag atgattttat atgtatgaca 7140  
 taaaaaaaaat ctgtttaaag tgcgcAAGTg caataatttta aagaggctt atctttgcatt 7200  
 ttataaaattttaaaatattgt acatgtgtgt aatttttcat gtattcattt gcagtctttg 7260  
 tattttaaaaa aactttactg ttatgtttgt ataatagaac attaattcatt tattataact 7320  
 cagacaagggt gtaaataaaat tcataattca aacagccagt atatatgcattt atatgggtgt 7380  
 tacattgcaa aaatctctat ctgttgcatttgc taaagaagta agaaatcttt 7440  
 tgtggatatg taatttataca tataaaggat atatataatgt atgatacatg aaatataattt 7500  
 agaaaatgttc ataattttaa tggatattct ttgggtgtgaa taattgaata caacattttt 7560  
 aaaatgaaaaa aaaaaaaaaa c 7581

<210> 12  
 <211> 7618  
 <212> DNA  
 <213> mouse

<400> 12  
 cgcccgggca ggtctgttgg agggcagttg gtcaacctga ccagagagag ctgagctgg 60  
 agaccccaact gatgggtgtgc tgcctttcag tccaggaaga aagaaaggaa ggattctgag 120  
 gatttgggca aagccacatt cctggagaag tctgtatact gatgccaaac ccaagagctg 180  
 agctgctgtat gaggccccagg gagtagccca cgcccccgtga gctgttgct agcaaggcct 240  
 tcctgctcca tgtggcatgg aaaaattata tggtttgacg gatgaaaagg tgaaggccta 300  
 tctttctctc catccccagg tatttagatga atttgtttct gaaagtgtta gtgcagagac 360  
 tgtggaaaaag tggctgaaga ggaaaaccaa caaagcaaaa gatgaaccat ctcccaagga 420  
 agtcagcagg taccaggata cgaatatgca gggagtcgtg tacgagctga acagctacat 480

agagcagcgc ctggcacacgg gcggggacaa ccacctgctc ctctatgagc tcagcagcat 540  
catcaggata gcccacaaaag ccgacggatt tgcactgtac ttcccttggag agtgcataa 600  
tagcctgtgt gtgttcatac cacccggat gaaggaaggc caaccccgcc tcatccctgc 660  
agggcccatc acccaggta ccaccatctc tgcctacgtg gccaagtcta ggaagacgtt 720  
gttggtagag gatatccttg gggatgagcg atttcctcga ggtactggcc tggaatcagg 780  
aacccgcatac cagtctgttc tttgcttgc cattgtcaact gccattggag acttgattgg 840  
catccttcaa ctgtacaggc actggggcaa agaggccttc tgcctcagcc atcaggaggt 900  
tgcaacagcc aatcttgctt gggcttccgt agcaatacac caggtgcagg tgttagagg 960  
tctcgccaaa cagaccgaac tgaatgactt cctactcgac gtatcaaaga catactttga 1020  
taacatagtt gccatagact ctctacttga acacatcatg atatatgcaa aaaatctagt 1080  
gaacgcccac cgctgcgcgc tcttccaggt ggaccacaag aacaaggagc tgtactcgga 1140  
cctgtttgac attggggagg agaaggaggg gaagcccatc ttcaagaaga ccaaggagat 1200  
cagattttcc attgagaaaag ggattgtcg tcaagtggca agaacaggcg aagtcttcaa 1260  
cattcccgat gcctacgcgg accctcgctt taacagggag gtggacctgt acacaggcta 1320  
caccacgagg aacattctgt gtatgccat agtgagccga ggcagcgtga ttggcgtggt 1380  
gcagatggtg aacaagatca gcggtagcgc cttctccaag acagacgaga acaacttcaa 1440  
gatgtttgct gtcttctgcg cactggcctt gcactgtgt aacatgtacc acaggatccg 1500  
ccactcgaaa tgcatctaca gggttaccat ggagaagctt tcctaccaca gcatctgcac 1560  
ctccgaggag tggcaaggcc tcatgcgcctt caacctacca gcacgcacatc gcccggacat 1620  
cgagctattc cactttgaca ttggcctttt cgagaacatg tggcctggaa tctttgtcta 1680  
catgatccat cggtcttgcg ggacatcctg tttgaactt gaaaaattgt gccgttttat 1740  
catgtctgtg aagaagaact atcggcggtt tccttaccac aactggaaagc atgcagtcac 1800  
ggtggcacac tgcatgtatg ccatacttca aaacaacaat ggcctcttca cagacctcgaa 1860  
gcgcaaaggc ctgctaattt cgtgtctgtg ccatgacctg gaccacaggg gcttcagtaa 1920  
cagctacctg cagaagttcg accacccctt ggcggcgctg tactccacat ccaccatggaa 1980  
gcaacaccac ttctcccaga cggtgtccat cttcagctg gaagggcaca atatcttctc 2040  
caccctgagc tccagcgagt acgagcaggat gctggagatc atccgcaaag ccatcatcg 2100  
caccgacccgc cccctataact ttgggaacag gaagcagttt gaggagatgt accagacagg 2160  
gtcgctgaac ctccacaacc agtcccacatcg agaccgtgtc atcggcttga tgatgactgc 2220  
ctgtgatctt tgctctgtga ccaaactatg gccagttaca aaattgacag cgaatgat 2280  
atatgcagaa ttctggctg agggtgatga gatgaagaag ctgggcatac agcccatattcc 2340  
tatgtggac agagacaagc gagatgaagt ccctcaaggg cagctcggt tctacaatgc 2400  
tgtggccatt ccctgctata ccacccgtac gcagatcctc ccacccacag agctctgtct 2460  
gaaggcctgc aggataacc tcaatcagtgg gagaaggta attcgcgggg aagagacagc 2520  
aatgtggatt tcagggccatg gcccggcgcc tagcaagagc acacctgaga agctgaacgt 2580  
gaagggtgaa gactgatcctt gaagtgcacgt cctgatgtctt gcccagcaac cgtactcaacc 2640  
tgcttctgtg acttcgttctt ttttgttttca aagggtgaa aacccctgt cagaaggta 2700  
cgctcgatcat ccatgtgaag cagacgactc cctgcttgc gcacacacat cggacagtga 2760  
gcaacccagg ctctgcccgtg ttcagacgtc ggctactccg tggctccacc tgacccatcg 2820

atgctatttgcactccaggccc agcactgcac tgtctggagg gggcagagac cacaggagag 2880  
gttcttgccct gcacatcccc atgagggtgt ggccagttcc ctagttctgt gccatgctgc 2940  
tgcttggtag cattggtag gaatggaca cacccccctt gttgtgaagt ttacatgtga 3000  
ccttcttata ggttaactga gtttggcc tgggacacat gtaatgaagg tcacagtcca 3060  
caggtgacag agaaatccaa actgttgatt acaggtgcac tacaggtatg ctcttcagt 3120  
ctatctgggg gcacataggt gagtctgctc cactcagaag gaagcataacc tctscctca 3180  
tccaggggac acagggtaca tcccaggcat cggggactg aagctctcac ttcaaaccat 3240  
gtcaaagaat taaaacacact cccctcccc tcactgttagc cttcggaac tgcccaatc 3300  
ccttataca aagaaaatat aagtaaggca tataaatttc ctccagcaag caaatcttgt 3360  
gggtaaaaaaaaaaaaatgtg aattttaca acctctatata ttcaactgta tgttatggca 3420  
gaatttttagt cacgtccaaa acaaaagatt attccagaag atacctcatc ctatgcctga 3480  
aagctccaca gcatggcgctc cgtctccag gtttctgatc cgtctcctca cggtgcaatc 3540  
aggcaggaca ggaggaggtg cagggctacc acattgaccc agatggtac tccttcacc 3600  
attcagacat ccataaggaa tgccaaatgc tgtattgaat agttctcctg tgtgactttc 3660  
tagagaagcc aggacaccccc tgagccttgc ctgggaactc ctaaggaagt cacaggttca 3720  
caccgtgggg attttcagga tagcatggag accagagaat cccggttcgg ttgttctcac 3780  
tcggtgagcc ttgagaagga agagactgac cagaaacact cactcagcac tctggcagga 3840  
gcaggagaag atacttaag atgaatctt gggatagatt ttgatacacc caataccata 3900  
cacacaggag cttggcattt gcaaagtcta ttcagttcc ttccacactc tgacccacgg 3960  
ttgttagcgga gtgggctgaa cactgtaaca ctgtacatgc gatttcccc tgggcttcta 4020  
aaatgtcacc atctcctccc ctgctgtgtc ctactccatt tactggttac aaggtgatgt 4080  
caacaagaga agctatcaca acaccaggc tgtgcacacg tgcacacaca tgtatgcaca 4140  
agcacacaga tgtatgtaca gcacacacac acacacacac cccaaaagga gagaaaagga 4200  
agaaaaacatt tataaaaagc gacagctacc cccatattca aaaatagttc tttccctgt 4260  
agggaaaacag gtagctctcc ataaggaaat tatcatgagt gtgttctccc atcagtgcac 4320  
ttctcccagg ggtgctcaact gaagctggc cacgtctata aacaggtgac actggctgca 4380  
gcaaaaagcc attcgatcca cacaatttga tcttctatca tcttggaaatc tgaattgcag 4440  
ggaggagcag catgtaagac gaccgttta ttcaggcatt ccgaaggcat gagcgcatgg 4500  
attctgtcac caagcgtata aaaggaccc ggcattggga aacctatgac ggactgttt 4560  
tgctgttagaa gtagggattt tacagaagtc tccttggatt tgccctgcct gggcagttt 4620  
tgcagagggaa cctgccagag atttattggc tggtcagtct cttgtgaaat agtacatgt 4680  
gagaaaacagt ttgttagaaaa aaactataacc tgggaagacc tttgcaacat tttcccttcc 4740  
atgggccaag actcagtttgc gaggcataaa tctgccccggaa ataaacttagg ccaggataca 4800  
gccatgttta gttataatt tggttttaga attcacacag gcaggattgg ttttttgg 4860  
tcttggcaag tggagcatat ttaacatata ggcattggaa tcctgcctct tagctttcc 4920  
caccctcttgc tctcaccaag tttttctct ccaaagggtt ccaggaattt ctcattaatg 4980  
gctgatgcaa acttagtgaa taataatgaa tataaacaat gtcacccatca ccaaaattat 5040  
attatttgca gtcattttgtg ataacacaaa ttttatcgca atggtttattttaatttgt 5100  
ggccacacac tgtggttatc ttttgggggg gttgtttctg agaaaatgtt cttggatatg 5160

taagtgccaa taccagtgtg aagtattgtat cccgggcagc aaaatacagc ctaaggttt 5220  
taaacatcaa ttctatctca gttcatcaga gggcctgaga agctgcgggg cagtgtaaag 5280  
taaagtatgc tgggtcggtg gtggtcagcc tccccttgcc aagaagagag caattgaatc 5340  
ctgtccccag ctccctccac gcctgaagag tgaccagtgc tggcccgacg gatcgctgag 5400  
atattctccc ataatggcaa aaaaataggc agtttgcgt gacctgtttt gtgtggctct 5460  
cctctttga gcatgtgttgc gcattttat tttatactca tccagtgaac tctgctttc 5520  
caagtgtgtt catgtatgtg cttagatatat tagcacagcc tgccttctgc tgcacaacgc 5580  
cttagagacc cgccctttca atgagcttag cttgtgtct gtttctgtc tcttaggtct 5640  
aaactatggt gtcagttta atagaacaaa agtatgcac ttgccttggc ttgagcctt 5700  
tcgtttcaa tgctgacttc tccccttct ctcctgtgtt caccttacct ttccagagt 5760  
taagggacaa ctttaagga ggcgtgtccc tggtaggggc atccctgttcc accaggtgcc 5820  
tgtcatcacc ccacttgact gacatctacc ctggtgacta tgggttcctc ttgtttgttag 5880  
gaaacgggtgg ctccaggtgg aggcatcaat ctgtgggtt ctgggtcccg gtcgcctt 5940  
gttttgaag tctcttctct gtatattcct accctgcatt tgctttgtgt ggtgctgtat 6000  
ctgtggcagt aggtacttgg atgactctcc atcagtcaca gactccccct gttgcaaaagt 6060  
gtcaggctga ctcgacagtc accgtaaaaat ctgagtcagt cacacacagg ctgtcagcca 6120  
cggttccac ttgcattggcatttccatcacatgttgc tggctggctg 6180  
actggcatta tctatgctaa gttgaaatca ggagtgtgcc cagcagagcc catcattctc 6240  
actgtcttg aaacaaagct gtacggtttgc atcgatgaac gtatttaaag catttcattgc 6300  
aatgacaaag tgctcgttag tggaaaggcag gctgtgacca gtctgcctgc tccttactat 6360  
aattgtgagg atttgttact ggaacagttac atggaggcct gaccttgggg gggcacaggg 6420  
tggAACCTTA gctgaatata gtgtgtgtct caagaggaag tcagggtact agtcagtgc 6480  
tcaatctcca ggtactatata atacatttc ccgtttatc tctaattgtt aataaatccc 6540  
caaacacttg tttatcgtgt agcgtaccta aaagactatt ctattatggg tgtccccact 6600  
ttcttgggtt ggtcaccccg atccccccgt cttctgtgtt atctagaaca gtgactataa 6660  
atgatgtatg ggaatagtgt ttccatata tctgtgtct ggagtatata gtcacatgttc 6720  
atttactgtt caaaaaccca gtgcagtcgtt tgatgcaaaag cagtctctct ctgtgtacag 6780  
tgccccacccat attttttttt cacgtacaan cccagaacac tggaaacac ttaacataag 6840  
aaacaaacgc agcgtctggaa ttctttccaa ggagagcagc tttctccaca ggaacacagt 6900  
aacaacaaagag gtccggccgc atccacaccc agccaagaca cctcagaggc catagggaca 6960  
accttcatttc tggccaacac ctgctggagc agggcacagg tcccagcaac tgatcctcag 7020  
tggatgggtc cgcagtcaaa gccttaatgg gctctttttt gaagggggaaa gaaannnttc 7080  
aagcttatgtt tatccaacat tattatagtt gatgagttt gaaattccga aaaaaaaaaa 7140  
tgatTTTATA tgtatgacat aaaaaaaaaatc tttgtaaagt ggcgaagtgc aataattttaa 7200  
agaggtcttata tctttgcatt tataaatttat aaatattgtt catgtgtgtt atttttcatg 7260  
tattcatttgc cagtctttgtt attttttttt actttactgtt tatgtttgtt taatagaaca 7320  
ttaatcattt attataactc agacaaggtt taaataaattt cataattcaa acagccagttt 7380  
tatatgcata tatgggtgtt acattgcaaa aatctctatc tttgttctat tcacatgtt 7440  
aaagaagttt gaaatctttt gtggatgtt aattatacat ataaagtata tatatatgtt 7500

tgatacatga aatatattta gaaatgttca taattttaat ggatattctt tggtgtgaat 7560  
aattgaatac aacattttta aaatgaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7618

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/24781 A3**

(51) International Patent Classification<sup>7</sup>: A61K 31/505, 31/4174, 31/65, 31/4985, 31/522, 31/4745, 31/519, 31/7048, 31/395, A61P 25/14, G01N 33/68

(74) Agent: HELLER, David, J.; Ridout & Maybee, One Queen Street East, Suite 2400, Toronto, Ontario M5C 3B1 (CA).

(21) International Application Number: PCT/CA00/01188

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 6 October 2000 (06.10.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2,285,690 7 October 1999 (07.10.1999) CA  
60/158,043 7 October 1999 (07.10.1999) US  
60/217,765 12 July 2000 (12.07.2000) US

(71) Applicant (*for all designated States except US*): NOVA-NEURON INC. [CA/CA]; 5859 University Avenue, Sir Charles Tupper Medical Bldg., Room 15D7, Halifax, Nova Scotia B3H 4H7 (CA).

**Published:**

— *with international search report*

(88) Date of publication of the international search report:  
7 February 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ROBERTSON, Harold, A. [CA/CA]; 2384 Clifton Street, Halifax, Nova Scotia B3K 4V1 (CA). DENOVAN-WRIGHT, Eileen, M. [CA/CA]; 22 Fleming Drive, Halifax, Nova Scotia B3P 1A9 (CA).



**WO 01/24781 A3**

(54) Title: GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME

(57) Abstract: PDE10A, a gene that is normally highly expressed in mammalian striatum and elsewhere, has been found to decrease in expression during the development of CAG repeat disorders such as Huntington's disease. The invention teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder. Compounds which modulate CAG repeat disorders and their uses are taught. Methods for screening for further compounds to modulate CAG repeat disorders are also taught.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

**A. CLASSIFICATION OF SUBJECT MATTER**

|       |             |             |             |             |            |
|-------|-------------|-------------|-------------|-------------|------------|
| IPC 7 | A61K31/505  | A61K31/4174 | A61K31/65   | A61K31/4985 | A61K31/522 |
|       | A61K31/4745 | A61K31/519  | A61K31/7048 | A61K31/395  | A61P25/14  |
|       | G01N33/68   |             |             |             |            |

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | US 5 789 395 A (ABRAMSON STEVEN B ET AL)<br>4 August 1998 (1998-08-04)<br>abstract<br>column 4, line 20 - line 62<br>column 6, line 59 - line 67<br>column 7, line 13 - line 30<br>column 8, line 39 - line 45<br>--- | 1,2,5-7               |
| X          | WO 99 48522 A (INOUE JUN ; SAKAMOTO YUJI (JP); YOSHIDA YUKUO (JP); SENJU PHARMA CO)<br>30 September 1999 (1999-09-30)<br>page 1, paragraph 2 -page 2, paragraph 1<br>---  | 1,4-7                 |
| X          | US 5 849 290 A (BROWN ROBERT ET AL)<br>15 December 1998 (1998-12-15)<br>abstract<br>column 6, line 17 - line 51<br>---  | 1,2,5-7               |
|            | -/-   |                       |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 April 2001

Date of mailing of the international search report

16/10/01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Cielan, E

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|----------|--|-----------------------|
| X        | WO 99 06545 A (MAX PLANCK GESELLSCHAFT ;LEHRACH HANS (DE); WANKER ERICH (DE); SCH) 11 February 1999 (1999-02-11)<br>page 1, paragraph 1 - paragraph 4<br>page 17, paragraph 3 - paragraph 6<br>claims 20-22<br>---   | 1,2,5-7               |
| X        | US 5 750 376 A (REYNOLDS BRENT ET AL)<br>12 May 1998 (1998-05-12)<br>column 1, line 40 - line 57<br>column 11, line 26 - line 29<br>column 18, line 6 - line 9<br>column 20, line 41 - line 56<br>column 26, line 63 -column 27, line 32<br>column 27, line 62 -column 28, line 6<br>--- | 1,4-7                 |
| X        | EP 0 930 069 A (JOHNSON & JOHNSON MEDICAL LTD) 21 July 1999 (1999-07-21)<br>abstract<br>page 2, line 54 - line 57<br>example 1<br>claims 1,6<br>---  | 1,4                   |
| X        | US 4 367 217 A (GRUBER PETER ET AL)<br>4 January 1983 (1983-01-04)<br>abstract<br>column 1, line 6 - line 11<br>example I<br>claim 1<br>---  | 1,4                   |
| X        | US 5 461 068 A (THALER IRWIN ET AL)<br>24 October 1995 (1995-10-24)<br>abstract<br>column 5, line 4 - line 14<br>claims 1,6<br>---   | 1,2                   |
| X        | US 4 292 312 A (GRIFFON HENRI)<br>29 September 1981 (1981-09-29)<br>abstract<br>examples<br>claims 9,10<br>---   | 1,2                   |
| X        | WO 97 03985 A (GLAXO WELLCOME LAB SA ;DAUGAN ALAIN CLAUDE MARIE (FR); GELIBERT F) 6 February 1997 (1997-02-06)<br>abstract<br>page 1, line 3 - line 14<br>page 2, line 13 -page 3, line 2<br>page 5, line 15 - line 17<br>page 12, line 6 - line 12<br>claims 5,11<br>---                | 1,3                   |
|          |  | -/-                   |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|----------|--|-----------------------|
| X        | VEMULAPALLI SUBBARAO ET AL: "Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor." JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 28, no. 6, 1996, pages 862-869, XP000998260<br>ISSN: 0160-2446<br>abstract<br>figures 2-5<br>page 867, column 2, paragraph 4<br>---   | 1,4                   |
| X        | ICHIMURA MICHIO ET AL: "KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase." BIOCHEMICAL JOURNAL, vol. 316, no. 1, 1996, pages 311-316, XP000998314<br>ISSN: 0264-6021<br>abstract<br>page 312, column 1, paragraph 1<br>page 315, column 2, paragraph 2 -<br>paragraph 3<br>---  | 1,4                   |
| A        | US 5 932 423 A (SEILHAMER JEFFREY J ET AL) 3 August 1999 (1999-08-03)<br>abstract<br>column 3, line 8 - line 18<br>column 4, line 27 - line 45<br>column 11, line 1 - line 7<br>column 12, line 24 - line 30<br>column 12, line 53 - line 63<br>column 19, line 55 - line 62<br>column 21, line 53 - line 65<br>column 22, line 10 - line 14<br>column 25, line 5 - line 17<br>---   | 1,4-7                 |
| A        | CEPEDA CARLOS ET AL: "Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons." EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 10, no. 11, November 1998 (1998-11), pages 3491-3497, XP000998317<br>ISSN: 0953-816X<br>abstract<br>page 3491, column 1, paragraph 1<br>figure 3C<br>page 3494, column 2, paragraph 2<br>page 3495, column 1, paragraph 2<br>page 3496, column 1, paragraph 3<br>--- | 1,2,5-7               |

-/-

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/CA 00/01188

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|----------|--|-----------------------|
| A        | WO 99 42596 A (ICOS CORP)<br>26 August 1999 (1999-08-26)<br>cited in the application<br>abstract<br>page 2, line 31 -page 3, line 8<br>page 4, line 27 -page 5, line 19<br>page 14, line 22 -page 15, line 23<br>page 18, line 25 - line 30<br>page 19, line 14 - line 16<br>---   |                       |
| A        | FUJISHIGE K ET AL: "CLONING AND<br>CHARACTERIZATION OF A NOVEL HUMAN<br>PHOSPHODIESTERASE THAT HYDROLYZES BOTH<br>CAMP AND CGMP (PDE10A)"<br>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN<br>SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE,<br>MD, US,<br>vol. 274, no. 26,<br>25 June 1999 (1999-06-25), pages<br>18438-18445, XP000983162<br>ISSN: 0021-9258<br>abstract<br>table II<br>page 18443, column 2, paragraph 3 -page<br>18444, column 1, paragraph 1<br>page 18444, column 2, paragraph 2<br>--- | 1,4                   |
| A        | LOUGHNEY K., SNYDER P.B. ET AL.:<br>"Isolation and characterisation of PDE10A,<br>a novel human 3',5'-cyclic nucleotide<br>phosphodiesterase."<br>GENE,<br>vol. 234, 1999, pages 109-117, XP002166002<br>abstract<br>page 114, column 2, paragraph 3<br>table 1<br>---   | 1,4                   |
| P,X      | WO 00 27422 A (BIOGEN INC ;GALDES ALPHONSE<br>(US); ONTOGENY INC (US); MAHANTHAPPA N)<br>18 May 2000 (2000-05-18)<br>page 3, line 25 - line 30<br>page 4, line 19 -page 7, line 7<br>page 10, line 6 - line 16<br>page 11, line 14 - line 18<br>page 13, line 1 - line 6<br>page 15, line 15 - line 25<br>---  | 1-4,6                 |
|          |  | -/-                   |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| P,X      | <p>CHEN MINGHUA ET AL: "Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease."</p> <p>NATURE MEDICINE,<br/>vol. 6, no. 7, July 2000 (2000-07), pages<br/>797-801, XP000998293<br/>ISSN: 1078-8956</p> <p>abstract<br/>page 797, column 2, paragraph 2 -page 798,<br/>column 1, paragraph 1<br/>figure 1<br/>page 800, column 2, paragraph 2 -<br/>paragraph 3<br/>-----</p> | 1,2,5-7               |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 00/01188

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See handwritten copy claims

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-7

A composition and its use for treating a CAG repeat disorder comprising a compound which modulates PDE10A expression and a pharmaceutically acceptable carrier.

2. Claims: 8-14

A method for identifying a compound which inhibits or promotes a CAG repeat disorder.

3. Claims: 15-19

A method for detecting the presence of or the predisposition for a CAG repeat disorder.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01188

| Patent document cited in search report | Publication date | Patent family member(s)  | Publication date   |
|--|------------------|--|--|
| US 5789395 A                           | 04-08-1998       | AU 718234 B<br>AU 4080897 A<br>EP 0966525 A<br>US 5919775 A<br>WO 9808480 A  | 13-04-2000<br>19-03-1998<br>29-12-1999<br>06-07-1999<br>05-03-1998   |
| WO 9948522 A                           | 30-09-1999       | AU 2852699 A<br>BR 9908948 A<br>CN 1301173 T<br>EP 1064021 A<br>HU 0101428 A<br>NO 20004679 A<br>PL 342970 A   | 18-10-1999<br>21-11-2000<br>27-06-2001<br>03-01-2001<br>28-09-2001<br>26-10-2000<br>16-07-2001   |
| US 5849290 A                           | 15-12-1998       | US 5843641 A<br>CA 2157041 A<br>EP 0686203 A<br>JP 8510377 T<br>WO 9419493 A   | 01-12-1998<br>01-09-1994<br>13-12-1995<br>05-11-1996<br>01-09-1994   |
| WO 9906545 A                           | 11-02-1999       | EP 1001987 A   | 24-05-2000   |
| US 5750376 A                           | 12-05-1998       | US 6071889 A<br>US 5981165 A<br>US 6294346 B<br>US 5980885 A<br>US 5851832 A<br>AU 697894 B<br>AU 8056194 A<br>CA 2175992 A<br>WO 9513364 A<br>CN 1141058 A<br>EP 0728194 A<br>FI 961855 A<br>JP 9507747 T<br>NO 961859 A<br>AU 714837 B<br>AU 3515295 A<br>CA 2200709 A<br>WO 9609543 A<br>EP 1130394 A<br>EP 0783693 A<br>FI 971168 A<br>JP 10505754 T<br>NO 971245 A<br>AU 716811 B<br>AU 3836795 A<br>WO 9615226 A<br>CN 1170435 A<br>EP 0792350 A<br>FI 971956 A<br>JP 10509592 T<br>NO 972171 A<br>AU 665012 B<br>AU 2242592 A<br>CA 2113118 A<br>WO 9301275 A<br>EP 0594669 A | 06-06-2000<br>09-11-1999<br>25-09-2001<br>09-11-1999<br>22-12-1998<br>22-10-1998<br>29-05-1995<br>18-05-1995<br>18-05-1995<br>22-01-1997<br>28-08-1996<br>04-06-1996<br>12-08-1997<br>03-07-1996<br>13-01-2000<br>09-04-1996<br>28-03-1996<br>28-03-1996<br>05-09-2001<br>16-07-1997<br>20-03-1997<br>09-06-1998<br>18-03-1997<br>09-03-2000<br>06-06-1996<br>23-05-1996<br>14-01-1998<br>03-09-1997<br>04-07-1997<br>22-09-1998<br>07-07-1997<br>14-12-1995<br>11-02-1993<br>21-01-1993<br>21-01-1993<br>04-05-1994 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01188

| Patent document cited in search report | Publication date | Patent family member(s)  | Publication date   |
|--|------------------|--|--|
| US 5750376 A                           |                  | FI 935929 A<br>JP 6509225 T<br>NO 940056 A<br>WO 9416718 A<br>AU 683023 B<br>AU 5147493 A<br>CA 2147162 A<br>WO 9409119 A<br>EP 0664832 A<br>FI 951677 A<br>JP 8502172 T<br>NO 951378 A<br>AU 703729 B   | 02-02-1994<br>20-10-1994<br>03-03-1994<br>04-08-1994<br>30-10-1997<br>09-05-1994<br>28-04-1994<br>28-04-1994<br>02-08-1995<br>07-04-1995<br>12-03-1996<br>07-04-1995<br>01-04-1999   |
| EP 0930069 A                           | 21-07-1999       | GB 2333041 A<br>AU 1129699 A<br>BR 9900046 A<br>JP 11279080 A<br>SG 77214 A  | 14-07-1999<br>05-08-1999<br>02-05-2000<br>12-10-1999<br>19-12-2000   |
| US 4367217 A                           | 04-01-1983       | DE 3000979 A<br>AR 221983 A<br>AT 6585 T<br>AU 539618 B<br>AU 6615681 A<br>CA 1148084 A<br>CS 8100232 A<br>DD 156943 A<br>DE 3067058 D<br>DK 9481 A,B,<br>EP 0032562 A<br>ES 498393 D<br>ES 8207428 A<br>FI 810058 A,B,<br>GB 2067073 A,B<br>GR 73102 A<br>HK 62184 A<br>HU 184366 B<br>IE 50807 B<br>IL 61887 A<br>IN 155158 A<br>JP 1350517 C<br>JP 56103111 A<br>JP 61016368 B<br>KE 3402 A<br>MY 55985 A<br>NO 810061 A,B,<br>NZ 195994 A<br>OA 6720 A<br>PH 17063 A<br>PL 229157 A<br>PT 72330 A,B<br>SG 28184 G<br>YU 3981 A<br>ZA 8100161 A | 23-07-1981<br>31-03-1981<br>15-03-1984<br>11-10-1984<br>16-07-1981<br>14-06-1983<br>18-06-1984<br>06-10-1982<br>19-04-1984<br>13-07-1981<br>29-07-1981<br>16-09-1982<br>16-12-1982<br>13-07-1981<br>22-07-1981<br>02-02-1984<br>17-08-1984<br>28-08-1984<br>23-07-1986<br>30-09-1984<br>05-01-1985<br>28-11-1986<br>18-08-1981<br>30-04-1986<br>08-06-1984<br>31-12-1985<br>13-07-1981<br>27-04-1984<br>30-06-1982<br>24-05-1984<br>18-09-1981<br>01-02-1981<br>15-02-1985<br>30-09-1983<br>29-09-1982 |
| US 5461068 A                           | 24-10-1995       | NONE   |  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01188

| Patent document cited in search report |   | Publication date | Patent family member(s)  | Publication date   |
|--|---|------------------|--|--|
| US 4292312                             | A | 29-09-1981       | FR 2459046 A<br>DE 3071091 D<br>DK 303679 A<br>EP 0021953 A<br>FR 2489148 A  | 09-01-1981<br>24-10-1985<br>16-12-1980<br>07-01-1981<br>05-03-1982   |
| WO 9703985                             | A | 06-02-1997       | AU 702324 B<br>AU 6419296 A<br>BR 9609780 A<br>CA 2226761 A<br>CN 1195349 A,B<br>CZ 9800032 A<br>EP 0846118 A<br>HR 960321 A<br>HU 9900006 A<br>JP 11509535 T<br>NO 980154 A<br>PL 324527 A<br>SK 3898 A<br>US 5981527 A<br>US 6143746 A | 18-02-1999<br>18-02-1997<br>09-03-1999<br>06-02-1997<br>07-10-1998<br>17-06-1998<br>10-06-1998<br>31-08-1998<br>28-04-1999<br>24-08-1999<br>10-03-1998<br>08-06-1998<br>04-11-1998<br>09-11-1999<br>07-11-2000 |
| US 5932423                             | A | 03-08-1999       | US 5798246 A<br>US 6080548 A<br>AU 724247 B<br>AU 2542797 A<br>CA 2248675 A<br>EP 0907742 A<br>WO 9735989 A  | 25-08-1998<br>27-06-2000<br>14-09-2000<br>17-10-1997<br>02-10-1997<br>14-04-1999<br>02-10-1997   |
| WO 9942596                             | A | 26-08-1999       | AU 3307999 A<br>EP 1060251 A   | 06-09-1999<br>20-12-2000   |
| WO 0027422                             | A | 18-05-2000       | AU 1611600 A<br>EP 1126865 A   | 29-05-2000<br>29-08-2001   |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.